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2 Abstract
Microbial resistance to antibiotics is a serious global health threat, and the discovery of new, safe and effective
antibiotics is required urgently. A new class of antibiotics, namely sideophore-antibiotic conjugates, has shown
promise in initial studies. Siderophores are used by bacteria for iron uptake, and so attaching antibiotics to
them allows the antibiotic to be carried across cell membranes. This study investigated conjugates designed
using a similar approach, but using bacterial autoinducers instead of siderophores. Autoinducers are required
for coordination of bacterial behaviours and are involved in the control of swarming, virulence factor production
and biofilm formation.
The quorum sensing molecules produced by Pseudomonas aeruginosa were chosen for investigation as P.
aeruginosa is a significant human pathogen which displays high resistance to many antibiotics and uses quo-
rum sensing to coordinate its group behaviours. Ciprofloxacin and trimethoprim were chosen as the antibiotic
partners. Ciprofloxacin is commonly used against P. aeruginosa but resistance to it is developing, whereas
P. aeruginosa is inherently resistant to trimethoprim. It was hypothesised that the autoinducers would aid
retention of the antibiotics in cells, hence increasing or restoring activity.
An initial library was synthesised in two halves which were coupled together using a copper(I)-catalysed
azide-alkyne cycloaddition. The autoinducers were functionalised with azide groups and the antibiotics (specif-
ically ciprofloxacin and trimethoprim) were functionalised with alkynes. Two cleavable alkynyl ciprofloxacin
derivatives were also included.
A second set of compounds, namely homoserine lactone analogue-ciprofloxacin conjugates were then synthe-
sised, building on the one known report of a conjugate of a quorum sensing modulator and an antibiotic.
The most active conjugate found was a cleavable conjugate of homocysteine thiolactone (a homoserine lac-
tone analogue) and ciprofloxacin. This compound showed enhanced antibacterial activity against P. aeruginosa
compared to ciprofloxacin, and P. aeruginosa may develop less resistance towards it.
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4 Nomenclature
m Mass
v Volume
J Coupling constant in Hz
m/z Mass to charge ratio in Daltons
Rf Retention factor
Ac Acetate
AIP Autoinducing peptide
aq. Aqueous
atm Atmosphere(s)
BHL Butyryl homoserine lactone = C4-HSL
Boc tert-Butyloxycarbonyl
Bu Butyl
Cip Ciprofloxacin
conc. Concentrated
COSY Correlation spectroscopy
d Day(s)
Da Daltons
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DIPEA N,N -Diisopropylethylamine
DMAP 4-Dimethylaminopyridine
DMF Dimethylformamide
DMP Dess-Martin periodinane
DMSO Dimethylsulfoxide
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
eq. Equivalents
ESI Electrospray ionization
Et Ethyl
FT Fourier transform
h Hour(s)
HCTL Homocysteine thiolactone
12
HHQ 2-Heptylquinolin-4(1H)-one
HMBC Heteronuclear multiple-bond correlation spectroscopy
HMQC Heteronuclear multiple-quantum correlation spectroscopy
HOBt 1-Hydroxybenzotriazole
HPLC High-performance liquid chromatography
HRMS High resolution mass spectroscopy
HSL Homoserine lactone
Hz Hertz
IR Infrared
LB Lysogeny broth
LCMS Liquid chromatography mass spectroscopy
LCT Liquid chromatography time-of-flight
lit. Literature value
M Molar
m.p. Melting point
Me Methyl
MIC Minimum inhibitory concentration
min Minute(s)
mol Mole(s)
Ms Methanesulfonyl
NMP N -Methyl-2-pyrrolidone
NMR Nuclear magnetic resonance
OD Optical density
OdDHL N -(3-Oxododecanoyl)-homoserine lactone = 3-oxo-C12-HSL
P.E. Petroleum ether
PAI-1 Pseudomonas autoinducer 1 = 3-oxo-C12-HSL
PAI-2 Pseudomonas autoinducer 2 = C4-HSL
Pd/C Palladium on carbon
PQS Pseudomonas Quinolone Signal
Q-TOF Quadrupole time-of-flight
r.t. Room temperature
s Second(s)
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SAM S-adenosyl-l-methionine
SAR Structure activity relationship
sat. Saturated
SD Standard deviation
spp. Species
TBAF Tetrabutylammonium fluoride
TBDMS tert-Butyldimethylsilyl
TEA Triethylamine
Tf Trifluoromethanesulfonyl
TFA Trifluoroacetic acid
THF Tetrahydrofuran
THPTA Tris(3-hydroxypropyltriazolylmethyl)amine
TLC Thin layer chromatography
TMS Trimethylsilyl
Ts para-Toluenesulfonyl
UV Ultraviolet
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5 Introduction
5.1 Antibiotic resistance
Antibiotics add, on average, twenty years to a person’s life.1 However, antibiotic resistance is increasing alarm-
ingly and is now recognised as a major threat to global health.1,2 Antibiotic discovery had its heyday in the
1940s to 60s, which saw the discovery of many new classes of antibiotic. Since then, the rate of discovery of new
classes has slowed, and resistance to existing treatments has increased.
The story of how Alexander Fleming discovered penicillin by accidentally allowing a Petri dish containing
Staphylococcus aureus to become contaminated with Penicillium mould whilst he was on holiday in Suffolk1 is
well known to many scientists. The initial serendipitous discovery of penicillin occurred in 1928 and was reported
in 1929,3 but it was not until 1943 that the drug was mass produced thanks to the research of Ernst Chain
and Howard Florey. Unfortunately, bacterial resistance to penicillin was being found in hospitals by the late
1940s.4,5 This alarmingly quick emergence of resistance is a common phenomenon for antibiotics (see Table 1)
as bacteria have multiple resistance mechanisms against antibacterial agents. These mechanisms can be broken
down into five main categories:1,6
1. The bacterium may inactivate the drug before it can cause damage, for example the hydrolysis of β-lactam
antibiotics such as penicillin by β-lactamase enzymes.
2. The bacterium may produce a membrane, cell wall or biofilm which does not allow the drug to pass
through. For example, biofilm formation may allow bacterial resistance to antibiotics to increase 1000-fold
compared with bacteria in suspension culture.7
3. The bacterium may pump antibacterial molecules out of its cell membrane using eﬄux pumps, for example
the MexAB and MexXY pumps used by Pseudomonas aeruginosa.8
4. Mutations may cause the target of the antibacterial molecule to alter such that the molecule no longer
effectively binds the target, for example the alteration of penicillin binding proteins which are involved
in the final stages of peptidoglycan biosynthesis in the cell walls of MRSA and other penicillin-resistant
bacteria.9
5. The bacterium may switch to using a metabolic pathway which does not involve the target of the anti-
bacterial molecule, for example sulfonamide resistance may be achieved by taking in folic acid from the
environment rather than synthesising it using para-aminobenzoic acid - a process which is blocked by
sulfonamides.10
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Antibiotic Introduction Resistance
Sulfonamides 1930s 1940s
Penicillin 1943 1946
Streptomycin 1943 1959
Chloramphenicol 1947 1959
Tetracycline 1948 1953
Erythromycin 1952 1988
Vancomycin 1956 1988
Methicillin 1960 1961
Ampicillin 1961 1973
Trimethoprim 1962 1972
Cephalosporins 1960s late 1960s
Ciprofloxacin 1987 1988
Linezolid 2000 1997*
Daptomycin 2003 2005
Table 1: A timeline of when various antibiotics were first introduced and when resistance to them first ap-
peared.11–16 *Resistance was seen during a compassionate-use program before the drug was widely released.15
The current pipeline of new antibiotics is widely thought to be worryingly inadequate.17–19 Significant
changes in how we use the antibiotics we already have, as well as investments in the discovery of new ones, are
required. Antibiotics currently in late-stage clinical trials nearly all rely on non-novel mechanisms of action,17
and so it is almost inevitable that resistance to them will develop quickly, as it has done for their predecessors.
There is therefore increasing interest in treatments which would not easily provoke the development of resis-
tance.20 These treatments often target bacterial virulence rather than killing bacteria outright, hence decreasing
selection pressure for resistance.11 One obvious target is toxin production, for example, an LpxC inhibitor was
shown to prevent lethal Acinetobacter baumannii infection in mice, despite being inactive against the bacterium
in vitro.21 This was due to inhibition of lipopolysaccharide shedding, and hence reduced inflammation in the
host. Co-ordination of virulence has also been targeted, for example, analogues of P. aeruginosa homoserine
lactone (HSL) autoinducers (see 5.3.1) inhibit the production of virulence factors and increase the survival time
of mice in a lethal P. aeruginosa lung infection model.11
A second strategy in novel antibiotic discovery is to enhance or restore activity of a known antibiotic by
lessening or avoiding a resistance mechanism. For example, antibiotics are often excluded from cells due to
membrane impermeability or eﬄux. This may be overcome by attaching the antibiotic ‘warhead’ to a molecule
which the cell imports. The most well known example of this strategy is antibody-drug conjugates22 in the
treatment of cancer, but progress has also made against bacteria. In particular, siderophore-antibiotic conjugates
(see 5.2) have been investigated in the hope of hijacking bacterial uptake mechanisms to import antibiotics,23
and the autoinducer-antibiotic conjugates in this study may gain activity by avoiding eﬄux pumps (see 5.3).
These conjugates may have competing mechanisms of action: either the antibiotic accumulates in the cell to a
greater extent and acts by its usual mechanism, or an important bacterial system must be disrupted to avoid
accumulation of the antibiotic, hence leading to decreased fitness and/or loss of virulence.
5.2 Siderophore-antibiotic conjugates
Siderophore-antibiotic conjugates have been receiving attention in recent years as a way to enhance the uptake
of known antibiotics.23 This section will discuss the role of siderophores, sideromycins (natural siderophore-
antibiotic conjugates), and the synthetic siderophore-antibiotic conjugates inspired by them. Many of the ob-
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servations made about these molecules could be relevant to the autoinducer-antibiotic conjugates synthesised
in this study.
5.2.1 Siderophores
Siderophores are peptides or small molecules used by microorganisms to chelate iron for the purposes of ‘iron
mining’.24 Soluble iron is often scarce but it is crucial for many cellular processes including respiration and DNA
synthesis. Siderophores are synthesised by the microorganisms and secreted into the extracellular environment
where they bind to Fe3+, often with exceptionally high affinities. The iron-bound siderophores are then brought
back into the cell by active transport and the iron is released, either by reduction of the Fe3+ to Fe2+ or
by enzymatic degradation of the siderophore. Siderophores have a wide range of structures (see Figure 2 and
Figure 1), possibly so one species can avoid its siderophores being taken up by another species.25
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Figure 1: Iron-siderophore complexes: pyoverdine PaA 726,27 (P. aeruginosa, PAO1 strain) and pyochelin 828,29
(P. aeruginosa). Note that pyochelin 8 is a tetradentate ligand, hence the iron ion has two sites which can bind
other ligands.
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Figure 2: Iron-siderophore complexes: Deferoxamine B 126 (Streptomyces pilosus and Streptomyces coelicolor),
rhodotorulic acid 230 (Rhodotorula pilimanae), fusarinine C 331 (Fusarium roseum), enterobactin 426 (Es-
cherichia coli and enteric bacteria), ferrichrome 532 (Ustilago sphaerogena, U. maydis, Aspergillus niger, A.
quadricintus, A. duricaulis and Penicillium resticolosum), yersiniabactin 626 (Yersinia pestis).
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5.2.2 Sideromycins
Siderophore-antibiotic conjugates are produced naturally by some bacteria and are known as sideromycins23
(see Figure 3). Bacteria produce these molecules to attack other bacteria by hijacking their siderophore uptake
mechanisms to introduce toxic compounds.
For example, albomycin 9 (see Figure 3) is a sideromycin produced by Actinomyces subtropicus and Strep-
tomyces griseus33,34 which has been used to treat infections caused by various bacteria including Yersinia
enterocolitica and Streptococcus pneumoniae in mice and humans.35,36 Albomycin 9 contains a siderophore cou-
pled to a nuceloside antibiotic via a peptide linker. The siderophore section is structurally similar to ferrichrome
5 (see Figure 2), a siderophore produced by various fungi, but also taken up by bacteria including Escherichia
coli, Salmonella typhimurium and P. aeruginosa.32,37 It has been shown that because of the structural similarity
to ferrichrome 5, E. coli will also take up albomycin 9.33 The linker is hydrolysed in the cytoplasm of the E.
coli, releasing the active nuceloside antibiotic. This leads to 500-fold concentration of the antibiotic within the
E. coli cells, enough to have significant effect on growth.
The success of albomycin35 and other sideromycins such as salmycin A24,38,39 and ferrimycin A140,41 has
served as encouragement to many researchers to explore synthetic siderophore-antibiotic conjugates, which will
be discussed in the next section.
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Figure 3: Iron-sideromycin complexes: Albomycin 924,42 (Actinomyces subtropicus and Streptomyces griseus),
salmycin A24,38,39 (Streptomyces violaceus) and ferrimycin24 (Streptomyces griseoflavus).
5.2.3 Synthetic siderophore-antibiotic conjugates
Sideromycins served as inspiration for the design, synthesis and biological evaluation of a wide range of synthetic
siderophore-antibiotic conjugates.23 Antibiotics used include β-lactams,43–45 nucleosides,46 glycopeptides47 and
macrolides.48 Sideromycin-fluoroquinolone conjugates have also been studied by several groups,49–51 including
conjugates with linkers which can be cleaved50,51 in a similar manner to albomycin.33 Some of these showed
comparable activity to the parent antibiotic, but it is not clear whether attachment of the siderophore improved
uptake or whether the conjugates acted as classical prodrugs.
β-lactam-sideromycin conjugates have been more widely investigated and show good activity in vitro How-
ever, resistance can evolve by loss of the TonB transporter or of the relevant siderophore receptor, e.g. Cir and
Fiu for catecholate siderophores or FhuA for hydroxamate siderophores.23 Recently a conjugate (Ent-Amp 12,
see Figure 4) of enterobactin and ampicillin joined using a copper(I)-catalyzed azide-alkyne cycloaddition has
been shown to have increased activity against pathogenic E. coli when compared to native ampicillin.52 Other
20
work has focused on monocyclic β-lactams, for example pirazmonam 13 and U-78608 14, which show high
potency against Gram-negative bacteria including P. aeruginosa,53,54 Monocyclic β-lactams are generally fairly
stable to β-lactamase activity, which is an advantage compared with many bicyclic β-lactams.
Three siderophore-antibiotic conjugates are reported as being in clinical trials:55 MC-1 15,56 BAL30072 1623
(see Figure 4) and cefiderocol 17.57,58
MC-1 15 is reported as being ‘in clinical phases of development’,55 but no reports of studies in humans
could be found. However, experiments in mice have been promising.56 BAL30072 16 is a siderophore-β-lactam
conjugate which showed initial promise as it is a poor substrate for β-lactamases, and resistance due to loss of
transport proteins is infrequent.23 However, it is unclear whether it will progress further in trials as it causes
liver toxicity.59 Cefiderocol 17 is a cephalosporin-catechol conjugate in phase 1 trials. Recent results indicate
that ‘single and 35 multiple intravenous doses of cefiderocol at up to 2000 mg were well tolerated in healthy 36
subjects’.58
These examples show that siderophore-antibiotic conjugates are a promising strategy to deliver antibiotics
across bacterial membranes, but it is worth noting that conjugation to a siderophore may lead to loss of activity,
or resistance may be acquired by loss of transport proteins. Encouragingly though, albomycin 9-resistant mutants
have been shown to be less virulent,36 indicating that bacteria may lose out either by susceptibility to the
antibiotic or by loss of fitness due to decreased iron transport.
Building on these positive examples, it is hoped that the strategy of conjugating a molecule which is im-
portant for virulence60 with an antibiotic can be extended to conjugates of autoinducers and antibiotics in a
similar ‘Trojan horse’ approach.
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Figure 4: Examples of siderophore-antibiotic conjugates: Ent-Amp 12,52 pirazmonam 13,53,54 U-78608 14,53,54
MC-1 15,56 BAL30072 1623 and cefiderocol 17.57,58
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5.3 Autoinducer-antibiotic conjugates
This study extends the conjugation strategy discussed above by creating autoinducer-antibiotic conjugates. It
was hypothesised that attaching an autoinducer to a known antibiotic could lead to increased cellular retention
of the antibiotic, and could potentially restore function against resistant strains. This is thought to be the first
large study of autoinducer-antibiotic conjugates, with only one such molecule having been reported previously61
(see 5.3.8). This section begins by introducing the concept of quorum sensing, followed by discussion of the
autoinducers and antibiotics used in this study and the mechanisms of their eﬄux from P. aeruginosa cells, and
how these mechanisms could be exploited by conjugates.
5.3.1 Quorum sensing
A quorum is defined as ‘A fixed minimum number of members of an assembly or society that must be present
at any of its meetings to make the proceedings of that meeting valid.’62 A similar concept is used in bacte-
rial signalling, whereby group behaviour is only triggered when a certain minimum concentration of bacteria
has been reached. Examples of group behaviour include bioluminescence, the production of virulence factors,
swarming and biofilm formation.63 It is advantageous for bacteria to coordinate such behaviours as they would
be ineffective, and therefore a waste of resources, when carried out by a single bacterium. The process by which
bacteria determine the concentration of similar bacteria in their vicinity, and act on that information, is known
as quorum sensing.
Quorum sensing has been observed in many species of bacteria, including Vibrio fischeri, P. aeruginosa,
Agrobacterium tumefaciens, Erwinia carotovora, Streptococcus pneumoniae, Bacillus subtilis, S. aureus, V. har-
veyi, Escherichia coli, Myxococcus xanthus, Salmonella enterica, Yersinia enterocolitica, Aeromonas spp. and
Acinetobacter spp.63–72 Many of these bacteria are significant causes of disease and death in humans, for ex-
ample, in a typical year in the U.S. P. aeruginosa causes 6,700 multidrug-resistant infections and 440 deaths,
methicillin-resistant S. aureus causes 80,500 severe infections and 11,300 deaths and non-typhoidal Salmonella
causes 1.2 million illnesses, 23,000 hospitalisations and 450 deaths.2
5.3.1.1 Vibrio fischeri
The first example of quorum sensing was discovered in V. fischeri, a symbiotic bacterium that produces bio-
luminescence in the photophore of the Hawaiian bobtail squid, Euprymna scolopes63,71,72 (see Figure 5). This
bacterium receives amino acids73,74 from its host in exchange for producing light which the squid uses for
counterillumination, to camouflage itself.75
If a low population of V. fischeri were present in the photophore, the light that the bacteria could produce
would be insufficient to provide counterillumination. Therefore, the bacteria conserve resources by not producing
light. However, if there is a high population of V. fischeri it is useful for them all to produce light, as this
incentives the squid to provide them with nutrients.
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Figure 5: ‘Euprymna scolopes, South shore of Oahu, Hawaii’ by Jamie Foster. Licensed under CC BY-SA 3.0
via Commons.
V. fischeri uses the LuxR-LuxI system to sense cell density. This system is seen as a paradigm of quorum
sensing, and a simplified explanation of it is presented to show typical features of such a system (see Figure 6).
Figure 6: The LuxR-LuxI quorum sensing system in V. fischeri.
V. fischeri senses cell concentration by the detection of 3-oxo-C6-HSL 1876 (see Figure 7), a freely diffusible77
molecule which is synthesised by LuxI78,79 and secreted by all V. fischeri cells80 at a low basal level.63 When
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the bacterial population density, and hence the concentration of 3-oxo-C6-HSL 18, reaches a threshold, 3-oxo-
C6-HSL 18 binds to LuxR,81–83 a receptor which is also synthesised at a low basal level.
PSfrag replacements
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Figure 7: 3-oxo-C6-HSL 18.
The LuxR complex binds to the lux operator, upregulating production of LuxI and hence 3-oxo-C6-HSL 18,
and luciferase enzymes and hence blue-green light.84–86 Production of more 3-oxo-C6-HSL 18 enables a positive
feedback loop, reinforcing the effect of high population density on 3-oxo-C6-HSL 18 concentration and hence
light production. This is the reason that 3-oxo-C6-HSL 18 is known as an autoinducer.
The system also contains a negatively feedback loop to avoid excessive expression of proteins: at high con-
centrations of 3-oxo-C6-HSL 18 production of LuxR is inhibited.87 Such balancing effects, as well as interactions
with other quorum sensing and metabolic systems, are seen in many bacteria.63,88
5.3.1.2 Pseudomonas aeruginosa
Another well-studied example of quorum sensing is in P. aeruginosa.88–90 P. aeruginosa is a Gram-negative op-
portunistic pathogen which typically infects immunocompromised individuals such as those with cystic fibrosis,
neutropenia and AIDS. It can infect the pulmonary and urinary tracts as well being the most frequent cause
of burn wound infections and the most frequent conloniser of medical devices such as catheters.91 Multidrug-
resistant P. aeruginosa is classified as a ‘serious threat’ by the United States Centers for Disease Control and
Prevention2 and carbapenem-resistant P. aeruginosa is classified as ‘priority 1: critical’ by the World Health
Organisation.18
P. aeruginosa has a low susceptibility to many antibiotics and readily acquires antibiotic resistance by
mutation or horizontal gene transfer.92 It is difficult for antibiotics to cross into cells due to low cell membrane
permeability,93 and they are pumped out again by its multiple chromosomally encoded multidrug eﬄux pumps.8
P. aeruginosa also forms biofilms: colonies of microbes held together and protected by a matrix containing
polysaccharides, proteins and DNA. Bacteria are usually studied in the planktonic state, where they are present
as free-floating cells which are often more metabolically active. However, the study of bacteria in biofilms is
important due to their importance in chronic infections and the colonisation of implanted medical devices.7,94 P.
aeruginosa biofilms are more resistant to many drugs including ciprofloxacin 24 and trimethoprim 25 compared
with planktonic cells.95,96 This high level of antibiotic resistance makes P. aeruginosa an important target for
drug discovery.
Quorum sensing in P. aeruginosa involves a complex interplay of five signalling molecules (see Figure 8) and
various proteins (see Figure 9).88–90 These can be broken down into three main, interacting systems: Las, Rhl
and Pqs.
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Figure 8: P. aeruginosa autoinducers.
In the Las system, LasI97 synthesises the 3-oxo-C12-HSL 2098 autoinducer. 3-oxo-C12-HSL 20 binds LasR,99
and this complex upregulates the production of LasI100 (thus causing autoinduction) as well as alkaline pro-
tease,101 elastase,99 exotoxin A,101 HCN102 and LasA protease.103 The LasR complex is also important in
late-stage biofilm formation,68 and upregulates the Rhl104 and Pqs systems.105,106
In the Rhl system, RhlI107 synthesises the C4-HSL 19108 autoinducer. C4-HSL 19 binds RhlR,109 and this
complex upregulates the production of RhlI100 (again causing autoinduction), alkaline protease,110 elastase,107
haemolysin,110 HCN,102,110 LasA protease,107 LecA,111 pyocyanin107,110 and rhamnolipids.107 The RhlR com-
plex also downregulates the Pqs system.106,112 The Rhl system is controlled by both the Las and Pqs systems,
as production of both RhlR and RhlI is upregulated by the LasR complex104 and production of both RhlR is
upregulated by the PqsR complex.113
In the Pqs system, the main autoinducer, PQS 22,114 is synthesised by multiple enzymes: PhnAB,115 PqsA,
PqsBC, PqsD116,117 and PqsE118,119 produce the precursor HHQ 21, and PqsH converts HHQ 21 to PQS 22.
PQS 22106 or HHQ 21 binds PqsR,120 and either complex can upregulate the synthesis of HHQ 21 causing au-
toinduction. The PqsR-PQS complex upregulates the production of chitinase,121 elastase,114 HCN,121 LecA,122
pyocyanin105,123 and pyoverdine,123 as well as increasing biofilm production122 and vesicle formation.124 The
PqsR-PQS complex also upregulates production of RhlR, so the Pqs system has control over the Rhl system.113
The Pqs system is controlled by both the Las and Rhl systems, as production of PqsR106 and PqsH105 is up-
regulated by the LasR complex and production of PqsA, PqsBC, PqsD, PqsE112 and PqsR106 is downregulated
by the RhlR complex.
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Figure 9: Quorum sensing in P. aeruginosa.88–90
In addition to the above systems, AI-2 (see Figure 8), an interspecies signalling molecule,125 is known to
increase biofilm production and virulence in P. aeruginosa.126,127 This is thought to be achieved by interaction
with the Las and Rhl systems, but the exact mechanism is not known.
In summary, P. aeruginosa uses the autoinducers shown in Figure 8 as part of three interacting quorum
sensing systems to coordinate virulence and biofilm production, and this makes these autoinducers interesting
therapeutic targets.
5.3.2 Autoinducers
Quorum sensing has been sucessfully targeted using many different modulators,89,128 but this study takes
a slightly different approach. Inspired by the success of various siderophore-antibiotic conjugates (see 5.2.3),
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a library of autoinducer-antibiotic conjugates was synthesised to test the hypothesis that the importance of
autoinducers in harmful cellular behaviours could lead to increased activity of the conjugates (see 5.3).
The P. aeruginosa autoinducers (see Figure 8) were chosen for use in this study as P. aeruginosa is a
significant human pathogen which shows high antibiotic resistance and utilises quorum sensing to coordinate
pathogenic behaviours (see 5.3.1.2). Specifically, C4-HSL 19, HHQ 21 and PQS 22 derivatives were chosen as
they were considered to be the most synthetically tractable.
5.3.3 Autoinducer eﬄux
Autoinducers must be exported from the cell in order to be used for intercellular communication, and the five
known P. aeruginosa autoinducers are exported by various different transport mechanisms. The mechanism is
not well known for HHQ 21 or AI-2 23, but it is know that PQS 22 is exported in vesicles,129 C4-HSL 19
passively diffuses in and out of cells,130 and 3-oxo-C12-HSL 20 is taken up passively, accumulates in the cell
membrane and is actively pumped out by eﬄux pumps. The difference in transport mechanism for C4-HSL 19
and 3-oxo-C12-HSL 20 is thought to be largely due to chain length rather than the 3-oxo modification, as a
shorter-chain version, 3-oxo-C6-HSL 18 has been shown to be freely diffusable through V. fischeri membranes.77
3-oxo-C12-HSL 20 is exported primarily via the MexAB-OprM eﬄux system.8,131 The increased removal
of 3-oxo-C12-HSL 20 from the cell by upregulation of the MexAB-OprM system leads to decreased production
of additional 3-oxo-C12-HSL 20 (as the positive feedback loop is disrupted, see 5.3.1.2), and hence decreased
production of pyocyanin, elastase and casein protease. It is expected that MexAB-OprM upregulation would
also disrupt biofilm formation as a decrease in 3-oxo-C12-HSL 20 levels would disrupt Las-mediated quorum
sensing,132 but no direct studies of this could be found.
5.3.4 Antibiotics
Ciprofloxacin 24 and trimethoprim 25 (see Figure 10) were chosen as the antibiotic sides of the conjugates.
Ciprofloxacin 24 is second-generation fluoroquinolone antibiotic used to treat both Gram-positive and Gram-
negative bacterial infections including P. aeruginosa.133,134 Ciprofloxacin 24 inhibits DNA replication by bind-
ing to DNA gyrase and topoisomerase IV.135
Trimethoprim 25 (see Figure 10) is a dihydrofolate reductase inhibitor used primarily to treat bladder
infections.136 It is active against several significant human pathogens including Streptococcus pneumoniae and
Haemophilus influenzae, but not against P. aeruginosa. It was primarily chosen in this study as it was considered
easy to functionalise, but also to test the feasibility of creating antibiotic activity against P. aeruginosa.
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Figure 10: The antibiotics used in this section.
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5.3.5 Antibiotic eﬄux
Ciprofloxacin 24 enters P. aeruginosa by diffusion,137 but is pumped out by eﬄux pumps.138 In the planktonic
state several eﬄux pumps are known to pump out ciprofloxacin 24, including MexAB–OprM, MexCD–OprJ,
MexEF–OprN, MexXY–OprM, MexJK–OprM and MexVW–OprM.8 However, in biofilms only MexEF-OprN
has an effect.139
Trimethoprim 25 is mainly exported by the MexAB–OprM,140 MexCD–OprJ141 and MexEF–OprN142 mul-
tidrug eﬄux systems8,143 in the planktonic state. It is not known which pumps are used to export trimethoprim
25 from biofilms, but biofilms do show increased resistance to it.96
5.3.6 Conjugate eﬄux and antibiotic action
There are two synergistic mechanisms by which the conjugates could disrupt P. aeruginosa growth:
1. P. aeruginosa could develop resistance to an autoinducer-antibiotic conjugate by upregulation of the
autoinducer’s export mechanism, but this would also lead to increased export of the native autoinducer,
thus disrupting the quorum sensing system and hence biofilm formation and virulence.88,131,132 For HSL
conjugates this would mean upregulation of the MexAB-OprM pump, as this is the pump used for export
of 3-oxo-C12-HSL 20.8,131 For PQS conjugates this would mean upregulation of vesicle formation.129
2. The autoinducer section could make the conjugate a poor substrate for the antibiotic section’s usual
eﬄux mechanism, leading to accumulation of the conjugate within cells and hence increased antibacterial
activity. For autoinducer-ciprofloxacin conjugates acting on planktonic P. aeruginosa this would mean the
conjugate being a poor substrate of the various eﬄux pumps listed in the previous section. For autoinducer-
ciprofloxacin conjugates acting on biofilms this would mean the conjugate being a poor substrate of
MexEF–OprN (the sole exporter of ciprofloxacin 24 in biofilms139 and not an exporter of HSLs 19 or 20,
or PQS 228). This mechanism could in principal work for trimethoprim 25 as well, but it is not known
which pumps are active against this antibiotic in biofilms.
It is worth noting that for either of these mechanisms we are primarily interested in the autoinducer’s
interaction with its import/export mechanism, rather than its receptor in the quorum sensing system. However,
binding to receptors could help retention within the cell, so either way it is important that both the autoinducer
and antibiotic sides of the conjugates closely resemble the unconjugated molecules. With this in mind, an
initial library was designed using a copper(I)-catalysed azide-alkyne cycloaddition reaction144,145 to join each
combination of autoinducer and antibiotic together, using relatively long linkers in order to stop one side
interferring with the binding of the other to its target protein.
5.3.7 Cleavable linkers
As part of the library, a set of cleavable HSL-Cip triazole conjugates was synthesised in collaboration with
Professor Eddy Sotelo. These were based on the cleavable pyochelin–norfloxacin conjugates synthesised by
Rivault et al.50 (see Figure 11). It was envisaged that the linker would be stable under the extracellular assay
conditions, but would be cleaved upon entry into the cell by intracellular esterases. It was hoped that the
attached HSLs would improve retention of the conjugate in cells.
29
SS
O N N
HOOH
N
H
O
N
O
N N
O O
OHF
O O
O
SS
O N N
HOOH
N
H
O
N
O
N N
O O
OHF
O O
O
PSfrag replacements
26
27
Figure 11: The cleavable pyochelin–norfloxacin conjugates synthesised by Rivault et al.50
The properties of similar linkers (see Figure 12, R = Me) were studied by Gogate et al., who found that they
were stable for more than 3 years under optimal conditions.146 The hydrolysis of a secondary amine prodrug is
dependent on ester hydrolysis rate, therefore the cleavage rate can be tuned by changing the R group between
the ester and amide.147 The N -(acetoxyethoxycarbonyl) (R = Me) linkers have been shown to be cleaved by
esterases at an enhanced rate compared to buffer, and thus show promise in prodrugs.148 It was therefore hoped
that they will allow intracellular release of the ciprofloxacin 24 payload from the conjugates in this study. Both
the N -(acetoxymethoxycarbonyl) (R = H) and N -(acetoxyethoxycarbonyl) (R = Me) were used, to investigate
whether differences in cleavage rate could tune activity.
NOO
OO R
Figure 12: The cleavable linkers investigated in this study.
5.3.8 Homoserine lactone analogue-ciprofloxacin conjugates
Following on from the library of compounds based on P. aeruginosa autoinducers, a series of conjugates based
on analogues of HSL were planned. This strategy was inspired by a paper61 and patent149 by Ganguly et al.,
who synthesised and characterised a conjugate 154 of methyl ciprofloxacin 151 with homocysteine thiolactone
(see Figure 13). Homocysteine thiolactone is an analogue of HSL with the ring oxygen replaced by sulfur, and
has been used as the head group in several other known quorum sensing modulators.80,150–156
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Figure 13: The HCTL-CipMe conjugate 154 studied by Ganguly et al.61,149
As part of their characterisation of the HCTL-CipMe conjugate 154, Ganguly et al. found the minimum
inhibitory concentration (MIC) of the conjugate in P. aeruginosa under standard planktonic conditions. The
MIC was found to be ten times higher for the conjugate vs. ciprofloxacin 24 (50 vs. 5 µm), indicating that the
conjgate was less effective than ciprofloxacin 24 under planktonic conditions.
Ganguly et al. then investigated the effect of the conjugate on biofilms. The conjugate 154 and ciprofloxacin
24 were first added to dilute P. aeruginosa liquid culture at 25 µm. As expected, the culture failed to grow
and form biofilm in the presence of ciprofloxacin 24, but did grow in the presence of the conjugate 154. They
then incubated cultures for 24 h, to allow biofilms to grow, before adding the compounds. In contrast, they
found that the conjugate 154 disrupted the biofilm more effectively than ciprofloxacin 24. When the biofilm
was grown for 48 or 72 hours the conjugate had similarly disruptive effects, whereas ciprofloxacin 24 ‘did not
show any significant antibacterial activity’.
These results are exciting as they hint that an autoinducer conjugate might be able to combat an estab-
lished P. aeruginosa infection more effectively than the unmodified antibiotic. Ganguly et al. suggest that their
conjugate 154 is more effective than ciprofloxacin 24 in penetrating biofilms, and/or better at avoiding being
pumped out by multidrug eﬄux pumps. They posit that this could be due to the thiolactone head, as they
also showed that unconjugated C4-HCTL 28 (see Figure 14) has ‘either enhanced uptake or functional activity’
when compared with C4-HSL 19.
It is possible that the conjugate 154 has higher activity against biofilms when compared with ciprofloxacin
24 because the conjugate 154 avoids being pumped out by multidrug eﬄux pumps, or selects for the survival
of mutants with upregulated eﬄux pumps, and hence disrupts quorum sensing systems (see 5.3.6).
While one might expect the conjugate 154 to behave like C4-HSL 19, and hence passively diffuse in and out
of cells, it is possible that its transport more closely resembles that of 3-oxo-C12-HSL 20. 3-oxo-C12-HSL 20’s
accumulation in membranes and interaction with eﬄux pumps is thought to be based primarily on tail chain
length (see 5.3.3), and the ciprofloxacin half of the conjugate 154 could be seen as a long tail, especially as the
carboxylic acid is methylated and hence less polar.
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Figure 14: C4-HSL 19 and C4-HCTL 28. Note that Ganguly et al. tested the S enantiomer of C4-HCTL 28,
but used a racemic mixture in their HCTL-CipMe conjugate.
While the results found by Ganguly et al. show promise, they only test one conjugate, and do not include
controls to show that the HCTL group specifically is necessary for the enhanced effect. It was therefore decided
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to build on this work by synthesising a series of ciprofloxacin conjugates with head groups taken from known
quorum sensing modulators,128,157 a selection of which are described in Table 2.
Head group
O O
8
O
S
O
H
N
Partial agonist and antagonist
against LasR.154 Shown to in-
crease biofilm formation in P.
aeruginosa.61
Strong agonist against LasR, with
comparable activity to the native
ligand.151,152,154,158
H
NO
Partial agonist against LasR.157 Strong antagonist against LasR.157
OH
H
N
Poor agonist and antagonist against
RhlR.159,160
Strong antagonist against LasR.159
O
H
N
Strong agonist against RhlR.159 SS
enantiomer is more potent.160
Partial agonist against LasR.159
OH H
N
Strong agonist against RhlR.159 SS
enantiomer is more potent, with
comparable activity to the native
ligand.160
Strong agonist against LasR.152,159
SS enantiomer is more potent, with
comparable activity to the native
ligand.160
O H
N
Strong agonist against RhlR.159 SS
enantiomer is more potent.160
Partial antagonist against LasR.159
Shown to reduce biofilm formation
in P. aeruginosa.159
Table 2: Activities of quorum sensing modulators containing the head groups used in this study.
6 Project aims and summary
The aim of this project is to produce and test a library of autoinducer-antibiotic conjugates with the goal
of producing conjugates with greater potency than the parent antibiotics. The work is divided into two main
sections. Section 7 focuses on conjugates of three P. aeruginosa autoinducers (see Figure 8) with ciprofloxacin
24 and trimethoprim 25 (see Figure 10) joined using a copper(I)-catalyzed azide-alkyne cycloaddition. Section 8
focuses on conjugates of HSL analogues with ciprofloxacin 24 (see 5.3.8) joined either using a copper(I)-catalyzed
azide-alkyne cycloaddition or an SN2 reaction or peptide coupling.
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7 Results and discussion: autoinducer-antibiotic conjugates
7.1 Overview
The first part of this project was focused on producing a library of autoinducer-antibiotic conjugates. P. aerugi-
nosa autoinducers were used, in particular C4-HSL 19, HHQ 21 and PQS 22 (see Figure 8). Azido derivatives of
these compounds were coupled to alkynyl dervitatives of antibiotics, specifically ciprofloxacin 24 and trimetho-
prim 25 (see Figure 10), using a copper(I)-catalysed azide-alkyne cycloaddition.144,145 The compounds were
then tested for antibiotic and anti-biofilm activity against P. aeruginosa. The decisions on where to attach the
azide or alkyne handles to the chosen molecules are discussed below.
7.1.1 Azido autoinducer derivatives
The structure-activity relationships in HHQ 21 and PQS 22 have been previously studied,161–163 and it was
shown various substitutions on the benzene ring could be made without significantly decreasing activity. The
6-azido derivatives (see Figure 15) were chosen for this study as routes to them have previously been found.164
PSfrag replacements
38
49 Figure 15: The azido derivatives of HHQ 21 and PQS 22: 38 and 49.
Alteration of the lactone group of HSL derivatives is known to significantly decrease activity, especially
where the number of H-bond donors or acceptors is altered.128 Hence, the azide group was included on the
tail.165 Acyl tail length is known to play an important role in affinity,128 so three derivatives of C4-HSL 19 were
synthesised: N3-C2-HSL 55, N3-C4-HSL 58 and N3-C6-HSL 61 (see Figure 16).
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Figure 16: The azido derivatives of C4-HSL 19: 55, 58 and 61.
7.1.2 Alkynyl antibiotic derivatives
The structure-activity relationships for ciprofloxacin 24 have been investigated166 and modifications at the
cyclopropane and piperazine groups were found not to cause loss of activity. It was decided an alkyne tail would
be added onto the free NH of the piperazine ring, as this position is more synthetically accessible. Alkynyl
ciprofloxacin derivative 68 (see Figure 17) was synthesised in this study (see 7.3.1), and two cleavable alkynyl
ciprofloxacin derivatives 90 and 91 were synthesised by Professor Eddy Sotelo and combined with the azido
HSL derivatives described above to create cleavable conjugates (see 7.4.3).
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Figure 17: The alkynyl ciprofloxacin derivatives 68, 90 and 91.
The choice to of alkyne tail attachment point on trimethoprin 25 (see Figure 18) is based on the use of that
same point in a fluorogenic trimethoprim tag synthesised by Jing et al.167
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Figure 18: The alkynyl trimethoprim derivative 71.
7.1.3 Synthesis of the conjugates
A copper(I)-catalysed azide-alkyne cycloaddition144,145 was used to join each combination of autoinducer and
antibiotic together (see Scheme 1).
Antibiotic
N N
N
Autoinducer
Antibiotic
Autoinducer
N3 +
Scheme 1: The construction of the triazole-linked autoinducer-antibiotic conjugate library using a copper(I)-
catalysed azide-alkyne cycloaddition.
7.2 Synthesis of the azido autoinducer derivatives
7.2.1 Synthesis of 6-N3-HHQ 38
The synthesis of 6-N3-HHQ 38 is shown in Scheme 2 and follows a route devised by Baker.164 Octanoyl chloride
32 was converted to β-ketoester 33 via a Meldrum’s acid adduct.168,169 The β-ketoester 33 was condensed with
N -Boc-para-phenylenediamine 35 to form enamine 36. The disappointing yield of this step was in part due to
the reaction proceeding to an equilibrium state rather than to completion, and hence not all of the starting
material being consumed; starting materials can be recycled to improve the yield. Alternatively, Baker later
found a higher-yielding reaction using a ZrCl4 catalyst.164
The enamine 36 was cyclised with polyphosphoric acid to form amino-HHQ 37 in good yield. The amine
group of amino-HHQ 37 was converted to a diazo group by reaction with NaNO2 and HCl, followed by dis-
placement with NaN3 to form the final azido-HHQ product 38.170
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Scheme 2: The synthesis of 38. a) i) Pyridine, CH2Cl2, 0 ◦C. ii) MeOH, reflux, 66% over two steps. b) MeOH,
reflux, 19%. c) Polyphosphoric acid, 120 ◦C, 72%. d) i) NaNO2, HCl, water, 0 ◦C. ii) NaN3, water, r.t., 41%.
7.2.2 Synthesis of 6-N3-PQS 49
The synthesis of 6-N3-PQS 49 is shown in Scheme 3, and also follows a route devised by Baker.164The Weinreb
amide 4389 was prepared from chloroacetyl chloride, followed by attack with heptyl magnesium bromide 40 to
form 1-chlorononan-2-one 44 following a procedure described by Hodgkinson et al.171
The synthesis of PQS 22 described by Hodgkinson et al.171 used a microwave reaction of 1-chlorononan-2-one
44 with anthranilic acid. It was hoped that the azide group could be installed by using 5-nitroanthranilic acid
45 in the place of anthranilic acid in this microwave reaction, so that the nitro group could then be converted
to an azide group via an amine. However, the microwave-catalysed reaction failed when 5-nitroanthranilic acid
45 was used.164 Therefore, a two step process was employed instead.
5-Nitroanthranilic acid 45 was heated with K2CO3 to deprotonate the carboxylic acid, followed by addition
of 1-chlorononan-2-one 44 to form the ester 46 by SN2 displacement of the chlorine atom in a procedure adapted
from Hlavác˘ et al.172 Cyclisation with polyphosphoric acid produced nitro-PQS 47 cleanly.172,173
Conditions for the reduction of the nitro group were then compared (see Table 3). Baker initially used Zn
and HCl, however this gave a yield over 100% suggesting coordination of Zn to the amino-PQS 48164 (this
product was taken through and purified after the next step). She also attempted reduction with Pd/C and H2
or ammonium formate, but no reaction was observed.
Further conditions were tested in this work in order to obtain a clean sample of amino-PQS 48. An initial
test of reduction with SnCl2 produced no detectable product by LCMS. Catalytic hydrogenation using harsher
conditions was then attempted, and it was determined that increasing the pressure to 3 atm using a Paar
hydrogenator causes full conversion in 4 h using Pd/C and H2. Good yields (80%) were also achieved using
PtO2 as a catalyst, with the advantage that the reaction proceeds more quickly, and at atmospheric pressure
and temperature.174
Finally, amino-PQS 48 was converted to azido-PQS 49 by reaction with NaNO2 and HCl to form diazo-
PQS, followed by displacement of the diazo group using NaN3 to give the azido-PQS 49.170 The yield of this
reaction was rather disappointing (28%), and is probably due to loss of product in the supernatant following
precipitation.164
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Conditions Outcome
H2, Pd/C, 1 atm, r.t., 18 h No reaction
NH4HCO2, Pd/C, 1 atm, r.t., 18 h No reaction
Zn, HCl (aq), r.t., 5 min h Product 48 + Zn, assumed quantitative yield
SnCl2 · 2H2O, MeOH, r.t., 18 h No reaction
H2, Pd/C, MeOH, 3 atm, r.t., 4 h. Product 48, >99% yield
H2, PtO2, MeOH, 1 atm, r.t., 45 min Product 48, 80% yield
Table 3: Conditions attempted for the synthesis of 48. Rows 1-3 were carried out by Baker,164 rows 4-6 were
carried out as part of this study.
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Scheme 3: The synthesis of 49. a) Mg turnings, THF, r.t., 2 h then reflux, 2 h. b) N,O-dimethylhydroxyl amine
hydrochloride, K2CO3, toluene, water, - 5 ◦C to r.t., 30 min, 71%. c) THF, 0 ◦C to r.t., 15 h, 96%. d) 45,
K2CO3, DMF, 90 ◦C, 1 h, then 44, r.t., 18 h, >99%. e) Polyphosphoric acid, 90 ◦C, 5.5 h, 40%. f) H2, PtO2,
MeOH, 1 atm, r.t., 45 min, 80%. g) i) NaNO2, HCl, water, 0 ◦C, 50 min. ii) NaN3, water, r.t., 4 h, 28% over
two steps.
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7.2.3 Synthesis of the azido C4-HSL derivatives 55, 58 and 61
N3-C2-HSL 55 (the azido derivative of C4-HSL with a C2 chain, see Scheme 4) has previously been prepared by
Stacy et al.165 Their synthesis was followed, starting with the cyclisation of l-methionine 50 using bromoacetic
acid to form the HSL HBr salt 52. The disappointing yield can be attributed to difficulties in precipitating the
final product. The HSL HBr salt 52 was then converted by a biphasic one-pot process to N3-C2-HSL 55 using
bromoacetyl bromide 53 and NaN3.
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Scheme 4: The synthesis of 55. a) Bromoacetic acid, i-PrOH:water:AcOH (5:5:2), r.t., 18 h, 41%. b) NaN3,
NaHCO3, water/CH2Cl2, r.t., 18 h, 41%.
It was hoped that this procedure could also be used to produce the C4 and C6 derivatives, however, attempts
to convert HSL 50 to N3-C4-HSL 58 using 4-bromobutyryl chloride 56 produced a complex mixture of products.
This is likely to be because the SN2 reaction in which the azide anion displaces bromine is slower for the C4
derivative as the bromine atom being displaced is no longer adjacent to a carbonyl group. In addition, the longer
chain length allows intramolecular cyclisation of the bromide with the secondary amide. The conversion was
therefore carried out as a two-step process, where a bromoacyl chain was initially installed, followed by the SN2
reaction with NaN3 (see Scheme 5).
Reaction of the HSL HBr salt 52 with 4-bromobutyryl chloride 56 or 6-bromohexanoyl chloride 59 produced
Br-C4-HSL 57 or Br-C6-HSL 60 respectively, in good yields. Heating with NaN3 in DMF converted Br-C6-HSL
60 to N3-C6-HSL 61. Similar conditions were used by Dr Bin Yu, a visiting PhD student in the Spring group,
to convert the bromo-C4 derivative 57 to the azido-C4 derivative 58, and this compound was kindly donated to
complete the set. Yields for the SN2 reaction could probably be improved by decreasing the temperature (see
Scheme 22, for example).
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Scheme 5: The synthesis of 58 and 61. a) Bromoacetic acid, i-PrOH:water:AcOH (5:5:2), r.t, 18 h, 41%. b)
NaHCO3, water/CH2Cl2, r.t., 18 h, 57: 80%, 60: 66%. c) NaN3, DMF, 100 ◦C, 5 h, 61: 27% (donated by Dr
Bin Yu), 61: 56%.
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7.3 Synthesis of the alkynyl antibiotic derivatives
7.3.1 Synthesis of the alkynyl ciprofloxacin derivative 68
The retrosynthesis of ciprofloxacin derivative 68 is shown in Scheme 6. The disconnection to an alkynyl piper-
azine 68 and a commercially available ciprofloxacin precursor 67 was chosen based on a study by Renau et
al., who found this route to be “...superior to previous reports which involved alkylation of piperazine with an
appropriate alkyl halide.”166,175
It was envisaged that the alkynyl piperazine 68 could be prepared from mono-Boc-protected piperazine 64
and hex-5-ynal 63 using conditions similar to those used by Renau et al.166
Unlike the aldehydes and ketones used by Renau et al.,166 hex-5-ynal 63 is not commercially available and
so it was hoped that this could be prepared by oxidation of hex-5-ynol 62.
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Scheme 6: The retrosynthesis of 68.
The synthesis of ciprofloxacin derivative 68 is shown in Scheme 7. Hex-5-ynal 63 was prepared by pyridinium
chlorochromate oxidation of hex-5-ynol 62 in good yield according to the procedure described by Kocsis et al.176
Renau et al.166 used sodium cyanoborohydride to facilitate the reductive amination of hex-5-ynal 63 and
1-Boc-piperazine 64. However, it was decided to attempt this transformation using the less toxic sodium triace-
toxyborohydride following a procedure reported by Abdel-Magid et al.177 This reaction yielded compound 65
in excellent yield, which was deprotected using TFA using the procedure described by Renau et al.166 to give
the alkynyl piperazine 66 quantitatively.
The alkynyl piperazine 66 was refluxed in acetonitrile with the ciprofloxacin precursor 67 according to the
procedure described by Renau et al.,166 however the reaction did not proceed. Addition of 2 eq. of TEA did not
lead to reaction, however it was found that refluxing in neat TEA led to conversion to the final ciprofloxacin
derivative 68.
With a small sample of the final product in hand, less harsh conditions were sought for a larger-scale version
of the final reaction. Mircowave irradiation at 115 ◦C was used, following a procedure by Reddy et al.178 DMSO
and NMP were tested as solvents, with or without the addition of TEA. The reactions were monitored using
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LCMS, and NMP without TEA was found to give the highest conversion.
Work-up of this reaction proved challenging, with an unknown dark brown viscous liquid being formed which
was difficult to separate from the white solid product. A pure sample was obtained by recrystalisation from
EtOAc, but the yield was poor (12%). The reaction was observed to stall after a certain point, while still having
some of the ciprofloxacin precursor 67 present. The alkynyl piperazine 66 was not observed by TLC despite
having been added in two-fold excess, suggesting that it degraded to a by-product before having chance to react.
Further attempts to refine this reaction might involve lower temperatures, higher ratios of the alkynyl
piperazine 66 or improvement of the purification, e.g. by finding better precipitation conditions or by using
reverse-phase chromatography. A Buchwald-Hartwig coupling or Ullmann reaction could also be attempted,
but, as seen later, coordination of ciprofloxacin 24 to Cu can hinder catalysis.
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Scheme 7: The synthesis of 68. a) Pyridinium chlorochromate, CH2Cl2, r.t., 5 h, 72%. b) NaBH(AcO)3, 1,2-
dichloroethane, r.t., 10.5 h, 99%. c) TFA, r.t., 1 h, >99%. d) NMP, microwave, 115 ◦C 24 h, 12%.
7.3.2 Synthesis of the alkynyl trimethoprim derivative 71
The synthesis of trimethoprim derivative 71 is shown in Scheme 8. Trimethoprim 25 was selectively deprotected
using HBr (aq.) using a procedure described by Jing et al.167 to form 69. A slightly longer reaction time (40
min vs 20 min) probably led to the yield being somewhat lower than that obtained by Jing et al.. The main
impurity was asymmetrically di-demethylated trimethoprim, which could be identified by the presence of two
aryl peaks at 6.41 (d, J=2.0 Hz, 1 H) and 6.34 (d, J=2.0 Hz, 1 H) and a corresponding methyl peak at 3.82 (s,
3 H) in the crude NMR.
The alkynyl trimethoprim derivative 71 was synthesised from the demethylated trimethoprim 69 and 6-
chloro-1-hexyne 70 using a Cs2CO3-catalysed SN2 reaction similar to that used by Jing et al.167
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Scheme 8: The synthesis of 71. a) HBr (aq.), 100 ◦C, 40 min, 43%. b) Cs2CO3, DMF, 70 ◦C, 7 h, 25%.
7.4 Synthesis of the triazole-linked autoinducer-antibiotic conjugates
7.4.1 Optimisation of the click reaction
Test reactions using N3-C2-HSL 55 and the alkynyl ciprofloxacin derivative 68 were performed to find conditions
for the click reactions between the azido autoinducers and the alkynyl antibiotics (see Table 4 and Scheme 9).
Stirring at r.t. had no effect even with an extended reaction time. Heating to 50 ◦C did lead to slow formation
of the product, but a mixture of the 1,4 72 and 1,5 73 isomers was observed in an approximately 4:1 ratio by
LCMS (see Figure 20). It is possible that the Cu(I) catalyst was not involved in this reaction because it had
been oxidised, and hence the mixture of products was formed by an uncatalysed cycloaddition. Such reactions
are known to produce a mixture of products.145
Use of the ligand tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) 74 (see Figure 19) led to some con-
version at room temperature (seen by LCMS), however the reaction stopped before completion, probably due
to oxidation of the Cu(I) catalytic species. When degassed solvent and an argon atmosphere were used the
reaction proceeded to completion at room temperature in around 3 h.
Conditions Outcome
CuSO4 · 5H2O, sodium ascor-
bate, water, t-BuOH, air, r.t., 7
d.
No reaction
CuSO4 · 5H2O, sodium ascor-
bate, water, t-BuOH, air, 50 ◦C,
5 d.
1,3-Triazole product 72 and 1,5
triazole impurity 73 4:1
CuSO4 · 5H2O, sodium ascor-
bate, THPTA 74, water, t-
BuOH, air, r.t., 3 h.
1,3-Triazole product 72 and
starting materials 55 and 68
5:4:4
CuSO4 · 5H2O, sodium ascor-
bate, THPTA 74, water, t-
BuOH, Ar, r.t., 3 h.
1,3-Triazole product 72, 30%
yield
Table 4: Conditions attempted for the synthesis of 72 (see Scheme 9).
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Scheme 9: Synthesis of 72. For conditions see Table 4.
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Figure 19: Tris[(1-benzyl-1H -1,2,3-triazol-4-yl)methyl]amine (THPTA) 74 .
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Figure 20: 1,4 (left) and 1,5 (right) triazoles.
7.4.2 Synthesis of the autoinducer-ciprofloxacin and autoinducer-trimethoprim triazole conju-
gates
Once conditions had been found for the click reaction, the synthesis of other conjugates was attempted. Two
additional azides were kindly donated by members of the Spring group: the azido derivative of 3-oxo-C12-HSL
75 was synthesised by Ryan Howard, a master’s student under my supervision179 and the tail azide derivative
of PQS 76 was synthesised by Dr Ysobel Baker164 (see Figure 21).
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Figure 21: Further azido autoinducer derivatives synthesised by Howard179 75 and Baker164 76.
Synthesis of the conjugates proved more difficult than expected, for several reasons. Firstly some com-
pounds did not dissolve in the reaction solvent (50% water/t-BuOH) requiring addition of co-solvents such as
CH2Cl2. Secondly, some compounds were unstable: HSL derivatives hydrolysed upon attempted preparative
HPLC purification and the 3-oxo-C12-HSL conjugates degraded during the reaction. Finally, the reaction was
highly air-sensitive which led to stalling. The most reliable procedure was determined over the course of several
reactions, and is shown in 9.25.
Despite the unforeseen difficulties in synthesis of the conjugates enough material was successfully prepared
for biological testing. The results of the reactions are shown in Table 5, Table 6, Table 7 and Table 8. It was
intended that the failed reactions would be repeated, but as preliminary biological testing (see 7.5) proved
unpromising it was decided that attention should be focused elsewhere.
R2
N N
N
R1
R2
R1 N3
a)
+
Scheme 10: General scheme for the click reaction, where R1-N3 is an azido autoinducer derivative and R2-≡ is
an alkynyl antibiotic derivative a)CuSO4, sodium ascorbate, THPTA, water, t-BuOH.
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Starting
materials
Product Outcome Yield
55 and 68 N
N
N
O O
OHF
O
O
H
N
O N N
N 3
72
3 Reaction
complete by
LCMS in 3
h. Purified by
column chro-
matography
(SiO2, 0-20%
MeOH/CH2Cl2).
30%
58 and 68 N
N
N
O O
OHF
O
O
H
N
O N N
N3 3
77
3 Reaction
complete by
LCMS in 3
h. Purified by
column chro-
matography
(SiO2, 0-20%
MeOH/CH2Cl2).
47%
61 and 68 N
N
N
O O
OHF
O
O
H
N
O N N
N5 3
78
3 Reaction
complete by
LCMS in 3
h. Purified by
column chro-
matography
(SiO2, 0-20%
MeOH/CH2Cl2).
38%
75 and 68
O
O
O
H
N
O N N
N
N
N
N
O O
OHF
9 3
79
7 Reaction
complete by
LCMS in 3.5
h, but prod-
uct degraded
when subjected
to column
chromatogra-
phy (SiO2, 20%
MeOH/CH2Cl2).
Table 5: Click reactions attempted.
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Starting
materials
Product Outcome Yield
38 and 68
N
NN
H
N
O
3
6 N
N
N
O O
OHF
80
3 Reaction
complete by
LCMS in 1.5
h. Purified by
prep. HPLC.
27%
49 and 68
N
NN
H
N
O
3
6 N
N
N
O O
OHF
HO
81
7 Reaction
did not go
to comple-
tion (approx.
6:1 starting
material 68
to product
81 seen by
LCMS). At-
tempted purifi-
cation by prep.
HPLC but
unsuccessful.
76 and 68
OH
O
N
H N N
N5 3
N
N
N
O O
OHF
82
7 No reaction
seen by LCMS.
Table 6: Click reactions attempted.
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Starting
materials
Product Outcome Yield
55 and 71
O
O
H
N
O N N
N
N
N
NH2
NH2
O
O
O
3
83
7 Reaction
complete by
LCMS in 2 h,
but lactone
hydrolysed on
prep. HPLC
column.
58 and 71
O
O
H
N
O N N
N
N
N
NH2
NH2
O
O
O
33
84
3 Reaction
complete by
LCMS in 2
weeks (stalled).
Purified by
column chro-
matography
(SiO2, 20%
MeOH/CH2Cl2).
17%
61 and 71
O
O
H
N
O N N
N
N
N
NH2
NH2
O
O
O
35
85
3 Reaction
complete by
LCMS in 2
weeks (stalled).
Purified by
column chro-
matography
(SiO2, 20%
MeOH/CH2Cl2).
27%
75 and 71 O
O
O
H
N
O N N
N
N
N
NH2
NH2
O
O
O
9 3
86
7 Degraded
during reac-
tion.
Table 7: Click reactions attempted.
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Starting
materials
Product Outcome Yield
38 and 71 N
NN
H
N
O N
N
NH2
NH2
O
O
O
3
6
87
3 Reaction
complete by
LCMS in 1.5
h. Purified by
prep. HPLC.
41%
49 and 71 N
NN
H
N
O
HO
N
N
NH2
NH2
O
O
O
3
6
88
7 Reaction
did not go
to comple-
tion (approx.
10:1 start-
ing material
71 to prod-
uct 88 seen
by LCMS).
Attempted
purification by
prep. HPLC
but unsuccess-
ful.
76 and 71
OH
O
N
H N N
N
N
N
NH2
NH2
O
O
O
5 3
89
3 Reaction
complete by
LCMS in 3
h. Purified
by column
chromatogra-
phy (SiO2, 20%
MeOH/CH2Cl2).
18%
Table 8: Click reactions attempted.
7.4.3 Synthesis of the homoserine lactone-ciprofloxacin triazole conjugates with cleavable linkers
In addition to the conjugates shown in the previous section, a further collection was synthesised in collaboration
with Professor Eddy Sotelo, a visiting researcher in the Spring group. Professor Sotelo synthesised two alkyne-
linked ciprofloxacin derivatives 90 and 91 (see Figure 22), both with cleavable linkers (see 5.3.7).
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Figure 22: The cleavable alkyne-Cip derivatives synthesised by Professor Sotelo.
Professor Sotelo then performed click reactions using the AHL azide derivatives 55, 58 and 61 synthesised
in 7.2.3 to form a new set of conjugates to add to the library (see Figure 23). It was hoped that these conjugates
would enter the cell and then be cleaved by esterases to release ciprofloxcin (see 5.3.7).
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Figure 23: The cleavable HSL-Cip triazole conjugates synthesised by Professor Sotelo.
Two control compounds 98 and 99 with benzyl head groups were also produced by Professor Sotelo (see
Figure 24). It was hoped that these would show whether the AHL head group is required for activity.
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Figure 24: The cleavable Bn-Cip triazole conjugates 98 and 99 synthesised by Professor Sotelo.
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7.5 Biological testing
7.5.1 Autoinducer-antibiotic conjugates
The eight triazoles made in 7.4 (see Figure 25) were tested for antibacterial and anti-biofilm activity in P.
aeruginosa PAO1180 and YM64.181 PAO1 is the P. aeruginosa wild-type strain. YM64 is a mutant lacking all of
the four major mex operons for multidrug eﬄux pumps: mexAB-oprM, mexXY, mexCD-oprJ and mexEF-oprN,
making it more sensitive to many antibiotics and hence able to show up moderate effects more clearly.
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Figure 25: The autoinducer-antibiotic conjugates.
7.5.1.1 Antibacterial and anti-biofilm testing against YM64
In YM64 at 5 h the HSL-Cip conjugates 72, 77 and 78 showed slight activity at the highest concentration, but
not as much as ciprofloxacin 24. This activity was not visible by 24 h (see Figure 27) and the compounds had
no effect on biofilm formation (see Figure 28).
A dose-dependant response was expected for these results, however this was not seen except for a slight
effect at 5 h in YM64 for some compounds. The dose-dependant response might potentially be seen if higher
concentrations were tested, although there could be problems with compound solubility. Conversely, the dose-
dependant response might be seen for ciprofloxacin 24 if lower concentrations were tested. Smaller ‘steps’ in
concentration could also be tested after establishing the range over which the dose-dependant response is seen.
The very high readings in the biofilm assays for ciprofloxacin 24 (see Figure 28 and Figure 31) could be due
to sub-MIC concentrations of the antibiotic causing the bacteria to respond by forming a protective biofilm. This
effect has been reported with cefotaxim, amoxicillin, azithromycin,182,183 tobramycin, amikacin, streptomycin
and gentamicin, but oddly not with ciprofloxacin 24,184,185 although this could be due to the exact conditions
of growth.
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Figure 26: YM64 optical density (OD) readings at 5 h for the autoinducer-antibiotic conjugates.
Figure 27: YM64 OD readings at 24 h for the autoinducer-antibiotic conjugates.
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Figure 28: YM64 biofilm quantification at 24 h for the autoinducer-antibiotic conjugates.
7.5.1.2 Antibacterial and anti-biofilm testing against PAO1
In PAO1 78 showed similar activity to ciprofloxacin 24 at the highest concentration (see Figure 29), but not
at lower concentrations. All other compounds did not show activity, and again there was no activity at 24 h or
against biofilms. Increased biofilm formation is again seen with intermediate concentrations of ciprofloxacin 24,
although PAO1 seems to be overwhelmed at the highest concentrations.
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Figure 29: PAO1 OD readings at 5 h for the autoinducer-antibiotic conjugates.
Figure 30: PAO1 OD readings at 24 h for the autoinducer-antibiotic conjugates.
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Figure 31: PAO1 biofilm quantification at 24 h for the autoinducer-antibiotic conjugates.
7.5.2 Cleavable homoserine lactone-ciprofloxacin conjugates
The eight cleavable HSL-Cip conjugates, two controls and two alkynes described in 7.4.3 (see Figure 32) were
tested for antibacterial and anti-biofilm activity in P. aeruginosa YM64.
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Figure 32: The cleavable HSL-Cip conjugates.
Here there was more success, although the activity was still not as high as for ciprofloxacin 24. The HSL-
Cip conjugates with N -(acetoxymethoxycarbonyl) linkers (R = H) showed activity at high concentrations. A
longer linker seems to give higher activity; 93 and 94 showed activity comparable with ciprofloxacin 24 at high
concentrations. Unfortunately the control 98 and alkyne 90 with N -(acetoxymethoxycarbonyl) linkers (R = H)
showed higher activity than the conjugates, indicating that the HSL head wasn’t contributing to the activity of
the conjugates.
The conjugates with an N -(acetoxyethoxycarbonyl) linker (R = Me) did not show any activity. This suggests
that they either didn’t enter cells or weren’t suitable substrates for esterases. The N -(acetoxyethoxycarbonyl)
linked alkyne (R = Me) did show some activity, indicating that maybe it could penetrate cells more easily than
the conjugates due to its lower molecular weight and/or lower polarity.
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Figure 33: YM64 OD readings at 5 h for the cleavable HSL-Cip conjugates.
7.6 Conclusions
7.6.1 Library synthesis
In this section, a range of 1,2,3-triazole-linked autoinducer-antibiotic conjugates was successfully synthesised and
tested for antibiotic and anti-biofilm activity. Reliable routes to the azido autoinducers and alkynyl antibiotics
were found, but the copper(I)-catalyzed alkyne-azide cycloaddition reactions used to link them proved rather
capricious. The main reasons for this were insolubility of the starting materials and air-sensitivity. Air-sensitivity
is not expected in a click reaction, but can be explained by many of the reactions being too dilute.186 This led
to ascorbate being used up by the oxygen dissolved in the reaction solvent and present in the air above the
reaction mixture. Even when the solvent was degassed and the reaction performed under argon, a small amount
of air leaking in through a perished septum was enough to cause the reaction to stall. Low concentrations
were used because of the insolubility of the starting materials, but this would have been better addressed by
more thorough screening of solvents. In addition, it was later shown that THPTA may not be necessary for a
sufficiently concentrated reaction to take place,187 so this expensive reagent could be omitted.
Assuming the click reaction could be further optimised, this library could be easily expanded by the addition
of more azido autoinducers and alkynyl antibiotics (see 7.7). In particular, autoinducers which are actively
transported into cells, such as AI-2, are attractive targets.
7.6.2 Biology
Little biological activity was seen in the non-cleavable autoinducer-antibiotic conjugates. This could be due to
a number of factors, including:
1. Restriction of the binding of ciprofloxacin 24 to DNA gyrase and topoisomerase IV135 or trimethoprim
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25 to dihydrofolate reductase.136 This could be investigated by measuring binding of the compounds to
the purified protein targets.
2. Failure to penetrate the cell wall/biofilm or non-specific binding to the cell wall. This could be investigated
by separation of the cultures by centrifugation and quantification of the compounds in each fraction by
HPLC.
3. Failure of the autoinducers to mask the antibiotics from recognition by eﬄux pumps. While the resistance
of YM64 to the conjugates suggests that this mechanism is unlikely, YM64 is not lacking every eﬄux
pump,8,181 so it is possible that the conjugates are still being pumped out. A strain with all pumps
knocked out, or a suitable cocktail of pump inhibitors, would be needed to investigate this mechanism
fully.
If binding of the antibiotics to target proteins is indeed restricted by the attachment of the autoinducer,
this could be affected by the size and polarity of the linker and autoinducer. With this in mind, the next set of
compounds synthesised contain HSL analogues, which are smaller than HHQ 21 and PQS 22, and some omit
the triazole in the linker, hence affecting polarity.
The cleavable HSL-Cip conjugates showed a little more activity, but unfortunately this did not require the
HSL, and probably was mostly affected by the polarity and size of the attached group and the ease of hydrolysis
of the linker.
7.7 Future work
This section begins with discussion of further autoinducers and antibiotics which could be used in future
conjugates. Some have have already been partially or fully synthesised by myself or other members of the
Spring group. Plans for further biological testing of the conjugates synthesised in this study are then presented.
7.7.1 Autoinducer derivatives
7.7.1.1 3-oxo-C12-HSL derivative 75
N3-3-oxo-C12-HSL 75 (see Scheme 11) was synthesised by Ryan Howard, a master’s student under my supervi-
sion. The synthesis was based on a synthesis of 3-oxo-C12-HSL 20 reported by Hodgkinson et al.89 Conjugates
of this compound were not included in the library as it degraded during the click reaction. However, reaction
conditions could be further optimised, or the acetal-protected azide 106 could be used in the click reaction,
followed by deprotection.
This compound would be a useful addition to the library as it would demonstrate whether the 3-oxo group
and/or longer alkyl chain are required for activity. As the head group is added fairly late in the synthesis it
would also be easy to swap it for the other head groups described in 8, thus expanding the library further.
55
OO
H
N
O O O
O
O
NH3Br
O O O
HO
O O O
O
O
O
O
N3
N3 N3
N3
HO
O
N3
b)
d)
e)
f)
O
O
H
N
O O
N3
g)
HO
O
Br
a)
c)Cl
O
N3
PSfrag replacements
100 101
102
103
104 105
52
106
75
Scheme 11: The synthesis of N3-3-oxo-C12-HSL 75 carried out by Ryan Howard. a) NaN3, DMF, 60 ◦C, 6 h,
93%. b) Oxalyl chloride, DMF, CH2Cl2, 3 h, r.t.. c) MeOAc, N -methyl imidazole, TiCl4, DIPEA, toluene, r.t.,
2 h, 43% over two steps. d) HO(CH2)2OH, TsOH, CH(OMe)3, r.t., 5 h, 78%. e) NaOH, water, r.t., 6 h, 85%. f)
EDC, DMAP, CH2Cl2, r.t., 16 h. g) TFA, r.t., 5 h, 29% over two steps.
7.7.1.2 AI-2 derivatives
AI-2 23 is perhaps a more attractive choice of autoinducer for inclusion in conjugates than the others used in this
study as it is actively transported into cells188 and used by a wide range of bacterial species.125 The synthesis
of conjugates of AI-2 23 with ciprofloxacin 24 and trimethoprim 25 has been attempted in the Spring group by
Dr Jamie Stokes. However, the protected azido AI-2 derivative 107 synthesised was found to be unstable, and
the click reactions attempted were unsuccessful.187 AI-2 23 is known to interconvert between multiple forms
(including forming a furanosyl borate diester)189 so it is to be expected that syntheses involving it might be
challenging. If a more stable azido AI-223 derivative cannot be developed, another approach would be to use
an azido AI-2 23 analogue which is capable of being taken up by the same active transport mechanism.
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Figure 34: AI-2 23 in its DPD form and the protected azido AI-2 derivative 107 synthesised by Dr Jamie
Stokes.187
Two types of AI-2 23 receptors have been identified: LuxP, present in Vibrio spp.,190 and LsrB, first dis-
covered in Salmonella enterica serovar Typhimurium.191 LuxP is a periplasmic binding protein that relays the
signal, but not the actual AI-2 23 molecule, into the cell and hence is not a useful target.192 LsrB is the ligand
binding protein of a system that transports AI-2 23 into the cell,188 and hence can be targeted. LsrB orthologs
are found in a wide range of bacterial families including Enterobacteriaceae, Rhizobiaceae, and Bacillaceae.193
In addition, several bacterial species, including P. aeruginosa, are known to respond to AI-2 23 but do not have
either of these two known types of receptors, and thus the discovery of new receptor types is expected.193 Any
postulated receptor would need to internalise the AI-2 analogue in order for conjugates to be effective against
the bacterium.
One example of an AI-2 analogue which could be derivatised is a geminal dibromo compound 108 synthesised
by Guo et al.189 (see Figure 35). It is as potent as AI-2 at dissociating the LsrR repressor from the promotor
region in a reporter strain, and may be more stable. It is also esterified, making it less volatile and thus easily
purified using column chromatography. The esters are presumably cleaved by cellular esterases as the compounds
can be used in QS assays without deprotection.194
A possible azido derivative 109 of this analogue is shown in Figure 35. If a route to it could be found, it
appears to be a promising partner in future conjugates given the known properties of AI-2 23.
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Figure 35: An AI-2 analogue 108 synthesised by Guo et al. and the proposed azido AI-2 analogue derivative
109.
7.7.2 Antibiotic derivatives
7.7.2.1 Ciprofloxacin derivative 120
A second alkynyl ciprofloxacin derivative 120 was planned and partially synthesised during this project, and
finishing this synthesis would provide a useful intermediate for future conjugates.
The derivative 120 has an alkyne tail attached in place of the cyclopropane ring as it has been shown
that bulkier groups in this position can be tolerated.195,196 This synthesis followed a conventional route to
ciprofloxacin 24 similar to that reported by Mitscher et al.195 but used hex-5-yn-1-amine 115 instead of cyclo-
propylamine.
The TiCl4-catalysed crossed Claisen condensation of the acid chloride 110 and ethyl acetate described by
Hashimoto et al.197 was used to produce the β-ketoester. The ethoxymethylene group in 112 was installed by
57
the reaction of β-ketoester 111 and triethyl orthoformate to give a mixture of the E and Z isomers.195,198 Hex-
5-yn-1-amine 115 was prepared using a Gabriel synthesis199 described by Rożkiewicz et al.200 Unfortunately
the amine was surprisingly volatile and was lost on evaporation of the reaction solvent. If a better purification
method could be found, or a longer-chain alkynyl amine was used, the rest of the synthesis could be performed
and the resulting alkynyl ciprofloxacin derivative 120 could be used to form more triazole-linked conjugates.
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Scheme 12: The synthesis of 120. a) EtOAc, TiCl4, DIPEA, N -methyl imidazole, toluene, r.t., 30 min. b)
Triethyl orthoformate, Ac2O, reflux, 2 h. c) Potassium phthalimide, potassium iodide, DMF, 80 ◦C, 18 h. d)
N2H2 ·H2O, EtOH, reflux, 18 h. e) EtOH. f) NaH, dioxane. g) KOH, THF. h) DMSO.
7.7.2.2 Sulfanilamide derivatives
Sulfanilamide antibiotics were the first class of antibiotics to be widely used.201,202 They are all derivatives of 4-
aminobenzenesulfonamide, very commonly with the sulfonamide nitrogen linking to a heterocycle. Sulfanilamide
antibiotics function by inhibiting bacterial synthesis of folic acid. P. aeruginosa has intrinsic resistance to
sulfanilamides mainly due to the MexAB-OprM eﬄux pump140 and so, as with trimethoprim 25, it is hoped
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that conjugation to an autoinducer would restore activity.
Derivatives of 4-aminobenzenesulfonamide 216 have previously been synthesised using copper(I)-catalyzed
alkyne-azide cycloaddition reactions to append various groups203 (see Scheme 13). However, if one considers
sulfonamide antibiotics already in use, nearly all have a heterocycle linked directly to the sulfur atom, rather
than with a methylene group in between.
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Scheme 13: The sulfanilamide derivatives synthesised using click chemistry by Wang et al.203
Therefore, it was postulated that a 1,2,3-triazole could be introduced in the position occupied by a heterocycle
in other known sulfonamide antibiotics by attachment of an alkyne directly to the sulfonamide nitrogen to form
an alkynyl sulfanilamide derivative 121 or a protected version of it (see Scheme 14).
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Scheme 14: Retrosynthesis of a 1,2,3-triazole-containing autoinducer-sulfonamide conjugate. R = autoinducer.
It was hoped that sulfanilamide derivative 121 could be synthesised and reacted with the azido autoinducer
derivatives directly. However, it appears that no secondary ynamides have been synthesised to date. Conversely,
the synthesis of tertiary ynamines has been studied more widely.204 In particular, tertiary ynamides have been
shown to be relatively stable and easy to work with in a variety of reactions including copper(I)-catalyzed
alkyne-azide cycloadditions.205,206
The study of copper(I)-catalyzed alkyne-azide cycloadditions of ynamides by IJsselstijn et al.205 includes
terminal ynamides protected using a benzyl and a tosyl group. Although their click reactions proceed with
high yield, they do not present the deprotection of their final compounds. However, these reactions provided
a promising suggestion that click reactions between a protected alkynyl sulfanilamide derivative and the azido
autoinducer derivatives are feasible. The tosyl group used by IJsselstijn et al.205 to protect their ynamide is very
similar to the p-aminobenzenesulfonyl group needed in the alkynyl-sulfanilamide derivative. However, because
installation of the alkyne could be problematic in the presence of a second amine, the NH2 group was installed
as a NO2 group and reduced after the click reaction.
The synthesis proceeded as shown in Scheme 15.205,207,208 It was hoped that the methoxybenzyl group
could be removed and the nitro group converted to an amine simultaneously by reduction in the last step, but
unfortunately the methoxybenzyl group proved difficult to remove. On reflection, methoxybenzene was a poor
choice of protecting group, and a more reduction-labile group such as benzyl or diphenylmethyl should have
been chosen.209 This reaction could be repeated with a different choice of protecting group to provide another
set of autoinducer-antibiotic conjugates.
59
NO2
S
O
OH
N
MeO
NO2
S
O
OCl
NH2
MeO
+
NO2
S
O
O
TIPS
MeO
N
TIPS TIPS Br
NO2
S
O
O
MeO
N
a)
b)
c)
d)
O
O
H
N
O
N
N N
N S
O
O
NO2
MeO
O
O
H
N
O
N
N N
H
N S
O
O
NH2
f)
e)
O
O
H
N
O
N3
PSfrag replacements
122
123
125 126
124
127
128
55
129
130
Scheme 15: Synthesis of a 1,2,3-triazole-containing sulfonamide antibiotic-autoinducer hybrid. a) CH2Cl2, r.t.,
24 h. b) AgNO3, acetone, r.t., 3 h. c) CuSO4 · 5H2O, 1,10-phenanthroline, K2CO3, toluene, 80 ◦C, 48 h. d)
TBAF, THF, −78 ◦C, 3 h. e) Cu(OAc)2, sodium ascorbate, CH2Cl2, t-BuOH, water, r.t., 16 h. f) H2, PtO2,
MeOH, 1 atm, r.t., 3 h.
7.7.2.3 Linezolid derivative 144
Linezolid is a monoamine oxidase inhibitor used for the treatment of infections caused by Gram-positive bacteria.
Gram-negative bacteria, including P. aeruginosa are resistant to linezolid due to the activity of eﬄux pumps,
and hence it might be possible to increase its activity in such organisms by increasing its uptake and/or retention
by conjugation to an autoinducer.
An alkynyl linezolid derivative 217 was partially synthesised by Ryan Howard (see Scheme 16). The route fol-
lows a procedure described by Phetsang et al210 where the morpholine ring of linezolid is replaced by piperazine,
allowing an alkynyl tail to be attached to the molecule.
The first three steps were carried out on a large scale, producing 55.7 g of 134. As all steps except the final
one are reported in the literature210,211 it is hoped that the alkynyl linezolid derivative 218 could be synthesised
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fairly straightforwardly.
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Scheme 16: Proposed and partially completed synthesis of linezolid derivative 218.210 a) MeCN, reflux, 3 h,
91%. b) H2, 10% Pd/C, THF, 40 psi, <50 ◦C, 1.5 h, 95%. c) CbzCl, Na2CO3, acetone, water, 5 ◦C, 1 h then
r.t., 16 h, 56%. d) n-BuLi, THF, -78 ◦C, 1 h then add epoxide then -78 ◦C to r.t., 5 h. e) TsCl, TEA, CH2Cl2,
0 ◦C to r.t. 4.5 h. f) Acetonitrile, water, reflux, 48 h. g) MeNH2, EtOH, water, reflux, 5.5 h. h) Ac2O, pyridine,
0 ◦C to r.t., 16 h. i) H2, 10% Pd/C, MeOH/CH2Cl2, 1 atm, r.t., 16 h. j) NEt3, EtOH, reflux.
7.7.2.4 Gentamicin derivative 147
Gentamicin is an aminoglycoside antibiotic used to treat many bacterial infections, particularly those caused by
Gram-negative organisms, by binding to the bacterial ribosome. Gentamicin is actually a mixture of components
(see Figure 36) synthesised by Micromonospora, a genus of Gram-positive bacteria. Separation of the gentamicin
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components has been achieved by Grote et al.212 by reaction with benzyl chloroformate followed by HPLC and
hydrogenolysis of the protecting groups. Gentamicin C1a 146 was isolated pure, and is particularly useful
because it the only component which contains a CH2NH2 group. This group is less hindered than all other
amine groups in gentamicin C1a 146 and hence it is possible to selectively derivatise the molecule at this
position. Grote et al. attached a tag needed for an immunoassay using a pentafluorophenyl ester.213 Hence, it
may be possible to achieve selective reaction of this site with the pentafluorophenyl ester of 5-hexynoic acid 145
(see Scheme 17). It may even be possible to react the original gentamicin mixture with the pentafluorophenyl
ester 145 and then separate out the desired component.
O
OH
OH
N
H
O
OH
O
O
R2HN
R1
NH2
NH2H2N
R3
Gentamicin R1 R2 R3
C1 Me Me H
C1a H H H
C2 H Me H
C2a H H Me
C2b Me H H
Figure 36: Gentamicin components.
O
OH
OH
N
H
O
OH
O
O
H
N
NH2
NH2H2N
O
OH
OH
N
H
O
OH
O
O
H2N
NH2
NH2H2N
O
O
O
F
F
F
F
F
+
a)
PSfrag replacements
145
146
147
Scheme 17: Proposed synthesis of gentamicin C1a derivative 147. a) DIPEA, DMF, - 55 ◦C.
7.7.2.5 Streptomycin derivative 150
Streptomycin 148 is an aminoglycoside antibiotic used to treat Mycobacterium tuberculosis and S. aureus which
works by binding to the bacterial ribosome. There is limited SAR data on streptomycin but it is known that
conversion of the aldehyde to a carboxylic acid destroys activity, whereas conversion to an alcohol retains it.214
Reductive amination can be used to install an alkyne group by reaction of the aldehyde with an amine such
as oct-7-yn-1-amine 219 (see Scheme 18). This approach has been used by Zhang et al.215 to form a conjugate
of streptomycin 148 and chitosan which was active against biofilms. Reductive amination replaces the aldehyde
O with NH; it is known that an OH is tolerated at this position so it makes sense that NH is as well.
62
NH
OH
OH
OH
O
O
HO
O
O
O
NH
HO
HO
HO
H
N NH2
NH
H2N
H
N
H
a)
NH
OH
OH
OH
O
O
HO
NH
O
O
NH
HO
HO
HO
H
N NH2
NH
H2N
H
N
NH2
PSfrag replacements
148
221
150
Scheme 18: Proposed synthesis of streptomycin derivative 150. a) NaBH3CN, water, r.t..
7.7.3 Biology
The following extra biological data are required for these compounds:
1. Repeats of the antibacterial and anti-biofilm assays in order to assess variability in the data.
2. Growth curves to 48 h and biofilm quantifications for the cleavable HSL-Cip conjugates.
3. Biofilm dispersal assays on all compounds (see 5.3.8 for a discussion of biofilm dispersal using a HSL
analogue-CipMe conjugate and 9.71.4 for the methodology to be used).
63
8 Results and discussion: homoserine lactone analogue-ciprofloxacin
conjugates
8.1 Overview
The second part of this project was focused on producing a library of HSL analogue-Cip and -CipMe conjugates.
The HSL head group was replaced with a selection of cyclic amines found in known quorum sensing modulators
(see 5.3.8). The analogues were linked to ciprofloxacin 24 in two ways: directly using either an SN2 reaction or
peptide coupling with methyl ciprofloxacin 151, and via the triazole linkage shown previously with ciprofloxacin
24 (see 7.4). The compounds were then tested for antibiotic and anti-biofilm activity against P. aeruginosa.
8.1.1 Head groups
The head groups used in this study are shown in Figure 37. The cyclohexanol derivatives were synthesised as
a diastereomerically pure racemate, whereas the cyclopentanol derivatives were synthesised as separate enan-
tiomers. Although the timescale of this project prevented the inclusion of the cyclopentanone derivatives, these
could be included in future work. The 2-methoxybenzene derivatives do not have precedents as quorum sens-
ing modulators in the literature, but they were included so as to be compared with the 3-methoxybenzene
derivatives.
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Figure 37: The head groups used in this section.
8.1.2 Library construction
As Ganguly et al.61 (see 5.3.8) synthesised their conjugate from Br-C4-HCTL, it was envisaged that a branching
strategy could be used to produce two sets of conjugates (see Scheme 19). The first set would be formed by
the SN2 reaction of the relevant bromide with methyl ciprofloxacin 151. The second set would be made by
displacing the bromide with azide, then performing a click reaction with the alkynyl ciprofloxacin derivative 68
made previously to form the triazole-linked product. Cyclohexanone conjugates would be formed by oxidation
of the alcohol conjugates.
64
H
N
O
H
N
O
c)
N
HN
N
O O
OF
Br
N3
b)
N
N
N
O O
OF
O
N
H
N N
H
N
O
N
d) N
N
N
O O
OHF
N
N
N
O O
OHF
NH2
Cl
O
Br
+
a)
H
N
S
O
H
N
H
N
O H
NO
OH
H
N
and enantiomer
H
N
OH
(±)
=
Scheme 19: General scheme showing the proposed branching synthesis of the HSL analogue-Cip and -CipMe
conjugates.
This strategy was successful for most head groups, but multiple side reactions were observed for the amino
alcohol head groups and so other routes to these conjugates were investigated (see 8.5).
8.2 Synthesis of the homocysteine thiolactone conjugates
8.2.1 Synthesis of methyl ciprofloxacin 151
The synthesis of the analogue conjugates began with the synthesis of methyl ciprofloxacin 151 (CipMe), which
would then be attached to the various head groups. Methyl ciprofloxacin 151 was synthesised from ciprofloxacin
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24 and MeOH in good yield using para-toluenesulfonic acid (TsOH) as a catalyst.216
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Scheme 20: Synthesis of methyl ciprofloxacin 151. a) TsOH, MeOH, 72 h, reflux, 83%.
8.2.2 Synthesis of Br-C4-HCTL 153
The HCTL head group was then attached to the linker to form Br-C4-HCTL 153, in preparation for coupling to
methyl ciprofloxacin 151. Br-C4-HCTL 153 was synthesised using the Schotten-Baumann conditions employed
previously for the HSL derivatives 57 and 60. Br-C4-HCTL 153 was isolated in markedly higher yield than
that achieved by Ganguly et al.61 (88% vs. 25%). It is possible that this was due to CH2Cl2 being used for the
extraction, whereas Ganguly et al. used EtOAc.
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Scheme 21: Synthesis of Br-C4-HCTL 153. a) NaHCO3, CH2Cl2, water, 0 ◦C, 1 h, 88%.
8.2.3 Synthesis of the HCTL-CipMe conjugate 154
The HCTL-CipMe conjugate 154 was synthesised using the procedure outlined by Ganguly et al.61 (see
Scheme 22). Monitoring by LCMS showed slow conversion to the product. Br-C4-HCTL 153 was presum-
ably consumed by side reactions as 4 eq. were required to reach full conversion. A likely potential side reaction
is internal cyclisation of the bromide with the amide NH, and the mass of this molecule was observed by LCMS
in the reaction mixture.
Ganguly et al. do not quote a yield for this reaction,61,149 but it is hoped that the 12% achieved here could
be improved upon. The side reactions led to the production of an unidentified brown, viscous contaminant which
made purification by flash column chromatography (as was used by Ganguly et al.) challenging. Preparatory
HPLC on a partially purified sample gave enough pure HCTL-CipMe conjugate 154 for biological testing.
Future optimisation of the synthesis could focus on different routes to the product, e.g. the peptide coupling
described in 8.5.5, or different purification methods, e.g. using just preparatory HPLC, or reverse phase flash
column chromatography.
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Scheme 22: Synthesis of the HCTL-CipMe conjugate 154. a) K2CO3, acetonitrile, reflux, 24 h, 12%.
8.2.4 Synthesis of the HCTL-Cip triazole conjugate 156
Br-C4-HCTL 153 was converted into N3-C4-HCTL 155 (see Scheme 22), by an SN2 reaction with sodium azide
which proceeded in excellent yield.
N3-C4-HCTL 155 was then subjected to the click reaction conditions optimised previously (see 9.25). The
reaction proceeded very slowly at first, as the azide did not dissolve in the reaction solvent and formed a single
solid clump. DMSO was added as a co-solvent, and the reaction began to proceed, albeit still slowly. Nonetheless,
the HCTL-Cip triazole conjugate 156 was isolated in good yield (see Scheme 23).
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Scheme 23: Synthesis of the HCTL-Cip triazole conjugate 156. a) NaN3, acetonitrile, reflux, 1.5 h, 89%. b)
CuSO4, THPTA, sodium ascorbate, water, t-BuOH, DMSO, r.t., 7 d, 71%.
8.2.5 Synthesis of the cleavable HCTL-Cip triazole conjugate 157
A cleavable conjugate 157 (see Scheme 24) was also synthesised from N3-C4-HCTL 155 by reaction with a
cleavable alkyne-Cip derivative 90 synthesised previously by Professor Eddy Sotelo (see 7.4.3).
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Scheme 24: Synthesis of the cleavable HCTL-Cip triazole conjugate 157. a) CuI, DIPEA, CH2Cl2, r.t., 3 h, 5%.
8.3 Synthesis of the 2-Methoxybenzene conjugates
8.3.1 Synthesis of Br-C4-2-methoxybenzene 159
Br-C4-2-methoxybenzene 159 was synthesised from 2-methoxyaniline 158 and 4-bromobutyryl chloride 56 using
Schotten-Baumann conditions in 50% yield (see Scheme 25). Br-C4-2-methoxybenzene 159, like all other 2- and
3-methoxyaniline derivatives mentioned below, appears to be air and/or light sensitive. For example, Br-C4-
2-methoxybenzene 159 turns from an initially colourless liquid to blue then black if left out on the bench. It
is possible that this sensitivity is due to oxidative polymerisation of the aniline,217,218 but given the lack of
catalysis it is likely that small amounts of highly-coloured polymer are being formed.
It is likely that the mediocre yield of Br-C4-2-methoxybenzene 159 is caused by degradation during column-
ing, probably due to SN2 reactions at the bromide, especially internal cyclisation with the amide NH. It is
therefore suggested that in future the compound should be used in its crude form to minimise losses, as it was
fairly pure by 1H NMR before columning.
a)Cl
O
Br+
NH2
O H
N
O
Br
O
PSfrag replacements
158 56 159
Scheme 25: Synthesis of Br-C4-2-methoxybenzene 159. a) NaHCO3, CH2Cl2, water, 0 ◦C, 1 h, 50%.
8.3.2 Synthesis of the 2-methoxybenzene-CipMe conjugate 160
The procedure outlined by Ganguly et al.61 was initially attempted in order to synthesise the 2-methoxybenzene-
CipMe conjugate 160, but the reaction was very slow and did not go to completion, presumably due to degra-
dation of Br-C4-2-methoxybenzene 159. New conditions, employing a microwave reactor and 2 eq. of Br-C4-2-
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methoxybenzene 159 were then attempted, with a much greater conversion observed by LCMS after 4 h (see
Scheme 26). However, a poor yield was obtained, possibly due to losses during column chromatography.
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Scheme 26: Synthesis of the 2-methoxybenzene-CipMe conjugate 160. a) NaI, DIPEA, acetonitrile, microwave
reactor, 100 ◦C, 4 h, 10%.
8.3.3 Synthesis of the 2-methoxybenzene-Cip triazole conjugate 162
N3-C4-2-methoxybenzene 161 was synthesised from Br-C4-2-methoxybenzene 159 by an SN2 reaction with
sodium azide (see Scheme 27). The yield of N3-C4-2-methoxybenzene 161 (27%) was a lot lower than for N3-
C4-HCTL 155 (89%). However, in this case it may not be better to use the product crude as several impurities
were formed during the reaction and could be observed by LCMS (see Figure 38).
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Figure 38: Suspected impurities observed by LCMS during the synthesis of N3-C4-2-methoxybenzene 161.
The 2-methoxybenzene-Cip triazole conjugate 162 was synthesised using the standard click conditions (see
9.25), with the addition of CH2Cl2 as a co-solvent to aid the dissolution of N3-C4-2-methoxybenzene 161 (see
Scheme 27).
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Scheme 27: Synthesis of the 2-methoxybenzene-Cip triazole conjugate 162. a) NaN3, acetonitrile, reflux, 2 h,
27%. b) CuSO4, THPTA, sodium ascorbate, water, t-BuOH, CH2Cl2, r.t., 16 h, 39%.
8.4 Synthesis of the 3-Methoxybenzene conjugates
8.4.1 Synthesis of Br-C4-3-methoxybenzene 164
Br-C4-3-methoxybenzene 164 was synthesised from 3-methoxyaniline 163 and 4-bromobutyryl chloride 56 using
Schotten-Baumann conditions as above in almost identical (50%) yield (see Scheme 28).
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Scheme 28: Synthesis of Br-C4-3-methoxybenzene 159. a) NaHCO3, CH2Cl2, water, 0 ◦C, 1 h, 50%.
8.4.2 Synthesis of the 3-methoxybenzene-CipMe conjugate 165
The 3-methoxybenzene-CipMe conjugate 165, was synthesised as above, in similar yield (see Scheme 29).
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Scheme 29: Synthesis of the 3-methoxybenzene-CipMe conjugate 165. a) NaI, DIPEA, acetonitrile, microwave
reactor, 100 ◦C, 4 h, 11%.
8.4.3 Synthesis of the 3-methoxybenzene-Cip triazole conjugate 167
N3-C4-2-methoxybenzene 161 and the 3-methoxybenzene-Cip triazole conjugate 167 were synthesised as above,
in similar yields (see Scheme 29 and Scheme 30).
N
N
N
O O
OHF
N N
N
H
N
O
H
N
O
N3
O
O
H
N
O
Br
O
a) b)
N
N
N
O O
OHF
PSfrag replacements
164 166
68
167
Scheme 30: Synthesis of the 3-methoxybenzene-Cip triazole conjugate 167. a) NaN3, acetonitrile, reflux, 7 h,
17%. b) CuSO4, THPTA, sodium ascorbate, water, t-BuOH, CH2Cl2, r.t., 2 h, 5%.
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8.5 Synthesis of the cyclopentanol conjugates
8.5.1 Synthesis of the 2-aminocyclopentan-1-ol head groups 172 and 173
Synthesis of the cyclopentanol derivatives began with the synthesis of (1S,2S)-2-aminocyclopentan-1-ol 172
and (1R,2R)-2-aminocyclopentan-1-ol 173 (see Scheme 31), using a procedure reported by Overman and
Sugai.219–221 These precursors were synthesised by opening cyclopentene oxide 168 using (S)-1-phenylethan-
1-amine 169 to give approximately equal amounts of two diastereomers, 170 and 171, which were separated
using column chromatography. The removal of the methylbenzyl groups proved more difficult than expected,
with the conditions reported by Overman and Sugai220 yielding only a salt of the starting material. After sev-
eral attempts under various conditions (including using the free amine vs. the salt, varying the temperature,
ensuring the dryness of the reagents and adding acetic acid), an approach using H2 gas was attempted (see
Table 9). This proceeded smoothly at 5 atm to give the two enantiomers of 2-aminocyclopentan-1-ol, 172 and
173, both in quantitative yield.
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Scheme 31: Synthesis of (1S,2S)-2-aminocyclopentan-1-ol 172 and (1R,2R)-2-aminocyclopentan-1-ol 173. a)
AlMe3, CH2Cl2, 0 ◦C, 170 (SSS): 35%, 171 (RRS): 32%. b) See Table 9. c) Pd(OH)2, MeOH, H2, 5 atm, r.t.,
1 d, >99%.
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Conditions Temperature
and pressure
Time Result
170 ·HCl, ammonium formate, 10%
Pd/C, DMF
r.t., 1 atm 2 d 170 salt
170, ammonium formate, 10% Pd/C,
DMF
r.t., 1 atm 2 d 170 salt
170 ·HCl, ammonium formate, 10%
Pd/C, dry DMF
r.t., 1 atm 2 d 170 salt
171, ammonium formate, 10% Pd/C,
dry DMF
r.t., 1 atm 2 d 171 salt
170, ammonium formate, 10% Pd/C,
dry DMF
70 ◦C, 1 atm 1 d 170 salt
170, ammonium formate, 10% Pd/C,
dry DMF, AcOH
70 ◦C, 1 atm 1 d Complex mixture
170 ·HCl, dry ammonium formate,
10% Pd/C, dry DMF
120 ◦C, 1 atm 7 d Complex mixture
170 ·HCl, Pd(OH)2, MeOH, H2 r.t., 1 atm 1 d 170 salt
170 ·HCl, Pd(OH)2, MeOH, H2 r.t., 3.4 atm 1 d 172 salt, 170 salt, and an unidentified
compound (approx. 7:2:10 by 1H NMR)
170, Pd(OH)2, MeOH, H2 r.t., 5 atm 1 d 172, >99% yield
Table 9: Conditions attempted for the synthesis of (1S,2S)-2-aminocyclopentan-1-ol 172 and (1R,2R)-2-
aminocyclopentan-1-ol 173 (see Scheme 31).
8.5.2 Initial branching route
An initial retrosynthesis of the conjugates is shown in Scheme 32, and follows a similar path to previous
conjugates.
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Scheme 32: Retrosynthesis of the cyclopentanol-CipMe conjugates 178 (SS) and 179 (RR), and the
cyclopentanol-Cip triazole conjugates 180 (SS) and 181 (RR). SS enantiomers are shown, but both are implied.
Synthesis of Br-C4-cyclopentanol-(SS) 174 from (1S,2S)-2-aminocyclopentan-1-ol 172 and 4-bromobutyryl
chloride 56 was attempted using Schotten-Baumann conditions (see Scheme 33). However, a large number of
impurities were observed by LCMS (see Figure 39), and so three new strategies were attempted: protection of
the alcohol (see 8.5.3), using 4-chlorobutyryl chloride 192 as the linker instead of 4-bromobutyryl chloride 56
(see 8.5.4), and installing the linker on methyl ciprofloxacin 151 and then attaching the head group by peptide
coupling (see 8.5.5).
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Scheme 33: Attempted synthesis of Br-C4-cyclopentanol-(SS) 174. a) NaHCO3, CH2Cl2, water, 0 ◦C, 2 h.
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Figure 39: Suspected impurities observed by LCMS during the synthesis of Br-C4-cyclopentanol-(SS) 174.
Regiochemistry is speculative.
8.5.3 TBDMS protection route
The first attempt at an alternative strategy for the synthesis of the conjugates involved TBDMS protection of
the alcohol (see Scheme 34). It was envisaged that protection would eliminate enough of the side reactions with
products shown in Figure 39 that intermediates Br-C4-cyclopentanol-(SS) 174 and N3-C4-cyclopentanol-(SS)
176 could be purified. The TBDMS group could be removed later in the synthesis using TBAF or acid.
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Scheme 34: Retrosynthesis of the cyclopentanol-CipMe conjugates 178 (SS) and 179 (RR), and the
cyclopentanol-Cip triazole conjugates 180 (SS) and 181 (RR) using a TBDMS protection strategy. SS enan-
tiomers are shown, but both are implied.
8.5.3.1 Synthesis of TBDMS-protected (1S,2S)-2-aminocyclopentan-1-ol 172
The synthesis began with the optimisation of the protection of (1S,2S)-2-aminocyclopentan-1-ol 172 with a
TBDMS group on the alcohol (see Scheme 36). This reaction proved more problematic than expected, possibly
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due to the amine group interfering with the reaction at the alcohol and/or the high polarity of the starting
material causing problems with solubility in the reaction mixture and extraction during the work-up. Conditions
attempted are summarised in Table 10. Protection attempts using TBDMSCl were generally unsuccessful, but
eventually a method employed by Wu et. al222 using TBDMSOTf was found to produce the desired product in
excellent yield. Water was used for the work-up rather than NH4Cl (sat. aq.), as the acidic work-up protonated
the product. The TEA was removed during column chromatography instead.
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Scheme 35: Synthesis of TBDMS protected (1S,2S)-2-aminocyclopentan-1-ol 182. a) See Table 10.
Conditions Temperature Time Result
TBDMSCl, DMAP, TEA, CH2Cl2223 r.t. 18 h Trace of 182, mostly 172
TBDMSCl, imidazole, CH2Cl2224 0 ◦C 1 h 172
TBDMSCl, DBU, acetonitrile225 0 ◦C 1 d 172
TBDMSOTf, TEA, CH2Cl2,222 aq.
workup then column
0 ◦C 6 h 182, 98% yield
Table 10: Conditions attempted for the synthesis of (1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentan-1-amine
182 (see Scheme 36).
8.5.3.2 Synthesis of Br-C4-cyclopentanol-TBDMS-(SS) 184
The TBDMS protected (1S,2S)-2-aminocyclopentan-1-ol 182 was reacted with 4-bromobutyryl chloride 56 to
form Br-C4-cyclopentanol-TBDMS-(SS) 184. The reaction was observed to go to completion by TLC, but it
became apparent that the product was reacting further during concentration and purification. Adding sodium
azide to the mixture obtained after the failed purification attempts was observed to convert the remaining Br-
C4-cyclopentanol-TBDMS-(SS) 184 to N3-C4-cyclopentanol-TBDMS-(SS) 186. A sequential one-pot reaction
was therefore used, so that the reactive intermediate did not need to be isolated.
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Scheme 36: Attempted synthesis of Br-C4-cyclopentanol-TBDMS-(SS) 184. a) NaHCO3, CH2Cl2, water, 0 ◦C,
2 h.
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8.5.3.3 Synthesis of N3-C4-cyclopentanol-TBDMS-(SS) 186 by one-pot reaction
N3-C4-cyclopentanol-TBDMS-(SS) 186 was finally synthesised by a two-step, one-pot reaction. Schotten-
Baumann conditions were used to form the bromide. The water was then removed, and DMF and sodium
azide were added. N3-C4-cyclopentanol-TBDMS-(SS) 186 was produced in excellent yield.
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Scheme 37: Synthesis of N3-C4-cyclopentanol-TBDMS-(SS) 186. a) NaHCO3, CH2Cl2, water, 0 ◦C, 3 h. b)
NaN3, DMF, CH2Cl2, r.t., 3 h. 99% over 2 steps.
8.5.3.4 Synthesis of the (SS)-TBDMS-cyclopentanol-Cip triazole conjugate 190
N3-C4-cyclopentanol-TBDMS-(SS) 186 and the alkynyl ciprofloxacin derivative 68 were subjected to standard
click conditions (see 9.25), and the (SS)-TBDMS-cyclopentanol-Cip triazole conjugate 190 was synthesised in
very good yield. However, removal of the TBDMS group proved difficult. Deprotection using 1.5 eq. TBAF in
THF proceeded slowly, reaching completion in 5 d. Increasing the amount of TBAF to 8 eq. allowed the reaction
to proceed overnight. Purification of the final conjugate 180 by column chromatography was not successful due
to streaking and poor separation. Purification using DOWEX resin and CaCO3226 was attempted, but the
product could not be recovered from the resin. The purification method could probably be optimised, e.g. by
varying the solvent used with the resin, but ultimately this route was abandoned due to the reduction in number
of steps afforded by the two methods described below.
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Scheme 38: Synthesis of the (SS)-TBDMS-cyclopentanol-Cip triazole conjugate 190. a) CuSO4, sodium ascor-
bate, THPTA, water, t-BuOH, r.t., 87%. b) TBAF, THF, r.t., 16 h.
8.5.4 Synthesis of the cyclopentanol-Cip triazole conjugates 180 and 181 via chloride interme-
diates
Given that the side product formation seen in the previous sections was most likely due to SN2 attack on
the bromide, we decided to use a chloride rather than a bromide intermediate (see Scheme 32 and Scheme 39
to compare). The bromide intermediate was initially chosen as it was used by Ganguly et. al,61 but it was
anticipated that using a chloride would reduce the side reactions seen with the more reactive bromide.
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Scheme 39: Retrosynthesis of the cyclopentanol-CipMe conjugates 178 (SS) and 179 (RR), and the
cyclopentanol-Cip triazole conjugates 180 (SS) and 181 (RR) via Cl-C4-cyclopentanol intermediates 193 (SS)
and 194 (RR). SS enantiomers are shown, but both are implied.
Attempts at this route began with the synthesis of Cl-C4-cyclopentanol-(RR) 194. Standard Schotten-
Baumann conditions failed to produce significant amounts of product. If prolonged reaction times were allowed,
degradation of the acid chloride to the carboxylic acid was observed. The reason for this is unclear, but it is
possible that bromide ions present in small amounts in previous reactions were helping to catalyse the reaction of
the acid chloride. Archer et al.227 propose that bromide ions can react with acid chlorides to form acid bromides,
which are then more susceptible to nucleophilic attack. As no bromide ions are present in this reaction, different
conditions were sought in order to increase the rate.
As (1R,2R)-2-aminocyclopentan-1-ol 173 is fairly polar, it is likely that it was staying in the aqueous layer
to some extent even when deprotonated, thus keeping the two reactants apart. Therefore, the solvent system
and base were changed to neat CH2Cl2 and TEA. This produced Cl-C4-cyclopentanol-(RR) 194 in good yield
(64%). Unlike the bromide 174, the chloride 194 was stable when concentrated.
Cl-C4-cyclopentanol-(RR) 194 was converted to N3-C4-cyclopentanol-(RR) 177 by reaction with sodium
azide. The reaction was slower than with previous bromides (~16 h vs. ~2 h), but much cleaner than with
Br-C4-cyclopentanol-(SS) 174 (see 8.5.2).
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The enantiomers Cl-C4-cyclopentanol-(SS) 193 and N3-C4-cyclopentanol-(SS) 176 were synthesised in lower
yields, in part because of the smaller amounts being used.
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Scheme 40: Synthesis of N3-C4-cyclopentanol-(SS) 176 and N3-C4-cyclopentanol-(RR) 177. SS enantiomers
are shown, but both were synthesised. a) TEA, CH2Cl2, 0 ◦C, 2 h, 193 (SS): 24%, 194 (RR): 64%. b) NaN3,
acetonitrile, 50 ◦C, 16 h, 176 (SS): 45%, 177 (RR): 88%.
The cyclopentanol-Cip triazole conjugates 180 (SS) and 181 (RR) were successfully synthesised using
standard click conditions (see 9.25). Despite low yields (presumably due to problems with purification, including
losses on the preparative HPLC column and high polarity leading to losses during extraction from aqueous
solvents) enough of the compounds were obtained for biological testing so the purification was not optimised
further.
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Scheme 41: Synthesis of the cyclopentanol-Cip triazole conjugates 180 (SS) and 181 (RR). SS enantiomers are
shown, but both were synthesised. a) CuSO4, THPTA, sodium ascorbate, water, t-BuOH, r.t., 16 h, 180 (SS):
22%, 181 (RR): 27%.
The SN2 reaction of Cl-C4-cyclopentanol-(RR) 194 and methyl ciprofloxacin 151 was attempted (see
Scheme 42) using the microwave conditions described previously (see 8.3), to see if the chloride produced better
results compared with the bromide. However, as was seen with the other microwave reactions, a substantial
amount of the disubstituted product 195 was seen by LCMS (in an approx 1:1 ratio with the desired product
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220).
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Scheme 42: Attempted synthesis of the cyclopentanol-CipMe-(RR) conjugate 179. a) NaI, DIPEA, acetonitrile,
microwave reactor, 100 ◦C.
8.5.5 Synthesis of the cyclopentanol-CipMe conjugates 178 and 179 by peptide coupling
Given the side-reactions and low yields associated with the literature synthesis of the SN2 conjugates proposed by
Ganguly et. al,61 an alternative synthesis was investigated, involving building up the linker on the ciprofloxacin
side before coupling with the head group (see Scheme 43).
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Scheme 43: Retrosynthesis of the cyclopentanol-CipMe conjugates 178 (SS) and 179 (RR). SS enantiomers are
shown, but both are implied.
The first step of the synthesis was an SN2 reaction between Boc-protected 4-bromobutyric acid 196 methyl
ciprofloxacin 151 (see Scheme 44). Intermediate 197 was obtained in acceptable yield after column chromatog-
raphy (50%). Intermediate 197 was deprotected in excellent yield using TFA in CH2Cl2 to give carboxylic
acid 198. Scale-up of this reaction allowed the easy synthesis of 600 mg of this useful intermediate, which can
be coupled with various amine head-groups to create a library. Carboxylic acid 198 was first coupled with
(1R,2R)-2-aminocyclopentan-1-ol 173 using standard peptide coupling conditions to give cyclopentanol-CipMe
conjugate 179. Purification by column chromatography was attempted twice with poor results, before mov-
ing on to using preparative HPLC, which gave 179 cleanly in 39% yield. Coupling was also performed with
(1S,2S)-2-aminocyclopentan-1-ol 172 to give the enantiomer 178 in 55% yield.
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Scheme 44: Synthesis of the cyclopentanol-CipMe conjugates 178 (SS) and 179 (RR) by peptide coupling.
SS enantiomers are shown, but both were synthesised. a) NaI, TEA, acetonitrile, 100 ◦C, 16 h, 50%. b) TFA,
CH2Cl2, r.t., 18 h, 96%. c) EDC, HOBt, DIPEA, DMF, r.t., 16 h, 178 (SS): 55%, 179 (RR): 39%.
With (unfortunately not branching) routes to the SN2 and click conjugates established (see 8.5.5 and 8.5.4
respectively), attention was turned to the cyclohexanol derivatives.
8.6 Synthesis of the cyclohexanol conjugates
8.6.1 Synthesis of the trans-2-aminocyclohexan-1-ol head group 200
It was decided to produce the cyclohexanol conjugates racemically, with the option of re-synthesising enan-
tiomerically pure versions via the route shown in 8.5.1 if the compounds showed biological activity.
Production of the cyclohexanol conjugates began with the synthesis of trans-2-aminocyclohexan-1-ol 200
(see Scheme 45), using a procedure reported by Xue et al.228 Cyclohexene oxide 199 was opened using ammonia
in water and methanol. Initially the reaction was carried out at 85 ◦C in a microwave reactor for 30 min, but
a large amount of the disubstituted amine could be seen by LCMS (in a ratio of 4:3 product to impurity by
NMR). The reaction was therefore attempted at room temperature, and proceeded overnight in high yield and
with minimal side reaction.
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Scheme 45: Synthesis of trans-2-aminocyclohexan-1-ol 200. a) NH3, water, MeOH, r.t., 72 h, 86%.
8.6.2 Synthesis of the trans-cyclohexanol- and cyclohexanone-CipMe conjugates 201 and 202
Carboxylic acid 198 was coupled with trans-2-aminocyclohexan-1-ol 200 using standard peptide coupling con-
ditions to give trans-cyclohexanol-CipMe conjugate 201 in 32% yield.
A portion of the trans-cyclohexanol-CipMe conjugate 201 was then oxidised to the ketone using Dess-Martin
periodinane and the product was isolated in good yield.
N
N
N
O O
OF
HO
O
N
N
N
O O
OF
O
N
H
a)
OH
NH2
OH
+
N
N
N
O O
OF
O
N
H
b)
O
(±)
(±)
(±)
PSfrag replacements
200
198
201
202
Scheme 46: Synthesis of the cyclohexanol-CipMe conjugate 201 and the cyclohexanone-CipMe conjugate 202.
a) EDC, HOBt, DIPEA, DMF, r.t., 16 h, 32%. b) DMP, CH2Cl2, r.t., 6 h, 69%.
8.6.3 Synthesis of the trans-cyclohexanol- and cyclohexanone-Cip triazole conjugates 205 and
206
The triazole conjugates were synthesised using the route described in 8.5.4. Cl-C4-trans-cyclohexanol 203 was
synthesised in good yield from trans-2-aminocyclohexan-1-ol 200 and 4-chlorobutyryl chloride 192. Cl-C4-
trans-cyclohexanol 203 was then converted to N3-C4-trans-cyclohexanol 204 by reaction with sodium azide in
excellent yield.
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Scheme 47: Synthesis of N3-C4-trans-cyclohexanol 204. a) TEA, CH2Cl2, 0 ◦C, 30 min, 76%. b) NaN3, acetoni-
trile, 50 ◦C, 16 h, 98%.
The trans-cyclohexanol-Cip triazole conjugate 205 was synthesised using standard click conditions (see 9.25)
in 49% yield. A portion of the trans-cyclohexanol-Cip triazole conjugate 205 was then oxidised to the ketone
using the same conditions used for the cyclohexanone-CipMe conjugate (see 8.6.2) in very good yield.
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Scheme 48: Synthesis of the trans-cyclohexanol-Cip triazole conjugate 205 and the cyclohexanone-Cip triazole
conjugate 206. a) CuSO4, THPTA, sodium ascorbate, water, t-BuOH, r.t., 16 h, 49%. b) DMP, CH2Cl2, r.t.,
4 h, 78%.
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8.7 Biological testing
The biological testing presented in this section was planned by me but carried out by Tom O’Brien, a PhD
student in the Department of Biochemistry.
The HSL analogue-Cip(Me) conjugates (see Figure 40), as well as C4-HSL 19, ciprofloxacin 24, methyl
ciprofloxacin 151, the alkynyl ciprofloxacin derivative 68, the tert-butyl ester methyl ciprofloxacin derivative
197 and the carboxylic acid methyl ciprofloxacin derivative 198 were tested for antibacterial and anti-biofilm
activity in P. aeruginosa PAO1180 and YM64.181 All compounds were tested in triplicate, and the ratio of the
standard deviation (SD) to the mean was less than 1 for all data points except one (68 at 25 µl in PAO1 at 8
h).
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Figure 40: The HSL analogue-Cip(Me) conjugates.
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8.7.1 Antibacterial testing
8.7.1.1 Antibacterial testing against YM64
In YM64 at 5 h several of the HSL analogue-Cip(Me) conjugates showed activity at the highest concentration
(see Figure 41 and Figure 42). Conjugates 162 and 167 showed similar activity to ciprofloxacin 24 and the
cleavable conjugate 157 showed better activity (see Figure 41). The activity of the cleavable conjugate 157 was
even more pronounced at 24 h (see Figure 43).
It should be noted that the highest concentration tested was 25 µM in this set of assays as opposed to 2
µM in the previous set (see 7.5), but oddly all compounds including ciprofloxacin 24 showed less activity. This
is thought to be due to a change in the plate seals used and/or the humidity of the incubation conditions (see
9.71).
Figure 41: YM64 OD readings at 5 h for the HCTL, 2-methoxybenzene and 3-methoxybenzene HSL analogue-
Cip(Me) conjugates.
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Figure 42: YM64 OD readings at 5 h for the alcohol and ketone HSL analogue-Cip(Me) conjugates.
Figure 43: YM64 OD readings at 24 h for the HCTL, 2-methoxybenzene and 3-methoxybenzene HSL analogue-
Cip(Me) conjugates.
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Figure 44: YM64 OD readings at 24 h for the alcohol and ketone HSL analogue-Cip(Me) conjugates.
8.7.1.2 Antibacterial testing against PAO1
In PAO1 at 5 h conjugates 157, 162 and 167 showed activity at the highest concentration (see Figure 45). The
cleavable conjugate 157 showed similar activity to ciprofloxacin 24. At 24 h conjugate 167 still showed some
activity, and cleavable conjugate 157 showed similar activity to ciprofloxacin 24 (see Figure 47).
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Figure 45: PAO1 OD readings at 5 h for the HCTL, 2-methoxybenzene and 3-methoxybenzene HSL analogue-
Cip(Me) conjugates.
Figure 46: PAO1 OD readings at 5 h for the alcohol and ketone HSL analogue-Cip(Me) conjugates.
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Figure 47: PAO1 OD readings at 24 h for the HCTL, 2-methoxybenzene and 3-methoxybenzene HSL analogue-
Cip(Me) conjugates.
Figure 48: PAO1 OD readings at 24 h for the alcohol and ketone HSL analogue-Cip(Me) conjugates.
In addition to its promising antibacterial activity, the cleavable HCTL-Cip triazole conjugate 157 has an
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interesting growth curve (see Figure 49). When P. aeruginosa PAO1 is treated with 25 µM ciprofloxacin 24 it
continues to grow slowly over the course of a 48 h assay, whereas growth is fully inhibited by treatment with the
cleavable HCTL-Cip triazole conjugate 157. However, the errors in this data are large and so the assay needs
repeating to confirm the effect.
Figure 49: PAO1 OD readings over 48 h for the cleavable HCTL-Cip triazole conjugate 157 and ciprofloxacin
24 at 25 µM.
8.7.2 Anti-biofilm testing
Biofilm inhibition and dispersal were measured using crystal violet staining (see 9.71). Unfortunately the results
were largely unreliable as it was obvious that staining was higher in the wells at the edges of the plates, and
that this was overwhelming any other trends. This effect was probably due to increased evaporation from the
outer wells. It is likely that this effect was seen in these results, but not those in 7.5, due to a change in the
conditions that the plates were incubated in. Specifically, a different type of plate seal was used and a humid
environment was maintained in the incubator in the previous experiments (see 9.71).
8.8 Conclusions
8.8.1 Library synthesis
In this section, a library of HSL analogue-Cip(Me) conjugates was successfully synthesised and tested for an-
tibiotic activity. A range of 7 head groups (see 8.1.1) and two linking strategies were used. Unfortunately the
branching route that was initially proposed (see 8.1.2) was not feasible for the alcohol-containing head groups
and was low yielding for others, probably due to internal cyclisation (this side reaction could with hindsight be
avoided by changing the linker length).
Given the difficulties in the branching synthesis, routes to the differently-linked compounds were optimised
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separately: the alkyl-linked conjugates were best formed using peptide coupling and the triazole-linked conju-
gates via a chloride intermediate. Direct comparisons of routes are not possible without repeating syntheses,
but if it is assumed that peptide coupling of homocysteine thiolactone hydrochloride 152 to carboxylic acid
198 would have a similar yield to the coupling with (1R,2R)-2-aminocyclopentan-1-ol 173, approximate com-
parisons can be made. The synthesis of the HCTL-CipMe conjugate 154 described in 8.2 has an overall yield of
11%, whereas the route to the cyclopentanol-CipMe conjugate 178 shown in Scheme 44 has an overall yield of
26%. Moreover, if the yield starting from the head group is considered, the yield is 55% vs. 11%. Therefore, the
peptide coupling route is recommended for further investigation if the alkyl-linked library is to be expanded.
Synthesis of the azido autoinducer analogues via the chloride is also recommended as the bromide is thought
to cyclise readily (this could explain the poor yields of the 2- and 3-methoxybenzene derivatives).
Preparative HPLC was identified as the best purification method for these conjugates (note that the standard
acidic method used hydrolyses the lactone of native HSL and so cannot be used in that case).
8.8.2 Biology
The ciprofloxacin triazole conjugates had higher activity than the methyl ciprofloxacin conjugates. This was
mirrored in the controls: methyl ciprofloxacin 151 showed little activity compared to ciprofloxacin 24. It was
assumed that methyl ciprofloacin 151 would act as a prodrug, as the HCTL-CipMe conjugate 154 synthesised
by Ganguly et al.61 was a methyl ester and showed activity, but these results suggest otherwise. However, the
HCTL-CipMe conjugate 154 showed better anti-biofilm activity than antibiotic, and it is possible that the other
CipMe conjugates will do the same.
The most promising compounds from this set were the methoxybenzene-ciprofloxacin triazole conjugates 162
and 167 and the cleavable HCTL-Cip triazole conjugate 157. The cleavable HCTL-Cip triazole conjugate 157
was also interesting in that it appeared to entirely inhibit the growth of P. aeruginosa, whereas ciprofloxacin
24 either allowed slow growth, or resistant mutants emerged and started to replicate.229 However, the errors in
these data were large and so the assays need to be repeated. Given the previous results for the cleavable HSL-
Cip conjugates (see 7.5.2) is not very likely that the quorum sensing modulation properties of the head group
contributed to its antibiotic effect, but the effect of different cleavable tails is certainly worth investigating.
Initial biofilm inhibition and dispersal assays were carried out (see 9.71), but unfortunately the results were
unreliable as the biofilm was growing more in the wells at the edges of the plates. As biofilm formation is
induced by hypoxia230 (which might occur in the centre of the plate when a plastic lid was used in addition to
the adhesive plate seal) this cannot account for the increased biofilm growth at the edges of the plate. Neither
can the increased concentration of NaCl that would occur due to evaporation of water from the edges of the
plate, as this too decreases biofilm formation.231 A reasonable explanation is that evaporation would leave a
residue of dried planktonic cells on the edges of the wells which would be stained by the crystal violet.
8.9 Future work
8.9.1 Further conjugates
An obvious addition to the library would be the HSL-CipMe conjugate (see Figure 50), to enable better com-
parisons between the triazole-linked and alkyl-linked libraries.
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As methyl ciprofloxacin 151 and its alkyl-linked conjugates had little antibiotic effect, it would be useful to
test the carboxylic acid versions of these compounds (see Figure 51). Ideally these would be synthesised directly
by hydrolysis of the methyl ciprofloxacin conjugate, but this could potentially cause hydrolysis of the lactone or
thiolactone as well. If mild enough hydrolysis conditions could not be found it might be possible to hydrolyse
both bonds and then re-form the ring.232 The cyclohexanone conjugate would be best formed by hydrolysis of
the cyclohexanol conjugate followed by oxidation of the alcohol to avoid exposing the ketone to extremes of pH.
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Figure 51: The proposed HSL analogue-Cip conjugates.
A selection head groups which could be used in future conjugates are shown in Figure 52. These have
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all been shown to modulate HSL-mediated quorum sensing as part of acyl-HSLs.152,157,159,233–236 The most
obvious targets are the cyclopentanone derivatives, as this could be synthesised from the alcohols above. The
aniline, pyridine, quinoline and cyclopentyl amine head groups are commercially available and hence derivatives
of these could be easily obtained. The 3- and 4-substituted HSL analogues require synthesis, but a route has
been devised.235
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Figure 52: HSL analogue head groups for use in future conjugates.
8.9.2 Biology
The most important next step is the repetition of the biofilm inhibition and dispersal assays with better control
over evaporation. This can be achieved in a low-tech but reliable manner by placing the sealed plates (without
the plastic plate lids) inside a high-sided, open plastic box lined with damp tissue paper.
It is worth noting that Ganguly et al. used LIVE/DEADR© BacLightTM staining and confocal microscopy
to image their biofilms, whereas so far we have used crystal violet staining. Crystal violet does not differentiate
between live and dead cells, and so does not pick up on how many cells have been killed within the biofilm but
stayed adhered to the plate (their confocal microscopy results do however show a decrease in biofilm thickness
so it should be possible to detect this using crystal violet).
We do not have access to a confocal microscope on which we can use P. aeruginosa, but alternative stains
which show cell viability could be used. Peeters et al.237 evaluated six assays used for the quantification of
biofilms and recommended fluorescein diacetate or resazurin viability assays for the quantification of live cells
in P. aeruginosa biofilms.
Given the interesting growth curve results for the cleavable HCTL-Cip triazole conjugate 157 it would be
useful to collect this data for the other cleavable compounds shown in 7.4.3 (previously OD readings were only
taken at 5 and 24 h).
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9 Experimental
9.1 General
Unless otherwise stated, reactions were performed in air-dried glassware under argon with dry, freshly-distilled
solvents. THF was distilled from LiAlH4 in the presence of triphenyl methane indicator. CH2Cl2, hexane, MeOH
and acetonitrile were distilled from calcium hydride. All other chemicals were used as obtained from commercial
sources.
Reactions using microwave heating were performed in sealed vials using a CEM Discover SP microwave
reactor.
Thin-layer chromatography (TLC) was performed using Merck pre-coated 0.23 mm thick plates of Keiselgel
60 F254 and visualised using UV (λ = 254 or 366 nm) or by staining with KMnO4 or ninhydrin. All retention
factors (Rf) are given to 0.01. All column chromatography was carried out using Merck 9385 Keiselgel 60
silica gel (230-400 mesh) or using a CombiFlashR© EZ Prep with RediSepR© normal-phase silica flash columns.
Preparative high-performance liquid chromatography (HPLC) was run on an Agilent 1260 Infinity machine,
using a SupelcosilTM ABZ+PLUS column (250 mm × 21.2 mm, 5 µm) with a linear gradient system (solvent A:
0.025% (v/v) TFA/water, solvent B: 0.05% (v/v) TFA/acetonitrile) at a flow rate of 20 mL min−1, visualised
by UV absorbance (λmax = 254 nm)
Nuclear magnetic resonance (NMR) spectra were recorded using an internal deuterium lock at ambient probe
temperatures on Bruker DPX-400, Bruker Avance DRX-400, Bruker Avance 500 BB-ATM or Bruker Avance
500 Cryo Ultrashield spectrometers. Data were processed using NMR Processor Academic Edition version 12
(ADC Labs) or TopSpin version 3.5 (Bruker). 1H and 13C spectra were assigned using DEPT, COSY, HMQC
and HMQC spectra where necessary, or by analogy to fully interpreted spectra of related compounds. The
following abbreviations are used to indicate the multiplicity of signals: s singlet, d doublet, t triplet, q quartet,
quin quintet, m multiplet and br broad.
1H chemical shifts (δ) are quoted to the nearest 0.01 ppm and are referenced relative to the residual solvent
peak.238 Coupling constants (J ) are given to the nearest 0.1 Hz. Diastereotopic protons are assigned as CHH
and CHH, where the latter designates the lower-field proton. Data are reported as follows: <chemical shift>
(<multiplicity>, <coupling constant(s) (if any)>, <integration>, <assignment>).
13C chemical shifts (δ) are quoted to the nearest 0.1 ppm and are referenced relative to the deuterated solvent
peak.238 Data are reported as follows: <chemical shift> (<multiplicity (if not s)>, <coupling constant(s) (if
any)>, <assignment>).
19F chemical shifts (δ) are quoted to the nearest 0.1 ppm. Data are reported as follows: <chemical shift>
(<assignment>).
High resolution mass spectrometry (HRMS) data were recorded using a Micromass LCT Premier spectrom-
eter or a Waters Vion IMS-QTOF spectrometer and reported mass values are within ± 5 ppm mass units.
Liquid chromatography–mass spectrometry (LCMS) data were recorded on an Agilent 1200 series LC with an
ESCi Multi-Mode Ionisation Waters ZQ spectrometer or a Waters ACQUITY H-Class UPLC with an ESCi
Multi-Mode Ionisation Waters SQD2 mass spectrometer.
Infrared (IR) spectra were recorded using neat sample on a PerkinElmer 1600 FT IR spectrometer. Selected
absorption maxima (νmax) are reported in wavenumbers (cm−1). Broad peaks are marked br.
Melting points (m.p.) were measured using a Buchi B-545 melting point apparatus and are uncorrected.
Optical rotations ([α]TD) were recorded on a PerkinElmer 343 polarimeter or an Anton-Paar MCP 100
polarimeter. [α]TD values are reported in ◦10−1cm2g−1 at 589 nm and concentration (c) is given in g (100
mL)−1.
All compounds subjected to biological testing were >95% pure unless otherwise stated.
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9.2 Methyl 3-oxodecanoate 33
O
O
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Meldrum’s acid 31 (9.00 g, 63.0 mmol, 1 eq.) was dissolved in anhydrous CH2Cl2 (150 mL) in an oven-dried
flask and cooled to 0 ◦C. Pyridine (10.2 mL, 126 mmol, 2 eq.) was added dropwise over 20 min. Octanoyl
chloride 32 (11.7 mL, 69.0 mmol, 1.1 eq.) was then added and the mixture was stirred at 0 ◦C for a further
4 h. The mixture was allowed to warm to r.t., diluted with CH2Cl2 (20 mL) and poured into a mixture of ice
(~30 g) and HCl (2 N, 90 mL). The solution was washed with NaCl (sat., aq., 150 mL) and dried over MgSO4.
The solvent was removed under vacuum to give an orange-brown oil. The oil was refluxed in anhydrous MeOH
(150 mL) for 5 h and the solvent was removed under vacuum. The resulting residue was purified by column
chromatography (SiO2, 5% Et2O/40-60 P.E.). A tautomeric mixture of 33 and 34 was obtained as a colourless
oil (8.34 g, 41.6 mmol, 66%. 92% 33 as determined by 1H NMR).
Keto form 33
TLC Rf = 0.12 (5% EtO2/PE)
IR (neat) νmax / cm−1 = 2928 (C-H), 2856 (C-H), 1747 (ester C=O), 1717 (ketone C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 3.74 (s, 3 H, OCH3), 3.45 (s, 2 H, C(=O)CH2C(=O)), 2.53 (t,
J = 7.4 Hz, 2 H, C(=O)CH2CH2), 1.60 (quin, J = 7.1 Hz, 2 H, C(=O)CH2CH2), 1.39 - 1.19 (m, 8 H,
CH2CH2CH2CH2CH3), 0.88 (t, J = 6.8 Hz, 3 H, CH2CH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 202.3 (CH3OC(=O)CH2C(=O)), 167.3 (CH3OC(=O)CH2C(=O)),
51.7 (OCH3), 48.5 (CH3OC(=O)CH2C(=O)), 42.5 (C(=O)CH2CH2), 31.3 (CH2), 28.7 (CH2), 28.6 (CH2), 23.1
(CH2), 22.2 (CH2), 13.6 (CH2CH3)
Enol form 34
TLC Rf = 0.12 (5% EtO2/PE)
IR (neat) νmax / cm−1 = 2928 (C-H), 2856 (C-H), 1654 (C=C), 1629 (α,β unsaturated C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 12.02 (s, 1 H, COH), 4.99 (s, 1 H, C(=O)CH=COH), 3.73 (s, 3
H, OCH3), 2.20 (t, J = 7.4 Hz, 2 H, COHCH2), 1.76 - 1.72 (m, 2 H, COHCH2CH2), 1.39 - 1.19 (m, 8 H,
CH2CH2CH2CH2CH3), 0.88 (t, J = 6.8 Hz, 3 H, CH2CH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 178.7 (CH3OC(=O)CH=COH), 172.7 (CH3OC(=O)CH=COH), 88.2
(CH3OC(=O)CH=COH), 50.5 (OCH3), 37.9 (COHCH2CH2), 34.6 (CH2), 31.2 (CH2), 29.0 (CH2), 25.9 (CH2),
22.3 (CH2), 13.6 (CH2CH3)
Spectroscopic data are consistent with the literature.168,169
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9.3 Methyl (E)-3-((4-((tert-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate 36
Methyl 3-oxodecanoate 33 (500 mg, 2.50 mmol, 1.00 eq.) and O-tert-butyl N -(4-aminophenyl)carbamate 35
(520 mg, 2.50 mmol, 1.00 eq.) were dissolved in MeOH (10 mL) and refluxed for 18 h. The solvent was removed
under vacuum and the resulting residue was purified by column chromatography (SiO2, gradient of 0 to 20%
Et2O/40-60 P.E.). 36 was obtained as a white amorphous solid (0.169 mg, 0.480 mmol, 19%).
TLC Rf = 0.30 (30% Et2O/40-60 P.E.)
mp T / ◦C = 79 (Et2O/40-60 P.E.)
IR (neat) νmax / cm−1 = 3337 (N-H), 2928 (C-H), 2857 (C-H), 1724 (carbamate C=O), 1635 (α,β unsaturated
C=O), 1611 (C=C), 1581 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 10.16 (s, 1 H, NHC(C7H15)=C), 7.35 (d, J = 8.6 Hz, 2 H, meta to
NHBoc), 7.02 (d, J = 8.7 Hz, 2 H, meta to enamine), 6.60 (br s, 1 H, NHBoc), 4.71 (s, 1 H, C=CH), 3.70 (s, 3
H, OCH3), 2.23 (t, J = 7.7 Hz, 2 H, CH2CH2CH2CH2CH2CH2CH3), 1.54 (s, 9 H, C(CH3)3), 1.40 (quin, J =
7.3 Hz, 2 H, CH2CH2CH2CH2CH2CH2CH3), 1.33 - 1.16 (m, 8 H, CH2CH2CH2CH2CH2CH2CH3), 0.86 (t, J =
7.1 Hz, 3 H, CH2CH2CH2CH2CH2CH2CH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 171.1 (C(=O)CH=C), 164.3 (C(=O)CH=C), 152.7 (OC(=O)NH),
136.0 (para to NHBoc), 134.1 (CNHBoc), 126.3 (meta to NHBoc), 119.1 (ortho to NHBoc), 83.8 (C(=O)CH=C),
80.7 (C(CH3)3), 50.2 (OCH3), 32.2 (CH2), 31.6 (CH2), 29.1 (CH2), 28.8 (CH2), 28.3 (C(CH3)3), 28.0 (CH2),
22.6 (CH2), 14.0 (CH3)
HRMS (ESI+) m/z / Da = 391.2589, [M+H]+, [C22H35N2O4]+ requires 391.2591
Spectroscopic data are consistent with the literature.164
9.4 6-Amino-2-heptylquinolin-4-ol 37
Methyl (E)-3-((4-((tert-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate 36 (168 mg, 0.649 mmol, 1 eq.) and
polyphosphoric acid (5 g) were heated to 90 ◦C for 1 h. The reaction mixture was then poured into NaHCO3
(sat., aq., 50 mL) cooled with ice. The precipitate was collected by vacuum filtration, washed with water (50
mL) and dried under high vacuum. 37 was obtained as a pale yellow amorphous solid (121 mg, 0.468 mmol,
100
72%).
mp T / ◦C = 249 (water)
IR (neat) νmax / cm−1 = 3337 (N-H), 2927 (C-H), 2857 (C-H), 1635 (C=O)
1H NMR (400 MHz, DMSO-d6) δ / ppm = 7.26 (d, J = 8.7 Hz, 1 H, meta to NH2), 7.15 (d, J = 2.6 Hz,
1 H, ortho to C(=O)), 6.95 (dd, J = 2.7, 8.8 Hz, 1 H, para to C(=O)), 5.74 (s, 1 H, ortho to CH2), 5.16 (s,
2 H, NH2), 2.52 (t, J = 7.4 Hz, 2 H, CCH2), 1.64 (quin, J = 7.6 Hz, 2 H, CCH2CH2), 1.36 - 1.19 (m, 8 H,
CH2CH2CH2CH2CH3), 0.86 (t, J = 7.0 Hz, 3 H, H3)
13C NMR (101 MHz, DMSO-d6) δ / ppm = 176.7 (C(=O)), 151.7 (CCH2), 145.1 (para to NH2 or ipso to
C(=O)), 132.4 (ipso to NH2), 126.6 (para to NH2 or ipso to C(=O)), 121.1 (para to C(=O)), 119.0 (meta to
NH2 and meta to C(=O)), 106.2 (CH=CCH2), 105.9 (ortho to NH2 and ortho to C(=O)), 33.6 (CCH2), 31.6
(CH2CH2CH3), 29.0 (CH2), 29.0 (CH2), 28.9 (CH2), 22.5 (CH2CH3), 14.4 (CH3)
HRMS (ESI+) m/z / Da = 259.1810, [M+H]+, [C16H23N2O]+ requires 259.1803
Spectroscopic data are consistent with the literature.164
9.5 6-Azido-2-heptylquinolin-4-ol 38
6-Amino-2-heptylquinolin-4-ol 37 (50 mg, 0.194 mmol, 1 eq) was dissolved in HCl (conc., aq., 1.20 mL), water
(1.80 mL) and MeOH (2.00 mL) and cooled to 0 ◦C. A solution of NaNO2 (16.0 mg, 0.232 mmol, 1.2 eq.) in
water (0.300 mL) was added dropwise over 10 min and the mixture was stirred for 1 h. A solution of NaN3 (15.1
mg, 0.232 mmol, 1.2 eq.) in water (0.300 mL) was then added. The mixture was warmed to room temperature
and stirred for a further 4 h. The resultant precipitate was filtered off and dried under reduced pressure. 38
hydrochloride salt* was obtained as a pale cream amorphous solid (25.6 mg, 0.0800 mmol, 41%).
TLC Rf = 0.40 (5% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3249 (N-H), 3065 (N-H), 2917 (C-H), 2853 (C-H), 2728 (C-H), 2107 (azide), 1635
(C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 7.73 (d, J = 8.6 Hz, 1 H, ortho to NH), 7.71 (d, J = 2.8 Hz, 1 H,
ortho to N3 and ortho to C(=O)), 7.47 (dd, J = 8.9, 2.7 Hz, 1 H, para to C(=O)), 6.24 (s, 1 H, C(=O)CH), 2.69
(t, J = 7.7 Hz, 2 H, CCH2), 1.68 (quin, J = 7.6 Hz, 2 H, CCH2CH2), 1.28 - 1.39 (m, 4 H, CCH2CH2CH2CH2),
1.18 - 1.28 (m, 4 H, CH2CH2CH3), 0.85 (t, J = 6.8 Hz, 3 H, CH3)
13C NMR (101 MHz, MeOD) δ / ppm = 172.3 (C(=O)), 155.5 (NHCCH2), 137.4 (CN3), 135.6 (para to N3),
124.6 (para to C(=O)), 124.1 (ipso to C(=O)), 120.7 (meta to N3 andmeta to C(=O)), 112.8 (ortho to N3 and or-
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tho to C(=O)), 107.0 (C(=O)CH), 33.3 (NHCCH2), 31.2 (CH2CH2CH3), 28.3 - 28.5 (CH2CH2CH2CH2CH2CH3),
22.1 (CH2CH3), 14.0 (CH3)
HRMS (ESI+) m/z / Da = 285.1728, [M+H]+ found, [C16H21N4O]+ requires 285.1715
Spectroscopic data are similar to the literature characterisation of the free amine.164
*Probably as the 4-hydroxyquinoline.89
9.6 Heptyl magnesium bromide 40
BrMg
Magnesium turnings (352 mg, 14.5 mmol, 1 eq.) were added to an oven-dried flask under argon. THF (15 mL)
was added, followed by bromoheptane 39 (2.40 mL, 14.5 mmol, 1 eq.) dropwise. The mixture was stirred at
r.t. for 2 h followed by heating to reflux for 2 h. Heptyl magnesium bromide 40 was obtained as a pale grey
suspension (15 mL, ~ 1 M) which was used without further purification.
9.7 2-Chloro-N -methoxy-N -methylacetamide 43
N,O-Dimethylhydroxyl amine hydrochloride 41 (6.00 g, 61.5 mmol, 1 eq.) and toluene (75 mL) were added
successively to a stirred solution of potassium carbonate (22.4 g, 162 mmol, 2.63 eq.) in water (75 mL) at 0 ◦C
under argon. The mixture was cooled to -5 ◦C and chloroacetyl chloride 42 (5.88 mL, 73.8 mmol, 1.20 eq.)
was added dropwise over 5 min. The mixture was allowed to warm to r.t. over 30 min, then the organic layer
was separated and the aqueous layer was extracted with toluene (3×20 mL). The combined organic extracts
were dried with MgSO4 and the solvent was removed by rotary evaporation followed by high vacuum. 43 was
obtained as white, prism-like crystals (7.24 g, 52.6 mmol, 71%).
mp T / ◦C = 39 (toluene)
IR (neat) νmax / cm−1 = 3016.7 (C-H), 2966.4 (C-H), 2946.7 (C-H), 2827.7 (C-H), 1666.2 (C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 4.20 (s, 2 H, ClCH2C=O), 3.71 (m, 3 H, OCH3), 3.18 (s, 3 H, NCH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 167.4 (C=O), 61.6 (OCH3), 40.9 (ClCH2C=O), 32.6 (NCH3)
Spectroscopic data are consistent with the literature.89
9.8 1-Chlorononan-2-one 44
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2-Chloro-N -methoxy-N -methylacetamide 43 (1.00 g, 7.26 mmol, 1 eq.) was added to a dry flask under argon.
THF (20 mL) was added and the flask cooled to 0 ◦C. Heptyl magnesium bromide 40 (~ 1 M, 15.0 mL, 15.0
mmol, 2.07 eq.) was added dropwise over 5 min, then the mixture was allowed to warm to r.t. and stirred for
15 h. The reaction mixture was then poured into HCl (aq., 2 N, 60 mL) at 0 ◦C and stirred for 10 min. The
mixture was extracted with toluene (30 mL) and the aqueous layer discarded. The organic layer was washed
with brine and dried with MgSO4, and the solvent was removed by rotary evaporation. 44 was obtained as a
colourless oil (1.23 g, 6.96 mmol, 96%).
IR (neat) νmax / cm−1 = 2952 (C-H), 2925 (C-H), 2856 (C-H), 1720 (C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 4.05 (s, 2 H, ClCH2C(=O)), 2.54 (t, J = 7.4 Hz, 2 H, C(=O)CH2CH2),
1.59 (quin, J = 7.0 Hz, 2 H, C(=O)CH2CH2), 1.34 - 1.21 (m, 8 H, CH2CH2CH2CH2CH3), 0.87 (t, J = 6.8 Hz,
3 H, CH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 202.6 (C(=O)), 48.1 (CH2Cl), 39.6 (C(=O)CH2CH2), 31.5 (CH2CH2
CH3), 28.9 (CH2), 28.9 (CH2), 23.5 (C(=O)CH2CH2), 22.5 (CH2CH3), 13.9 (CH3)
Spectroscopic data are consistent with the literature.89
9.9 2-Oxononyl 2-amino-5-nitrobenzoate 46
O2N
NH2
O
O
O
5-Nitroanthranilic acid 45 (500 mg, 2.75 mmol, 1.38 eq.) and potassium carbonate (270 mg, 2.00 mmol, 1 eq.)
were dissolved in DMF (5 mL). The mixture was heated under argon to 90 ◦C and stirred for 1 h then cooled
to r.t.. 1-Chlorononan-2-one 44 (353 mg, 2.00 mmol, 1 eq.) was added and the mixture was stirred for 15 h.
The solution was poured into Na2HCO3 (aq., 10%, 50 mL) and ice (~ 20 g). The precipitate was collected by
vacuum filtration, washed with water and dried under high vacuum. 46 was obtained as a yellow amorphous
solid (0.674 g, 2.00 mmol, >99%).
mp T / ◦C = 135 (water)
IR (neat) νmax / cm−1 = 3453 (N-H), 3351 (N-H), 2925 (C-H), 2854 (C-H), 1720 (ester C=O) 1704 (ketone
C=O) 1626 (N-H bend) 1603 (aromatic) 1573 (N-O) 1507 (N-O)
1H NMR (400 MHz, DMSO-d6) δ / ppm = 8.66 (d, J = 2.8 Hz, 1 H, ortho to C(=O)), 8.12 (dd, J = 2.8,
9.4 Hz, 1 H, para to C(=O)), 6.93 (d, J = 9.4 Hz, 1 H, meta to C(=O)), 5.05 (s, 2 H, OCH2C(=O)), 2.49
(t, J = 7.4 Hz, 2 H, C(=O)CH2CH2), 1.52 (quin, J = 7.2 Hz, 2 H, C(=O)CH2CH2), 1.32 - 1.20 (m, 8 H,
CH2CH2CH2CH2CH3), 0.86 (t, J = 6.8 Hz, 3 H, CH3)
13C NMR (101 MHz, DMSO-d6) δ / ppm = 204.4 (OCH2C(=O)), 165.6 (C(=O)O), 156.3 (ipso to NH2),
135.7 (ipso to NO2), 129.6 (para to C(=O)), 128.9 (ortho to C(=O)), 117.4 (meta to C(=O)), 107.5 (ipso
to C(=O)), 68.8 (OCH2C(=O)), 38.3 (C(=O)CH2CH2), 31.6 (CH2CH2CH3), 28.9 (CH2), 28.9 (CH2), 23.2
(C(=O)CH2CH2), 22.5 (CH2CH3), 14.4 (CH3)
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HRMS (ESI+) m/z / Da = 323.1610, [M+H]+, [C16H23N2O5]+ requires 323.1607
Spectroscopic data are consistent with the literature.164
9.10 6-Nitro-2-heptyl-3-hydroxyquinolin-4(1H )-one 47
O2N
N
H
O
OH
2-Oxononyl 2-amino-5-nitrobenzoate 46 (100 mg, 0.340 mmol, 1 eq.) and polyphosphoric acid (300 mg) were
stirred for 5.5 h at 90 ◦C under argon. The mixture was then poured into NaHCO3 (sat., aq., 50 mL) cooled
on ice. The precipitate was collected by vacuum filtration, washed with water (50 mL) and dried under high
vacuum. 47 was obtained as a yellow-brown amorphous solid (44 mg, 0.145 mmol, 43%).
mp T / ◦C = 223 (water, EtOAc)
IR (neat) νmax / cm−1 = 3436 (N-H), 3000 (O-H, br), 2955 (C-H), 2926 (C-H), 2851 (C-H), 1648 (C=O), 1571
(N-O), 1536 (N-O)
1H NMR (400 MHz, DMSO-d6) δ / ppm = 12.00 (s, 1 H, NH), 8.91 (d, J = 2.8 Hz, 1 H, ortho to C=O), 8.29
(dd, J = 2.7, 9.2 Hz, 1 H, para to C=O), 7.70 (d, J = 9.3 Hz, 1 H, meta to C=O), 2.75 (t, J = 7.7 Hz, 2 H,
CCH2), 1.67 (quin, J = 7.3 Hz, 2 H, CCH2CH2), 1.36 - 1.23 (m, 8 H, CH2CH2CH2CH2CH3), 0.85 (t, J = 7.0
Hz, 3 H, CH3)
13C NMR (101 MHz, DMSO-d6) δ / ppm = 169.7 (C=O), 141.9 (para to NO2), 140.7 (ipso to NO2), 139.6
(ipso to OH), 137.3 (C=COH), 124.3 (para to C=O), 122.3 (ortho to NO2 and ortho to C=O), 121.5 (ipso to
C=O), 120.0 (meta to NO2 and meta to C=O), 31.6 (CH2CH2CH3), 29.2 (CH2), 28.9 (CH2), 28.5 (CCH2),
28.1 (CCH2CH2), 22.5 (CH2CH3), 14.4 (CH3)
HRMS (ESI+) m/z / Da = 305.1501, [M+H]+, [C16H21N2O4]+ requires 305.1500
Spectroscopic data are consistent with the literature.164
9.11 6-Amino-2-heptyl-3-hydroxyquinolin-4(1H )-one 48
6-Nitro-2-heptyl-3-hydroxyquinolin-4(1H )-one 47 (20 mg, 0.0658 mmol, 1 eq.) and PtO2 (2 mg, 10 weight %)
were stirred in MeOH (1 mL) under a H2 atmosphere for 45 min at room temperature and pressure. The
reaction mixture was then filtered through celite and the solvent was removed under vacuum. 48 was obtained
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as a yellow-brown amorphous solid (14.5 mg, 0.0529 mmol, 80%).
mp (MeOH) T / ◦C = 176
IR (neat) νmax / cm−1 = 30000 (O-H, br) 29251 (C-H), 28549 (C-H), 16133 (C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 11.12 (s, 1 H, NH), 7.47 (d, J = 8.9 Hz, 1 H, meta to C=O), 7.40
(d, J = 2.4 Hz, 1 H, ortho to C=O), 7.16 (dd, J = 2.6, 9.0 Hz, 1 H, para to C=O), 2.86 (t, J = 7.5 Hz, 2 H,
CCH2), 1.75 (quin, J = 7.8 Hz, 2 H, CCH2CH2), 1.48 - 1.22 (m, J = 5.4 Hz, 8 H, CH2CH2CH2CH2CH3), 0.89
(t, J = 6.7 Hz, 3 H, CH3)
13C NMR (101 MHz, MeOD) δ / ppm = 166.8 (C(=O)), 144.8 (para to NH2 or ipso to C(=O)), 140.5 (COH),
138.6 (C=COH), 132.6 (ipso to NH2), 124.8 (para to NH2 or ipso to C(=O)), 123.8 (para to C(=O)), 107.7
(meta to NH2 and meta to C(=O)), 106.4 (ortho to NH2 and ortho to C(=O)), 33.0 (CH2CH2CH3), 29.5 - 31.0
(CCH2CH2CH2CH2), 23.8 (CH2CH3), 14.5 (CH3)
HRMS (ESI+) m/z / Da = 275.1760, [M+H]+, [C16H23N2O2]+ requires 275.1762
Spectroscopic data are not consistent with the literature.164 It is possible that Baker’s product is a Zn adduct.
9.12 6-Azido-2-heptyl-3-hydroxyquinolin-4(1H )-one 49
6-Amino-2-heptyl-3-hydroxyquinolin-4(1H )-one 48 (18.2 mg, 0.0664 mmol, 1 eq.) was dissolved in HCl (conc.,
aq., 0.8 mL) and MeOH (0.5 mL) at 0 ◦C. NaNO2 (5.0 mg, 0.0725 mmol, 1.09 eq.) in water (0.2 mL) was added
dropwise over 2 min and the mixture was stirred at 0 ◦C for 50 min, during which time the solution turned from
yellow to orange. NaN3 (4.9 mg, 0.0754 mmol, 1.14 eq.) in water (0.2 mL) was then added and the mixture
was allowed to warm to r.t. and stirred for 4 h. The reaction mixture was then filtered and the solid was dried
under reduced pressure. 49 was obtained as a brown amorphous solid (5.5 mg, 0.0183 mmol, 28%).
IR (neat) νmax / cm−1 = 3089 (N-H), 2921 (C-H), 2851 (C-H), 2108 (azide), 1632 (C=O)
1H NMR (400 MHz, DMSO-d6) δ / ppm = 7.74 (s, 1 H, ortho to C=O), 7.65 (d, J = 6.9 Hz, 1 H, meta to
C(=O)), 7.32 (d, J = 7.4 Hz, 1 H, para to C(=O)), 2.75 (t, J = 7.5 Hz, 2 H, CCH2), 1.67 (quin, J = 6.4 Hz, 2
H, CCH2CH2), 1.43 - 1.13 (m, 8 H, CH2CH2CH2CH2CH3), 0.85 (t, J = 6.8 Hz, 3 H, CH3)
13C NMR (101 MHz, DMSO-d6) δ / ppm = 166.3 (C(=O)), 137.9 (), 137.8 (CN3), 134.5 (ipso to C(=O)), 133.9
(C=COH), 122.7 (para to C(=O)), 122.6 (meta to N3 and meta to C(=O)), 120.4 (para to N3), 112.4 (ortho to
N3 and ortho to C(=O)), 31.2 (CH2CH2CH3), 28.8 (CCH2), 28.4 (CCH2CH2CH2), 28.3 (CCH2CH2CH2CH2),
27.8 (CCH2CH2), 22.1 (CH2CH3), 14.0 (CH3)
HRMS (ESI+) m/z / Da = 301.1649, [M+H]+, [C16H21N4O2]+ requires 301.1659
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Spectroscopic data are consistent with the literature.164
9.13 (S)-3-Aminodihydrofuran-2(3H )-one hydrobromide 52
l-Methionine 50 (3.04 g, 20.4 mmol, 1 eq.) and bromoacetic acid 51 (3.08 g, 22.2 mmol, 1.09 eq.) were dissolved
in i-PrOH (12.5 mL), H2O (12.5 mL) and AcOH (5 mL). The reaction was refluxed for 15 h then concentrated
under vacuum. The resulting brown oil was added to a mixture of i-PrOH (16 mL) and HBr (33% in AcOH, 4
mL), causing the precipitation of a pale pink amorphous solid. The precipitate was collected by filtration and
washed with i-PrOH (20 mL). The filtrate was concentrated under vacuum and precipitated again using the
same procedure. The two crops of precipitate were combined. 52 was obtained as a pale pink amorphous solid
(1.73 g, 9.50 mmol, 41% yield).
mp T / ◦C = 242 (i-PrOH/AcOH, gas evolved)
IR (neat) νmax / cm−1 = 2972 (N-H), 2878 (N-H), 1772 (C=O), 1585 (N-H bend), 1572 (N-H bend)
1H NMR (400 MHz, DMSO-d6) δ / ppm = 8.59 (br s, 3 H, NH+3 ), 4.46 (dt, J = 1.3, 8.9 Hz, 1 H, OCHH),
4.37 (dd, J = 8.8, 11.4 Hz, 1 H, CHNH+3 ), 4.29 (ddd, J = 6.1, 8.8, 10.9 Hz, 1 H, OCHH), 2.57 (dddd, J = 1.2,
6.1, 8.9, 12.3 Hz, 1 H, OCH2CHH), 2.26 (dtd, J = 9.0, 11.2, 12.2 Hz, 1 H, OCH2CHH)
13C NMR (101 MHz, DMSO-d6) δ / ppm = 173.3 (C=O), 66.2 (OCH2), 47.8 (CHNH+3 ), 27.0 (OCH2CH2)
[α]20D / ◦10−1cm2g−1 = -30.0, lit. = -25.0 (c / g(100 mL)−1 = 0.0200, DMSO)
The data are consistent with the literature.165
9.14 (S)-2-Bromo-N -(2-oxotetrahydrofuran-3-yl)acetamide 54
(S)-3-Aminodihydrofuran-2(3H )-one hydrobromide 52 (100 mg, 0.549 mmol, 1.08 eq.) and NaHCO3 (84.9 mg,
1.01 mmol, 2.00 eq.) were dissolved in CH2Cl2 (2 mL) and water (2 mL). Bromoacetyl bromide 53 (44.0 µL, 102
mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 24 h, after which the
CH2Cl2 was removed under vacuum. The aqueous phase was extracted with EtOAc (4×10 mL). The combined
organic layers were dried with MgSO4 and the solvent was removed under reduced pressure. 54 was obtained
as white, needle-like crystals (88.0 mg, 0.396 mmol, 74%).
mp T / ◦C = 132 (EtOAc)
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IR (neat) νmax / cm−1 = 3256 (N-H), 3067 (C-H), 1763 (lactone C=O), 1658 (amide C=O), 1553 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.94 (br s, 1 H, NH), 4.57 (ddd, J = 11.7, 8.6, 5.9 Hz, 1 H, CHNH),
4.51 (td, J = 9.2, 1.0 Hz, 1 H, OCHH), 4.32 (ddd, J = 11.3, 9.4, 5.9 Hz, 1 H, OCHH), 3.93 (s, 1 H, CHHBr),
3.93 (s, 1 H, CHHBr), 2.87 (dddd, J = 12.6, 8.6, 5.9, 1.3 Hz, 1 H, OCH2CHH), 2.22 (dtd, J = 12.6, 11.5, 11.5,
8.9 Hz, 1 H, OCH2CHH)
13C NMR (101 MHz, CDCl3) δ / ppm = 174.6 (OC=O), 166.4 (C(=O)NH), 66.1 (OCH2), 49.8 (CHNHC=O),
29.9 (OCH2CH2), 28.2 (O=CCH2Br)
HRMS The compound does not ionise.
[α]20D / ◦10−1cm2g−1 = 27.0, lit. = 20.5 (c / g(100 mL)−1 = 0.00740, CHCl3)
The data are consistent with the literature.165,239
9.15 (S)-2-Azido-N -(2-oxotetrahydrofuran-3-yl)acetamide 55
(3S)-2-Oxotetrahydrofuran-3-aminium bromide 52 (100 mg, 0.552 mmol, 1.08 eq.), NaN3 (85.7 mg, 1.32 mmol,
2.61 eq.) and NaHCO3 (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH2Cl2 (2 mL) and water (2 mL).
Bromoacetyl bromide 53 (44.0 µL, 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture
was stirred for 48 h, after which the CH2Cl2 was removed under vacuum. The aqueous phase was extracted
with EtOAc (4×10 mL). The combined organic layers were dried with MgSO4 and the solvent was removed
under reduced pressure. 55 was obtained as white, needle-like crystals (38.4 mg, 0.209 mmol, 41%).
mp T / ◦C = 87 (EtOAc)
IR (neat) νmax / cm−1 = 3284 (N-H), 2923 (C-H), 2853 (C-H), 2130 (N3), 1783 (lactone C=O), 1661 (amide
C=O), 1537 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 7.05 (br d, J = 6.5 Hz, 1 H, NH), 4.64 (ddd, J = 11.6, 8.7, 6.8 Hz, 1
H, CHNH), 4.48 (td, J = 9.1, 1.3 Hz, 1 H, OCHH), 4.30 (ddd, J = 11.2, 9.2, 6.0 Hz, 1 H, OCHH), 4.04 (s, 2
H, CH2N3), 2.76 (dddd, J = 12.5, 8.8, 6.0, 1.4 Hz, 1 H, OCH2CHH), 2.25 (dtd, J = 12.5, 11.4, 11.4, 8.9 Hz, 1
H, OCH2CHH)
13C NMR (101 MHz, CDCl3) δ / ppm = 174.9 (OC=O), 167.5 (C=ONH), 66.0 (OCH2), 52.2 (O=CCH2N3),
48.9 (CHNHC=O), 29.7 (OCH2CH2)
HRMS The compound does not ionise.
[α]20D / ◦10−1cm2g−1 = -32.6, lit. = -24.4 (c / g(100 mL)−1 = 0.0430, DMSO)
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The data are consistent with the literature.165
9.16 (S)-4-Bromo-N -(2-oxotetrahydrofuran-3-yl)butanamide 57
(S)-3-Aminodihydrofuran-2(3H )-one hydrobromide 52 (200 mg, 1.10 mmol, 1.00 eq.) and NaHCO3 (170 mg,
2.02 mmol, 1.84 eq.) were dissolved in CH2Cl2 (2 mL) and water (2 mL). Bromobutyryl chloride 56 (140 µL,
224 mg, 1.21 mmol, 1.10 eq.) was then added dropwise. The reaction mixture was stirred for 1 h, after which the
CH2Cl2 was removed under vacuum. The aqueous phase was extracted with EtOAc (7×5 mL) and the combined
organic layers were dried with MgSO4. The solvent was removed under vacuum to give white crystals which
were recrystallised from EtOAc. 57 was obtained as white, needle-like crystals (219 mg, 0.878 mmol, 80%).
mp T / ◦C = 105 (EtOAc)
IR (neat) νmax / cm−1 = 3308 (N-H), 3074 (C-H), 2949 (C-H), 1774 (lactone C=O), 1644 (amide C=O), 1541
(N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.31 (br d, J = 5.5 Hz, 1 H, NH), 4.59 (ddd, J = 6.2, 8.7, 11.5 Hz,
1 H, CHNH), 4.48 (dt, J = 1.2, 8.9 Hz, 1 H, OCHH), 4.30 (ddd, J = 5.8, 9.3, 11.3 Hz, 1 H, OCHH), 3.49 (t,
J = 6.3 Hz, 2 H, CH2Br), 2.82 (dddd, J = 1.3, 5.9, 8.7, 12.5 Hz, 1 H, OCH2CHH), 2.47 (t, J = 7.3 Hz, 2 H,
C(=O)CH2), 2.26 - 2.15 (m, 3 H, OCH2CHH and CH2CH2Br)
13C NMR (101 MHz, CDCl3) δ / ppm = 175.4 (OC=O), 172.3 (C(=O)NH), 66.1 (OCH2), 49.3 (CHNHC=O),
33.9 (C(=O)CH2), 33.1 (CH2Br), 30.3 (OCH2CH2), 27.9 (C(=O)CH2CH2)
HRMS The compound does not ionise.
[α]26.6D / ◦10−1cm2g−1 = -78 (c / g(100 mL)−1 = 0.0833, MeOH)
The compound has not been reported previously.
9.17 (S)-6-Bromo-N -(2-oxotetrahydrofuran-3-yl)hexanamide 60
(S)-3-Aminodihydrofuran-2(3H )-one hydrobromide 52 (100 mg, 0.549 mmol, 1.00 eq.) and NaHCO3 (84.9 mg,
1.01 mmol, 1.84 eq.) were dissolved in CH2Cl2 (2 mL) and water (2 mL) at r.t.. Bromohexanoyl chloride 59
(93.0 µL, 130 mg, 0.608 mmol, 1.11 eq.) was then added dropwise. The reaction mixture was stirred for 4 h,
after which the CH2Cl2 was removed under vacuum. The mixture was then filtered, washed with water (10 mL)
and dried under high vacuum. 60 was obtained as white, needle-like crystals (101 mg, 0.362 mmol, 66%).
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mp T / ◦C = 106 (CH2Cl2, water)
IR (neat) νmax / cm−1 = 3300 (N-H), 3068 (C-H), 2937 (C-H), 2857 (C-H), 1785 (lactone C=O), 1639 (amide
C=O), 1540 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.09 (br d, J = 5.7 Hz, 1 H, NH), 4.57 (ddd, J = 5.9, 8.6, 11.6 Hz, 1
H, CHNH), 4.50 (dt, J = 1.3, 9.1 Hz, 1 H, OCHH), 4.31 (ddd, J = 5.9, 9.3, 11.3 Hz, 1 H, OCHH), 3.43 (t, J
= 6.7 Hz, 2 H, CH2Br), 2.88 (dddd, J = 1.3, 5.9, 8.6, 12.6 Hz, 1 H, OCH2CHH), 2.30 (dt, J = 1.8, 7.5 Hz, 2
H, C(=O)CH2), 2.16 (dtd, J = 8.9, 11.5, 12.5 Hz, 1 H, OCH2CHH), 1.90 (quin, J = 7.2 Hz, 2 H, CH2CH2Br),
1.71 (quin, J = 7.6 Hz, 2 H, C(=O)CH2CH2), 1.59 - 1.46 (m, 2 H, C(=O)CH2CH2CH2)
13C NMR (101 MHz, CDCl3) δ / ppm = 175.5 (OC=O), 173.3 (C(=O)NH), 66.1 (OCH2), 49.3 (CHNHC=O),
35.8 (CH2Br), 33.5 (C(=O)CH2), 32.3 (CH2CH2Br), 30.5 (OCH2CH2), 27.6 (C(=O)CH2CH2), 24.4 (C(=O)CH2
CH2CH2)
HRMS (ESI+) m/z / Da = 278.0381, [M+H]+, [C10H17BrNO3]+ requires 278.0386
[α]26.6D / ◦10−1cm2g−1 = -16 (c / g(100 mL)−1 = 0.208, MeOH)
The compound has not been reported previously.
9.18 (S)-6-Azido-N -(2-oxotetrahydrofuran-3-yl)hexanamide 61
(S)-6-Bromo-N -(2-oxotetrahydrofuran-3-yl)hexanamide 60 (80 mg, 0.320 mmol, 1.00 eq.) and NaN3 (26.3 mg,
0.405 mmol, 1.27 eq.) were heated in DMF (0.5 mL) for 5 h at 100 ◦C. The reaction mixture was then parti-
tioned between CH2Cl2 (5 mL) and water (5 mL). The aqueous phase was extracted twice more with CH2Cl2
(2×5 mL) and the organic layers were combined and dried over MgSO4. The solvent was removed by rotary
evaporation followed by high vacuum. 61 was obtained as white, needle-like crystals (42.7 mg, 0.178 mmol,
56%).
mp T / ◦C = 90 (CH2Cl2)
IR (neat) νmax / cm−1 = 3314 (N-H), 2932 (C-H), 2863 (C-H), 2095 (N3), 1775 (lactone C=O), 1643 (amide
C=O), 1548 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 5.96 (d, J = 4.2 Hz, 1 H, NH), 4.54 (ddd, J = 11.7, 8.6, 5.7 Hz, 1
H, CHNH), 4.49 (td, J = 9.1, 1.0 Hz, 1 H, OCHH), 4.30 (ddd, J = 11.3, 9.4, 5.8 Hz, 1 H, OCHH), 3.29 (t, J
= 6.9 Hz, 2 H, CH2N3), 2.88 (dddd, J = 12.5, 8.6, 5.8, 1.1 Hz, 1 H, OCH2CHH), 2.28 (t, J = 7.5 Hz, 1 H,
C(=O)CHH), 2.28 (t, J = 7.4 Hz, 1 H, C(=O)CHH), 2.14 (dtd, J = 12.3, 11.5, 11.5, 8.8 Hz, 1 H, OCH2CHH),
1.70 (quin, J = 7.6 Hz, 2 H, CH2CH2N3), 1.63 (quin, J = 7.2 Hz, 2 H, C(=O)CH2CH2), 1.38 - 1.49 (m, 2 H,
C(=O)CH2CH2CH2)
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13C NMR (101 MHz, CDCl3) δ / ppm = 175.4 (OC=O), 172.2 (C(=O)NH), 66.1 (OCH2), 51.2 (CH2N3), 49.4
(CHNHC=O), 35.9 (C(=O)CH2), 30.7 (OCH2CH2), 28.6 (CH2CH2N3), 26.3 (C(=O)CH2CH2), 24.8 (C(=O)CH2
CH2CH2)
HRMS (ESI+) m/z / Da = 241.1289, [M+H]+, [C10H17N4O3]+ requires 241.1295
[α]26.6D / ◦10−1cm2g−1 = -16 (c / g(100 mL)−1 = 0.208, MeOH)
The compound has not been reported previously.
9.19 Hex-5-ynal 63
Pyridinium chlorochromate (14.6 g, 68.1 mmol, 1.50 eq) and CH2Cl2 (500 mL) were stirred at r.t. under argon.
5-Hexyn-1-ol 62 (5.00 mL, 45.4 mmol, 1 eq.) was added and the reaction mixture was stirred for 5 h followed
by addition of Et2O (125 mL) and silica gel (62.5 g). The suspension was stirred for 1 h then filtered through a
pad of silica (100 g) and washed with Et2O. The solvent was removed by rotary evaporation. 63 was obtained
as a pale yellow-green oil (4.72 g, 49.1 mmol, 72%).
IR (neat) νmax / cm−1 = 3293 (alkyne C-H), 2943 (alkane C-H), 2831 (aldehyde C-H), 2729 (aldehyde C-H),
1720 (aldehyde C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 9.80 (s, 1 H, C(=O)H), 2.60 (t, J = 7.1 Hz, 2 H, CH2C(=O)H),
2.26 (dt, J = 2.6, 6.8 Hz, 2 H, HC≡CCH2), 1.98 (t, J = 2.7 Hz, 1 H, HC≡C), 1.85 (quin, J = 7.0 Hz, 2 H,
HC≡CCH2CH2)
13C NMR (101 MHz, CDCl3) δ / ppm = 201.6 (C(=O)), 83.1 (HC≡C), 69.3 (HC≡C), 42.4 (CH2C(=O)), 20.7
(CH2CH2C(=O)), 17.6 (HC≡CCH2)
Spectroscopic data are consistent with the literature.176
9.20 tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 65
Hex-5-ynal 63 (0.407 g, 4.24 mmol, 1.00 eq.) and tert-butyl piperazine-1-carboxylate 64 (0.791 g, 4.24 mmol,
1.00 eq.) were stirred under a N2 atmosphere in 1,2-dichloroethane (20 mL) for 2.5 h followed by addition of
sodium triacetoxyborohydride (6.25 g, 29.5 mmol, 7 eq.) in four portions over 4 d. The mixture was stirred for
a further day then NaHCO3 (sat., aq., 120 mL) was added and the product extracted with EtOAc (2×100 mL).
The solvent was dried over MgSO4 and removed by rotary evaporation. 65 was obtained as a colourless liquid
(1.12 g, 4.21 mmol, 99%).
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TLC Rf (10% MeOH/CH2Cl2) = 0.55
IR (neat) νmax / cm−1 = 3304 (alkyne C-H), 2940 (alkane C-H), 2865 (C-H), 2810 (C-H), 1691 (carbamate
C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 3.44 (t, J = 5.2 Hz, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 2.39 (t,
J = 5.1 Hz, 4 H, CH2CH2CH2N(CH2)CH2), 2.37 (t, J = 7.3 Hz, 2 H, CH2CH2CH2N), 2.23 (dt, J = 2.7, 6.8
Hz, 2 H, HC≡CCH2), 1.96 (t, J = 2.7 Hz, 1 H, HC≡C), 1.65 - 1.53 (m, 4 H, HC≡CCH2CH2CH2), 1.47 (s, 9
H, CH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 154.7 (NC(=O)O), 84.2 (HC≡C), 79.6 (C(CH3)3), 68.5 (HC≡C), 60.4
(CH2CH2CH2N), 58.0 (CH2CH2CH2N(CH2)CH2), 53.0 (CH2CH2CH2N(CH2CH2)CH2CH2), 28.4 (C(CH3)3),
26.3 (CH2CH2N), 25.7 (HC≡CCH2CH2), 18.3 (HC≡CCH2)
HRMS (ESI+) m/z / Da = 267.2073, [M+H]+, [C15H27N2O2]+ requires 267.2064
The compound has not been reported previously.
9.21 1-(Hex-5-yn-1-yl)piperazine 66
tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 65 (763 mg, 2.86 mmol) was stirred in TFA (10 mL) at r.t.
for 2 h. The TFA was removed under vacuum followed by co-evaporation with CH2Cl2 (2×20 mL). The oil was
diluted with water (10 mL) and the pH adjusted to 14 with NaOH (10% aq.). This mixture was extracted with
CH2Cl2 (2×20 mL) and the combined organic layers were dried over MgSO4. The solvent was removed under
vacuum and purified by column chromatography (SiO2 MeOH/CH2Cl2 3:7). 66 was obtained as a colourless
liquid (476 mg, 2.86 mmol, >99%).
TLC Rf (30% MeOH/CH2Cl2) = 0.20
IR (neat) νmax / cm−1 = 3296 (alkyne C-H), 2941 (alkane C-H), 2811 (alkane C-H), 1637 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 2.88 (t, J = 4.9 Hz, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 2.39 (m,
4 H, CH2CH2CH2N(CH2)CH2), 2.31 (t, J = 7.1 Hz, 2 H, HC≡CCH2CH2CH2CH2N), 2.20 (dt, J = 2.7, 6.8 Hz, 2
H, HC≡CCH2), 2.05 (br s, 1 H, NH), 1.93 (t, J = 2.7 Hz, 1 H, HC≡C), 1.65 - 1.48 (m, 4 H, HC≡CCH2CH2CH2-
CH2N)
13C NMR (101 MHz, CDCl3) δ / ppm = 84.3 (HC≡C), 68.4 (HC≡C), 58.6 (CH2CH2CH2N), 54.5 (CH2CH2
CH2N(CH2)CH2), 46.0 (CH2CH2CH2N(CH2CH2)CH2CH2), 26.4 (CH2CH2CH2N), 25.7 (HC≡CCH2CH2), 18.3
(HC≡CCH2)
HRMS (ESI+) m/z / Da = 167.1548, [M+H]+, [C10H19N2]+ requires 167.1548
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The compound has not been reported previously.
9.22 1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydro-
quinoline-3-carboxylic acid 68
7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquino-line-3-carboxylic acid 67 (1.27 g, 4.51 mmol, 1 eq.), 1-
(hex-5-yn-1-yl)piperazine 66 (1.5 g, 9.02 mmol, 2 eq.) and N -methyl-2-pyrrolidone (10 mL) were stirred in a
microwave reactor at 115 ◦C for 24 h. The reaction mixture was cooled to r.t. and water (80 mL) was added. The
mixture was stirred for 3 h and then filtered, and residue was washed with MeOH (50 mL). The resulting solid
(0.571 g) was further purified by recrystalisation from EtOAc (50 mL). 68 was obtained as off-white crystals
(0.219 g, 0.531 mmol, 12%).
TLC Rf = 0.02 (10% MeOH/CH2Cl2)
mp T / ◦C = 220 (MeOH, decomposes)
IR (neat) νmax / cm−1 = 3212 (alkyne C-H), 2459 (O-H), 1723 (carboxylic acid C=O), 1627 (quinolone C=O)
1H NMR (500 MHz, DMSO-d6) δ / ppm = 15.12 (br s, 1 H, C(=O)OH), 8.69 (s, 1 H, ortho to C(=O)OH),
7.96 (d, J = 13.0 Hz, 1 H, ortho to F), 7.61 (d, J = 7.6 Hz, 1 H, meta to F), 3.82 - 3.92 (m, 3 H, NCH(CH2)2
and CH2CH2CH2N(CH2CH2)CH2CH2), 3.54 - 3.68 (br m, 2 H, CH2CH2CH2N(CH2)CH2), 3.45 (br. t, J =
11.6 Hz, 2 H, CH2CH2CH2N(CH2CH2)CH2CH2), 3.21 - 3.29 (br m, 2 H, CH2CH2CH2N(CH2CH2)CH2CH2),
3.11 - 3.20 (br m, 2 H, CH2CH2CH2N(CH2)CH2), 2.84 (t, J = 2.7 Hz, 1 H, HC≡C), 2.24 (td, J = 7.0, 2.7
Hz, 2 H, HC≡CCH2), 1.83 (br. quin, J = 7.5 Hz, 2 H, HC≡CCH2CH2CH2), 1.52 (quin, J = 7.4 Hz, 2 H,
HC≡CCH2CH2), 1.29 - 1.36 (m, 2 H, NCH(CHH)2), 1.16 - 1.23 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO-d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 165.8 (C(=O)OH), 152.8 (d, J =
248.5 Hz, ipso to F), 148.2 (CHCC(=O)OH), 143.7 (d, J = 11.1 Hz, para to C(=O)), 139.1 (para to F), 119.4
(d, J = 6.9 Hz, ipso to C(=O)), 111.2 (d, J = 22.5 Hz, ortho to F and ortho to C(=O)), 106.9 (meta to
F and meta to C(=O)), 106.9 (C(=O)CC(=O)OH), 83.9 (HC≡C), 71.8 (HC≡C), 55.0 (CH2CH2CH2N), 50.5
(CH2CH2CH2N(CH2)CH2), 46.3 (CH2CH2CH2N(CH2CH2)CH2CH2), 36.0 (NCH(CH2)2), 25.2 (HC≡CCH2CH2),
22.3 (HC≡CCH2CH2CH2), 17.4 (HC≡CCH2), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -121.8 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 412.2036, [M+H]+, [C23H27N3O3F]+ requires 412.2030
The compound has not been reported previously.
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9.23 4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenol 69
Hydrobromic acid (48% w/w, aq., 50 mL) was heated to 100 ◦C. Trimethoprim 25 (5.00 g, 17.2 mmol) was
added, and the suspension was stirred for 40 min under Ar. The mixture was removed from the heat, and NaOH
(50% w/w, aq., 15 mL) was added dropwise. The reaction mixture was then cooled slowly to 0 ◦C, and the
resulting crystals were filtered out and washed with cold water. The crystals were then dissolved in hot water
(80 mL), neutralized with NH4OH (sat., aq.) and cooled slowly to 0 ◦C. The resulting crystals were filtered
out, washed with cold water and dried under vacuum. 69 was obtained as pale pink prisms (2.06 g, 7.46 mmol,
43%).
TLC Rf = 0.04 (5% MeOH/CHCl2)
mp T / ◦C = 238 (water, decomposes)
IR (neat) νmax / cm−1 = 3314 (N-H), 3137 (N-H), 3045 (C-H), 3001 (C-H), 2938 (C-H), 2839 (C-H), 1663
(pyrimidine), 1645 (pyrimidine), 1627 (pyrimidine)
1H NMR (400 MHz, MeOD) δ / ppm = 7.21 (s, 1 H, CHN), 6.54 (s, 2 H, meta to OCH2), 4.87 (br s, 5 H,
OH, NH2 × 2), 3.82 (s, 6 H, OCH3), 3.63 (s, 2 H, CCH2C)
13C NMR (101 MHz, MeOD) δ / ppm = 166.4 (CH2CCNH2), 162.0 (CHNCNH2), 156.2 (CHNCNH2), 149.8
(ipso to OCH3), 135.9 (ipso to OH), 128.2 (para to OH), 111.7 (CH2CCNH2), 107.5 (meta to OH), 57.0 (OCH3),
33.9 (CCH2C)
HRMS (ESI+) m/z / Da = 277.1295, [M+H]+ found, [C13H17N4O3]+ requires 277.1301
The data are consistent with the literature.167
9.24 5-(4-(Hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71
4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenol 69 (1.00 g, 3.62 mmol, 1 eq.), 6-chloro-1-hexyne
70 (0.524 mL, 0.420 g, 4.34 mmol, 1.2 eq.), Cs2CO3 (2.36 g, 7.24 mmol, 2 eq.) and anhydrous DMF (30 mL)
were stirred at 70 ◦C for 7 h. The solvent was removed under reduced pressure, then CH2Cl2 (30 mL) was
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added and the mixture filtured. The filtrate was concentrated under reduced pressure and purified by column
chromatography using a Combiflash (SiO2, 5% MeOH/CH2Cl2). 71 was obtained as a pale cream amorphous
solid (0.327 g, 0.917 mmol, 25%).
TLC Rf = 0.14 (5% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3451 (alkyne C-H), 3313 (N-H), 3137 (N-H), 3114 (N-H), 2944 (C-H), 2839 (C-H),
1635 (pyrimidine)
1H NMR (400 MHz, MeOD) δ / ppm = 7.77 (s, 1 H, CHN), 6.37 (s, 2 H, meta to OCH2), 4.83 (br s, 2 H,
CHNCNH2), 4.63 (br s, 2 H, CH2CCNH2), 3.95 (t, J = 6.3 Hz, 2 H, CH2O), 3.79 (s, 6 H, OCH3), 3.65 (s, 2 H,
CCH2C), 2.28 (td, J = 7.1, 2.6 Hz, 2 H, HC≡CCH2), 1.94 (t, J = 2.7 Hz, 1 H, HC≡C), 1.81 - 1.90 (m, 2 H,
CH2CH2O), 1.71 - 1.80 (m, 2 H, CH2CH2CH2O)
13C NMR (101 MHz, MeOD) δ / ppm = 162.7 (CH2CCNH2), 162.0 (CHNCNH2), 156.4 (CHNCNH2), 153.8
(ipso to OCH3), 136.0 (ipso to OCH2), 133.6 (para to OCH2), 106.5 (CH2CCNH2), 105.0 (meta to OCH2), 84.5
(HC≡C), 72.6 (CH2O), 68.3 (HC≡C), 56.1 (OCH3), 34.7 (CCH2C), 29.1 (CH2CH2O), 24.9 (CH2CH2CH2O),
18.0 (HC≡CCH2)
HRMS (ESI+) m/z / Da = 357.1920, [M+H]+ found, [C19H25N4O3]+ requires 357.1927
The compound has not been reported previously.
9.25 Optimised general procedure for the click reaction
Azide (1 eq.) and alkyne (1 eq.) were dissolved in 50% t-BuOH/water in a round-bottomed flask with a stirrer
bar, closed with a new septum. The mixture was degassed by bubbling through N2. The mixture was placed
under positive pressure of Ar using a balloon. Equimolar amounts of CuSO4 · 5H2O and THPTA 74 were
dissolved in water to make a 50 mM solution and similarly degassed. Sodium ascorbate was dissolved in water
to make a 100 mM solution and similarly degassed. The Cu/THPTA solution (0.05 eq.) was added to the reaction
mixture, followed by the sodium ascorbate solution (0.1 eq.). The mixture was stirred for 2 h and monitored
using LCMS. HL derivative conjugates were dry-loaded onto SiO2 and purified by column chromatography
(SiO2, 0-20% MeOH/CH2Cl2). Other conjugates were purified by preparative HPLC (5-95% acetonitrile/water
over 20 min).
9.26 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(2-oxo-2-((2-oxotetrahydrofuran-
3-yl)amino)ethyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquin
oline-3-carboxylic acid 72
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50% water/t-BuOH (2 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (20.6
mg, 50.0 µmol, 1 eq.) and (S)-2-azido-N -(2-oxotetrahydrofuran-3-yl)acetamide 55 (9.2 mg, 50.0 µmol, 1 eq.).
A similarly degassed solution of CuSO4 · 5H2O (624 µg, 2.5 µmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5
µmol, 0.05 eq. 50 mM) and sodium ascorbate (991 µg, 5 µmol, 0.1 eq., 100 mM) in 50% water/t-BuOH (50
µl) was then added. The mixture was stirred at r.t. under argon for 3 h. On observation that the reaction had
stalled, the reaction was degassed again, and a further portion of cataylst solution (50 µl) was added. After
a further 3 h the reaction mixture was dry-loaded onto SiO2 and purified by column chromatography using a
Combiflash (SiO2, 0-20% MeOH/CH2Cl2 over 15 min). The combined pure fractions were dried with MgSO4
and evaporated under reduced pressure. 72 was obtained as a white amorphous solid (8.8 mg, 14.8 µmol, 30%).
IR (neat) νmax / cm−1 = 3266 (N-H), 2949 (C-H), 2935 (C-H), 2827 (C-H), 1778 (lactone C=O), 1725 (car-
boxylic acid C=O), 1665 (amide C=O), 1626 (quinolone C=O)
1H NMR (400 MHz, DMSO d6) δ / ppm = 15.23 (s, 1 H, C(=O)OH), 8.84 (d, J = 7.9 Hz, 1 H, NH), 8.66
(s, 1 H, ortho to C(=O)OH), 7.90 (d, J = 13.3 Hz, 1 H, ortho to F), 7.82 (s, 1 H, CH=CCH2), 7.57 (d, J =
7.6 Hz, 1 H, meta to F), 5.13 (s, 1 H, C(=O)CHHN), 5.12 (s, 1 H, C(=O)CHHN), 4.64 (ddd, J = 10.9, 9.0, 7.8
Hz, 1 H, CHNH), 4.36 (td, J = 8.9, 1.7 Hz, 1 H, OCHH), 4.23 (ddd, J = 10.6, 8.8, 6.4 Hz, 1 H, OCHH), 3.83
(tt, J = 7.0, 4.0 Hz, 1 H, NCH(CH2)2), 3.32 (br s, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 2.67 (t, J = 7.4
Hz, 2 H, CH=CCH2), 2.58 (br t, J = 5.0 Hz, 4 H, CH2CH2CH2N(CH2)CH2), 2.42 - 2.49 (m, 1 H, OCH2CHH),
2.40 (t, J = 7.1 Hz, 2 H, CH=CCH2CH2CH2CH2), 2.17 (dtd, J = 11.7, 10.8, 9.0 Hz, 1 H, OCH2CHH), 1.66
(quin, J = 7.2 Hz, 2 H, CH=CCH2CH2), 1.53 (quin, J = 7.2 Hz, 2 H, CH=CCH2CH2CH2), 1.28 - 1.35 (m, 2
H, NCH(CHH)2), 1.16 - 1.21 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 174.9 (OC(=O)), 166.0 (C(=O)OH),
165.9 (NHC(=O)), 153.1 (d, J = 250.8 Hz, ipso to F), 148.0 (CH=CC(=O)OH), 146.6 (CH=CCH2), 145.3
(d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 123.4 (CH=CCH2), 118.5 (d, J = 7.5 Hz, para to
piperazine), 110.9 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.4 (d, J = 3.2 Hz,
meta to C=O and meta to F), 65.4 (OCH2), 57.3 (CH=CCH2CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2),
51.2 (C(=O)CH2N), 49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 48.2
(CHNH), 35.9 (NCH(CH2)2), 28.2 (CH2CHNH), 26.8 (CH=CCH2CH2), 25.7 (CH=CCH2CH2CH2), 24.9 (CH=C
CH2), 7.6 (NCH(CH2)2)
HRMS (ESI+) m/z / Da = 596.2627, [M+H]+ found, [C29H35FN7O6]+ requires 596.2633
[α]20D / ◦10−1cm2g−1 = -3.5 (c / g(100 mL)−1 = 0.0575 , MeOH)
The compound has not been reported previously.
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9.27 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrofuran-
3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquin
oline-3-carboxylic acid 77
50% water/t-BuOH (2 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (20.6
mg, 50.0 µmol, 1 eq.) and (S)-4-azido-N -(2-oxotetrahydrofuran-3-yl)butanamide 58 (10.6 mg, 50.0 µmol, 1 eq.).
A similarly degassed solution of CuSO4 · 5H2O (624 µg, 2.5 µmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 µmol,
0.05 eq. 50 mM) and sodium ascorbate (991 µg, 5 µmol, 0.1 eq., 100 mM) in 50% water/t-BuOH (50 µl) was then
added. The mixture was stirred at r.t. under argon for 3 h, then dry-loaded onto SiO2 and purified by column
chromatography using a Combiflash (SiO2, 0-20% MeOH/CH2Cl2 over 15 min). The combined pure fractions
were dried with MgSO4 and evaporated under reduced pressure. 77 was obtained as a white amorphous solid
(14.6 mg, 23.4 µmol, 47%).
IR (neat) νmax / cm−1 = 3287 (N-H), 2950 (C-H), 2821 (C-H), 2778 (C-H), 1778 (lactone C=O), 1726 (car-
boxylic acid C=O), 1664 (amide C=O), 1626 (quinolone C=O)
1H NMR (500 MHz, DMSO d6) δ / ppm = 15.22 (br s, 1 H, C(=O)OH), 8.65 (s, 1 H, ortho to C(=O)OH),
8.40 (d, J = 8.0 Hz, 1 H, NH), 7.88 (d, J = 13.4 Hz, 1 H, ortho to F), 7.85 (s, 1 H, CH=CCH2), 7.55 (d, J
= 7.5 Hz, 1 H, meta to F), 4.53 (ddd, J = 10.9, 9.0, 8.1 Hz, 1 H, CHNH), 4.33 (td, J = 8.9, 1.8 Hz, 1 H,
OCHH), 4.31 (t, J = 7.0 Hz, 2 H, CH2NCH=C), 4.20 (ddd, J = 10.5, 8.8, 6.5 Hz, 1 H, OCHH), 3.82 (tt, J
= 6.9, 4.0 Hz, 1 H, NCH(CH2)2), 3.32 (br. t, J = 4.2 Hz, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 2.64 (t,
J = 7.4 Hz, 2 H, CH=CCH2), 2.57 (br. t, J = 5.0 Hz, 2 H, CH2CH2CH2N(CH2)CH2), 2.34 - 2.42 (m, 3 H,
OCH2CHH and CH=CCH2CH2CH2CH2), 2.09 - 2.19 (m, 3 H, OCH2CHH and C(=O)CH2), 2.02 (quin, J =
7.2 Hz, 2 H, C(=O)CH2CH2), 1.64 (quin, J = 7.6 Hz, 2 H, CH=CCH2CH2), 1.52 (quin, J = 7.2 Hz, 2 H,
CH=CCH2CH2CH2), 1.29 - 1.34 (m, 2 H, NCH(CHH)2), 1.15 - 1.21 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO d6) δ / ppm = 176.3 (C(=O)CC(=O)OH), 175.4 (OC(=O)), 171.2 (NHC(=O)),
166.0 (C(=O)OH), 153.0 (d, J = 248.6 Hz, ortho to F), 148.0 (CH=CC(=O)OH), 146.8 (CH=CCH2), 145.2
(d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 121.7 (CH=CCH2), 118.5 (d, J = 7.5 Hz, para to
piperazine), 110.9 (d, J = 22.4 Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.3 (d, J = 3.2 Hz,
meta to C=O and meta to F), 65.3 (OCH2), 57.3 (CH=CCH2CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2),
49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.4 (CH2CH2CH2N(CH2CH2)CH2CH2), 48.6 (CH2NCH=C), 47.9
(OC(=O)CHNH), 35.9 (NCH(CH2)2), 31.7 (NHC(=O)CH2), 28.2 (CH2CHNH), 26.9 (CH=CCH2CH2), 25.8
(NHC(=O)CH2CH2 and CH=CCH2CH2CH2), 24.9 (CH=CCH2), 7.6 (NCH(CH2)2)
HRMS (ESI+) m/z / Da = 624.2928, [M+H]+ found, [C31H39FN7O6]+ requires 624.2946
[α]20D / ◦10−1cm2g−1 = -10.6 (c / g(100 mL)−1 = 0.094 , MeOH)
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The compound has not been reported previously.
9.28 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(6-oxo-6-((2-oxotetrahydrofuran-
3-yl)amino)hexyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquin
oline-3-carboxylic acid 78
50% water/t-BuOH (2 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (20.6
mg, 50.0 µmol, 1 eq.) and (S)-6-azido-N -(2-oxotetrahydrofuran-3-yl)hexanamide 61 (12.0 mg, 50.0 µmol, 1 eq.).
A similarly degassed solution of CuSO4 · 5H2O (624 µg, 2.5 µmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 µmol,
0.05 eq. 50 mM) and sodium ascorbate (991 µg, 5 µmol, 0.1 eq., 100 mM) in 50% water/t-BuOH (50 µl) was then
added. The mixture was stirred at r.t. under argon for 3 h, then dry-loaded onto SiO2 and purified by column
chromatography using a Combiflash (SiO2, 0-20% MeOH/CH2Cl2 over 15 min) The combined pure fractions
were dried with MgSO4 and evaporated under reduced pressure. 78 was obtained as a white amorphous solid
(12.4 mg, 19.0 µmol, 38%).
TLC Rf = 0.30 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3302 (N-H), 2940 (C-H), 2858 (C-H), 1785 (lactone C=O), 1729 (carboxylic acid
C=O), 1658 (amide C=O), 1626 (quinolone C=O)
1H NMR (500 MHz, DMSO d6) δ / ppm = 15.22 (br s, 1 H, C(=O)OH), 8.65 (s, 1 H, ortho to C(=O)OH),
8.32 (d, J = 8.0 Hz, 1 H, NH), 7.89 (d, J = 13.3 Hz, 1 H, ortho to F), 7.84 (s, 1 H, CH=CCH2), 7.55 (d, J
= 7.6 Hz, 1 H, meta to F), 4.51 (ddd, J = 10.9, 9.1, 7.9 Hz, 1 H, CHNH), 4.33 (td, J = 8.8, 1.8 Hz, 1 H,
OCHH), 4.28 (t, J = 7.1 Hz, 2 H, CH2NCH=C), 4.19 (ddd, J = 10.5, 8.7, 6.6 Hz, 1 H, OCHH), 3.82 (tt, J =
7.0, 4.0 Hz, 1 H, NCH(CH2)2), 3.32 (br t, J = 4.5, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 2.63 (t, J = 7.5
Hz, 2 H, CH=CCH2), 2.57 (br t, J = 4.2 Hz, 4 H, CH2CH2CH2N(CH2)CH2), 2.33 - 2.41 (m, 3 H, OCH2CHH
and CH=CCH2CH2CH2CH2), 2.06 - 2.16 (m, 3 H, OCH2CHH and C(=O)CH2), 1.79 (quin, J = 7.4 Hz, 2 H,
C(=O)CH2CH2CH2CH2), 1.63 (quin, J = 7.5 Hz, 2 H, CH=CCH2CH2), 1.45 - 1.56 (m, 4 H, C(=O)CH2CH2
and CH=CCH2CH2CH2), 1.29 - 1.34 (m, 2 H, NCH(CHH)2), 1.19 - 1.25 (m, 2 H, C(=O)CH2CH2CH2), 1.15 -
1.19 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 175.4 (OC(=O)), 172.1 (NHC(=O)),
166.0 (C(=O)OH), 153.0 (d, J = 250.2 Hz, ipso to F), 148.0 (CH=CC(=O)OH), 146.8 (CH=CCH2), 145.2
(d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 121.6 (CH=CCH2), 118.5 (d, J = 8.0 Hz, para to
piperazine), 110.9 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.3 (d, J = 2.1 Hz,
meta to C=O and meta to F), 65.3 (OCH2), 57.4 (CH=CCH2CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2),
49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.0 (CH2NCH=C), 47.8
(CHNH), 35.9 (NCH(CH2)2), 34.8 (NHC(=O)CH2), 29.5 (CH2CH2NCH=C), 28.3 (CH2CHNH), 26.9 (CH=C
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CH2CH2), 25.7 (CH=CCH2CH2CH2), 25.4 (NHC(=O)CH2CH2CH2), 24.9 (CH=CCH2), 24.5 (NHC(=O)CH2C
H2), 7.6 (NCH(CH2)2)
HRMS (ESI+) m/z / Da = 652.3254, [M+H]+ found, [C33H43FN7O6]+ requires 652.3248
[α]20D / ◦10−1cm2g−1 = -8.5 (c / g(100 mL)−1 = 0.106 , MeOH)
The compound has not been reported previously.
9.29 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-1
H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carbo
xylic acid 80
50% water/t-BuOH (1 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (4.1
mg, 10.0 µmol, 1 eq.) and 6-azido-2-heptylquinolin-4(1H )-one 38 (2.8 mg, 10.0 µmol, 1 eq.). A similarly de-
gassed solution of CuSO4 · 5H2O (125 µg, 0.5 µmol, 0.05 eq. 50 mM), THPTA (218 µg, 0.5 µmol, 0.05 eq.
50 mM) and sodium ascorbate (198 µg, 1 µmol, 0.1 eq., 100 mM) in 50% water/t-BuOH (10 µl) was then
added. The mixture was stirred at r.t. under argon for 1.5 h, then the reaction mixture was evaporated under
reduced pressure. The residue was purified by preparative HPLC (50-100% acetonitrile/water over 20 min). The
combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO3 (aq.,
sat., 10 mL) and 10% i-PrOH/CHCl3 (10 mL). The organic layer was dried with MgSO4 and evaporated under
reduced pressure. 80 was obtained as a white amorphous solid (8.6 mg, 2.7 µmol, 27%).
IR (neat) νmax / cm−1 = 2927 (C-H), 2866 (C-H), 1716 (carboxylic acid C=O), 1631 (ciprofloxacin quinolone
C=O and HHQ C=O)
1H NMR (500 MHz, DMSO d6) 15.12 (br s, 1 H, C(=O)OH), 11.79 (s, 1 H, NH), 8.75 (s, 1 H, NCH=CCH2),
8.71 (s, 1 H, ortho to C(=O)OH), 8.40 (d, J = 2.7 Hz, 1 H, ortho to C(=O) and ortho to N), 8.18 (dd, J = 8.9,
2.6 Hz, 1 H, para to C(=O) and ortho to N), 7.99 (d, J = 13.0 Hz, 1 H, ortho to F), 7.75 (d, J = 9.0 Hz, 1 H,
meta to C(=O) and meta to N), 7.62 (d, J = 7.8 Hz, 1 H, meta to F), 6.02 (s, 1 H, NHC=CHC(=O)), 3.85 (tt,
J = 7.0, 4.0 Hz, 1 H, NCH(CH2)2), 3.23 - 3.30 (m, 10 H, CH2N(CH2CH2)CH2CH2), 2.82 (t, J = 5.9 Hz, 2 H,
NCH=CCH2), 2.63 (t, J = 7.9 Hz, 2 H, CH2C=CHC(=O)), 1.76 - 1.81 (m, 4 H, NCH=CCH2CH2CH2), 1.70
(quin, J = 7.2 Hz, 2 H, CH2CH2C=CHC(=O)), 1.15 - 1.38 (m, 12 H, CH3CH2CH2CH2CH2, NCH(CHH)2 and
NCH(CHH)2), 0.87 (t, J = 6.9 Hz, 3 H, CH3)
13C NMR (126 MHz, DMSO d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 176.3 (CHC(=O)), 165.8 (C(=O)OH),
154.3 (CCHC(=O)), 152.9 (d, J = 240.1 Hz, ipso to F), 148.3 (CH=CC(=O)OH), 147.5 (NCHCCH2), 143.3
(d, J = 8.5 Hz, ortho to F and ipso to N), 139.6 (ipso to NH), 139.0 (para to F), 132.0 (para to NH), 124.9 (ipso
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to C(=O) and ortho to NH), 123.6 (para to C(=O) and meta to NH), 120.5 (NCH=CCH2), 120.0 (meta to
C(=O) and meta to N), 119.6 (d, J = 9.6 Hz, ipso to C(=O) and para to N), 115.1 (ortho to C(=O) and ortho
to N), 111.3 (d, J = 28.8 Hz, ortho to F and ortho to C(=O)), 107.9 (meta to F and meta to C(=O)),
107.2 (CHC(=O)), 106.9 (CC(=O)OH), 55.4 (CH=CCH2CH2CH2CH2N), 50.6 (CH2CH2CH2N(CH2)CH2),
46.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 46.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 36.0 (NCH(CH2)2), 33.2
(CH2CNH), 31.2 (CH3CH2CH2), 28.3 - 28.5 (CH3CH2CH2CH2CH2CH2), 25.6 (CH=CCH2CH2), 24.4 (CH=C
CH2), 22.7 (CH=CCH2CH2CH2), 22.0 (CH3CH2), 13.9 (CH3), 7.6 (NCH(CH2)2)
HRMS (ESI+) m/z / Da = 696.3667, [M+H]+ found, [C39H47FN7O4]+ requires 696.3668
The compound has not been reported previously.
9.30 (S)-4-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)
butyl)-1H -1,2,3-triazol-1-yl)-N -(2-oxotetrahydrofuran-3-yl)butanamide 84
50% water/t-BuOH (2 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71 (20.6 mg, 50.0 µmol, 1 eq.) and (S)-4-
azido-N -(2-oxotetrahydrofuran-3-yl)butanamide 58 (15.9 mg, 75.0 µmol, 1.5 eq.). Similarly degassed solutions
of CuSO4 · 5H2O (624 µg, 2.5 µmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 µmol, 0.05 eq. 50 mM) and sodium
ascorbate (991 µg, 5 µmol, 0.1 eq., 100 mM) in water (50 µl) were then added. An extra portion of 58 (10.6
mg, 50.0 µmol, 1 eq.) was added after 4 d. Extra portions of the catalysts were added after 9 d. After 2 weeks,
the reaction mixture was extracted with CH2Cl2 (6×10 mL) then dry-loaded onto SiO2 and purified by column
chromatography using a Combiflash (SiO2, 0-20% MeOH/CH2Cl2).The combined pure fractions were dried with
MgSO4 and evaporated under reduced pressure. 84 was obtained as a pale brown gum (4.8 mg, 8.4 µmol, 17%,
purity 77% by NMR, contaminant was 58).
TLC Rf = 0.30 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3341 (N-H), 3303 (N-H), 3183 (N-H), 2934 (C-H), 1774 (lactone C=O), 1660 (amide
C=O and pyrimidine)
1H NMR (500 MHz, DMSO d6) δ / ppm = 8.43 (d, J = 8.0 Hz, 1 H, NH), 7.80 (s, 1 H, NCH=CCH2), 7.46
(s, 1 H, CHN=CNH2), 6.68 (br s, 2 H, CH2CCNH2), 6.53 (s, 2 H, meta to CH2), 6.21 (br s, 2 H, CHN=CNH2),
4.49 (dt, J = 10.7, 8.6 Hz, 1 H, CHNH), 4.32 (td, J = 8.7, 1.6 Hz, 1 H, CHHOC(=O)), 4.29 (t, J = 6.8 Hz,
2 H, CH2N), 4.19 (ddd, J = 10.6, 8.7, 6.5 Hz, 1 H, CHHOC(=O)), 3.79 (t, J = 6.2 Hz, 2 H, CH2CH2CH2O),
3.68 (s, 6 H, CH3), 3.53 (br s, 2 H, CCH2C), 2.63 (t, J = 7.5 Hz, 2 H, CH=CCH2), 2.37 (dddd, J = 12.2, 8.9,
6.7, 1.8 Hz, 1 H, CHHCHNH), 2.08 - 2.15 (m, 3 H, CHHCHNH and C(=O)CH2), 2.00 (quin, J = 7.2 Hz, 2 H,
CH2CH2N), 1.72 (quin, J = 7.3 Hz, 2 H, CH=CCH2CH2), 1.61 (quin, J = 6.7 Hz, 2 H, CH2CH2O)
13C NMR (126 MHz, DMSO d6) δ / ppm = 175.8 (OC=O), 171.9 (NHC=O), 163.1 (CC(NH2)N), 159.7
119
(br s, NC(NH2)N), 153.2 (ipso to OCH3), 150.5 (br s, CHNC(NH2)N), 147.3 (NCH=CCH2CH2), 135.2 (para
to CH2O), 135.0 (ipso to CH2O), 122.1 (CH=CCH2CH2), 107.3 (CH2CC(NH2)=N), 106.2 (meta to CH2O),
72.3 (CH2CH2CH2O), 65.7 (OCH2CH2CHNH), 56.2 (OCH3), 48.9 (CH2N), 48.3 (CHNH), 32.9 (CCH2C), 32.0
(C(=O)CH2), 29.3 (CH2CH2CH2O), 28.4 (OCH2CH2CHNH), 26.0 (CH2CH2N), 25.7 (CH=CCH2CH2), 24.9
(CH=CCH2CH2)
HRMS (ESI+) m/z / Da = 569.2834, [M+H]+ found, [C27H37N8O6]+ requires 569.2836
[α]20D / ◦10−1cm2g−1 = -4.6 (c / g(100 mL)−1 = 0.0433 , MeOH)
The compound has not been reported previously.
9.31 (S)-6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)
butyl)-1H -1,2,3-triazol-1-yl)-N -(2-oxotetrahydrofuran-3-yl)hexanamide 85
50% water/t-BuOH (2 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71 (20.6 mg, 50.0 µmol, 1 eq.) and (S)-6-
azido-N -(2-oxotetrahydrofuran-3-yl)hexanamide 61 (18.0 mg, 75.0 µmol, 1.5 eq.). Similarly degassed solutions
of CuSO4 · 5H2O (624 µg, 2.5 µmol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 µmol, 0.05 eq. 50 mM) and sodium
ascorbate (991 µg, 5 µmol, 0.1 eq., 100 mM) in water (50 µl) were then added. An extra portion of 61 (12.0
mg, 50.0 µmol, 1 eq.) was added after 4 d. Extra portions of the catalysts were added after 9 d. After 2 weeks
the reaction mixture was extracted with CH2Cl2 (6×10 mL) then dry-loaded onto SiO2 and purified by column
chromatography using a Combiflash (SiO2, 0-20% MeOH/CH2Cl2). The combined pure fractions were dried
with MgSO4 and evaporated under reduced pressure. 85 was obtained as a clear gum (8.0 mg, 13.4 µmol, 27%).
TLC Rf = 0.35 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3336 (N-H), 3209 (N-H), 2941 (C-H), 2869 (C-H), 1775 (lactone C=O), 1657 (amide
C=O and pyrimidine)
1H NMR (500 MHz, DMSO d6) δ / ppm = 8.34 (d, J = 8.0 Hz, 1 H, NH), 7.83 (s, 1 H, NCH=CCH2), 7.50
(s, 1 H, CHN=CNH2), 6.54 (s, 2 H, meta to CH2), 6.17 (br s, 2 H, CH2CCNH2), 5.77 (br s, 2 H, CHN=CNH2),
4.51 (ddd, J = 11.0, 9.0, 8.1 Hz, 1 H, CHNH), 4.33 (td, J = 8.8, 1.9 Hz, 1 H, CHHOC(=O)), 4.27 (t, J = 7.1
Hz, 2 H, CH2N), 4.19 (ddd, J = 10.5, 8.7, 6.5 Hz, 1 H, CHHOC(=O)), 3.80 (t, J = 6.3 Hz, 2 H, CH2CH2CH2O),
3.70 (s, 6 H, CH3), 3.52 (s, 2 H, CCH2C), 2.64 (t, J = 7.5 Hz, 2 H, CH=CCH2), 2.36 (dddd, J = 12.1, 8.9,
6.7, 1.8 Hz, 1 H, CHHCHNH), 2.06 - 2.16 (m, 3 H, CHHCHNH and C(=O)CH2), 1.78 (quin, J = 7.4 Hz, 2 H,
CH2CH2N), 1.73 (quin, J = 7.7 Hz, 2 H, CH=CCH2CH2), 1.63 (quin, J = 6.8 Hz, 2 H, CH2CH2O), 1.52 (quin,
J = 7.5 Hz, 2 H, C(=O)CH2CH2), 1.17 - 1.27 (m, 2 H, C(=O)CH2CH2CH2)
13C NMR (125 MHz, DMSO d6) δ / ppm = 175.4 (OC=O), 172.0 (NHC=O), 162.2 (CC(NH2)N), 161.8
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(NC(NH2)N), 154.8 (CHNC(NH2)N), 152.8 (ipso to OCH3), 146.7 (CH=CCH2CH2), 135.5 (para to CH2O),
134.8 (ipso to CH2O), 121.6 (CH=CCH2CH2), 105.9 (CH2CC(NH2)=N), 105.8 (meta to CH2O), 71.9 (CH2CH2
CH2O), 65.2 (OCH2CH2CHNH), 55.8 (OCH3), 49.0 (CH2N), 47.8 (CHNH), 34.8 (C(=O)CH2), 32.9 (CCH2C),
29.4 (CH2CH2N), 29.1 (CH2CH2CH2O), 28.2 (OCH2CH2CHNH), 25.5 (CH=CCH2CH2), 25.3 (C(=O)CH2CH2
CH2), 24.7 (CH=CCH2CH2), 24.4 (C(=O)CH2CH2)
HRMS (ESI+) m/z / Da = 597.3149, [M+H]+ found, [C29H41N8O6]+ requires 597.3144
[α]20D / ◦10−1cm2g−1 = -3.6 (c / g(100 mL)−1 = 0.11 , MeOH)
The compound has not been reported previously.
9.32 6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)buty
l)-1H -1,2,3-triazol-1-yl)-2-heptylquinolin-4(1H )-one 87
50% water/t-BuOH (1 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71 (3.6 mg, 10.0 µmol, 1 eq.) and 6-azido-
2-heptylquinolin-4(1H )-one 38 (2.8 mg, 10.0 µmol, 1 eq.). A similarly degassed solution of CuSO4 · 5H2O (125
µg, 0.5 µmol, 0.05 eq. 50 mM), THPTA (218 µg, 0.5 µmol, 0.05 eq. 50 mM) and sodium ascorbate (198 µg,
1 µmol, 0.1 eq., 100 mM) in water (10 µl) was then added. The mixture was stirred at r.t. under argon for
1.5 h, then evaporated under reduced pressure. The residue was purified by preparative HPLC (5-100% ace-
tonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure and then
partitioned between NaHCO3 (aq., sat., 10 mL) and 10% i-PrOH/CHCl3 (10 mL). The organic layer was dried
with MgSO4 and evaporated under reduced pressure. 87 was obtained as a clear gum (2.6 mg, 4.1 µmol, 41%).
TLC Rf = 0.17 (20% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2928 (C-H), 2856 (C-H), 1664 (pyrimidine), 1645 (pyrimidine and HHQ C=O)
1H NMR (500 MHz, DMSO d6) δ / ppm = 11.80 (s, 1 H, NH), 8.69 (s, 1 H, NCH=CCH2), 8.41 (d, J = 2.7
Hz, 1 H, ortho to C=O), 8.17 (dd, J = 9.0, 2.6 Hz, 1 H, para to C=O), 7.73 (d, J = 9.0 Hz, 1 H, ortho to
NH), 7.51 (br s, 4 H, NH2), 7.41 (s, 1 H, CHN=CNH2), 6.61 (s, 2 H, meta to CH2), 6.02 (d, J = 1.8 Hz, 1 H,
C(=O)CH), 3.86 (t, J = 6.3 Hz, 2 H, CH2O), 3.73 (s, 6 H, OCH3), 3.57 - 3.62 (m, 2 H, CCH2C), 2.78 (t, J =
7.5 Hz, 2 H, CH=CCH2), 2.63 (t, J = 7.3 Hz, 2 H, HNCCH2), 1.85 (quin, J = 7.5 Hz, 2 H, CH=CCH2CH2),
1.61 - 1.78 (m, 4 H, HNCCH2CH2 and CH=CCH2CH2CH2), 1.31 - 1.40 (m, 4 H, HNCCH2CH2CH2CH2), 1.25
- 1.31 (m, 4 H, CH3CH2CH2), 0.86 (t, J = 7.2 Hz, 3 H, CH3CH2)
13CNMR (125 MHz, DMSO d6) δ / ppm = 176.4 (C=O), 164.1 (CC(NH2)N), 154.3 (HNC), 154.2 (NC(NH2)N),
153.1 (ipso to OCH3), 148.3 (CH=CCH2CH2), 140.2 (CHNC(NH2)N), 139.6 (ipso to NH), 135.4 (ipso to CH2O),
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132.8 (para to CH2O), 132.1 (para to NH), 124.9 (ipso to C=O), 123.7 (para to C=O), 120.3 (CH=CCH2CH2),
120.0 (meta to C=O and ortho to NH), 115.1 (ortho to C=O and meta to NH), 109.0 (CH2CC(NH2)=N), 108.0
(C(=O)CH), 106.3 (meta to CH2O), 72.0 (CH2CH2CH2O), 56.0 (OCH3), 33.3 (HNCCH2), 32.1 (CCH2C),
31.2 (CH3CH2CH2), 29.1 (CH2CH2O), 28.3 - 28.6 (CH3CH2CH2CH2CH2CH2), 25.3 (CH2CH2CH2O), 24.7
(CH=CCH2), 22.1 (CH3CH2), 14.0 (CH3CH2)
HRMS (ESI+) m/z / Da = 641.3557, [M+H]+ found, [C35H45N8O4]+ 641.3558
The compound has not been reported previously.
9.33 2-(6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)bu
tyl)-1H -1,2,3-triazol-1-yl)hexyl)-3-hydroxyquinolin-4(1H )-one 89
50% water/t-BuOH (1 mL) was degassed by bubbling N2 through it. This was then added to a mixture of
5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71 (14.2 mg, 39.8 µmol, 1 eq.) and 2-
(6-azidohexyl)-3-hydroxyquinolin-4(1H)-one 30 (11.4 mg, 39.8 µmol, 1 eq.). A similarly degassed solution of
CuSO4 · 5H2O (1.25 mg, 5 µmol, 0.125 eq. 50 mM), THPTA (2.18 mg, 5 µmol, 0.125 eq. 50 mM) and sodium
ascorbate (1.98 mg, 10 µmol, 0.25 eq., 100 mM) in water (100 µl) was then added. The mixture was stirred at
r.t. under argon for 3 h, then MeOH (1 mL) was added and the reaction mixture was dry-loaded onto SiO2 and
purified by column chromatography (SiO2, 0-20% MeOH/CH2Cl2). The combined pure fractions were dried
with MgSO4 and evaporated under reduced pressure. 89 was obtained as a pale brown amorphous solid (4.7
mg, 7.3 µmol, 18%).
TLC Rf = 0.21 (20% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2925 (C-H), 2853 (C-H), 1660 (pyrimidine), 1639 (pyrimidine and PQS C=O)
1H NMR (500 MHz, DMSO d6) δ / ppm = 11.53 (br s, 1 H, NH), 8.09 (d, J = 8.0 Hz, 1 H, ortho to C=O),
7.83 (s, 1 H, NCH=CCH2), 7.48 - 7.57 (m, 3 H, para to C=O, ortho to NH and CHN=CNH2), 7.21 (ddd, J =
8.0, 6.3, 1.5 Hz, 1 H, para to NH), 6.55 (s, 2 H, meta to CH2), 4.28 (t, J = 7.1 Hz, 2 H, CH2N), 3.80 (t, J = 6.2
Hz, 2 H, CH2O), 3.70 (s, 6 H, CH3), 3.53 (d, J = 0.3 Hz, 2 H, CCH2C), 2.73 (t, J = 7.5 Hz, 2 H, HNCCH2),
2.64 (t, J = 7.4 Hz, 2 H, CH=CCH2), 1.80 (quin, J = 7.4 Hz, 2 H, CH2CH2N), 1.73 (quin, J = 7.5 Hz, 2 H,
CH=CCH2CH2), 1.66 (quin, J = 7.2 Hz, 2 H, HNCCH2CH2), 1.62 (quin, J = 6.8 Hz, 2 H, CH2CH2O), 1.33 -
1.40 (m, 2 H, HNCCH2CH2CH2), 1.27 - 1.32 (m, 2 H, HNCCH2CH2CH2CH2)
13C NMR (125 MHz, DMSO d6) δ / ppm = 168.9 (C=O), 162.5 (CC(NH2)N), 162.5 (NC(NH2)N), 152.9
(CHNC(NH2)N), 152.8 (ipso to OCH3), 146.8 (CH=CCH2CH2), 137.7 (COH), 137.3 (para to OH), 135.4
(HNC), 135.1 (para to CH2O), 134.8 (ipso to CH2O), 129.9 (para to C=O), 124.4 (ortho to C=O and meta
to NH), 122.1 (ipso to C=O), 121.5 (para to NH), 121.4 (CH=CCH2CH2), 117.7 (meta to C=O and ortho to
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NH), 106.2 (CH2CC(NH2)=N), 105.8 (meta to CH2O), 71.9 (CH2CH2CH2O), 55.8 (OCH3), 49.0 (CH2N), 32.8
(CCH2C), 29.5 (CH2CH2N), 29.0 (CH2CH2O), 28.1 (HNCCH2CH2CH2), 27.9 (HNCCH2), 27.6 (HNCCH2CH2),
25.6 (CH2CH2CH2N), 25.4 (CH2CH2CH2O), 24.6 (CH=CCH2CH2)
HRMS (ESI+) m/z / Da = 643.3365, [M+H]+ found, [C34H43N8O5]+ requires 643.3351
The compound has not been reported previously.
9.34 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-
3-carboxylate 151
Ciprofloxacin 24 (10.0 g, 30 mmol, 1 eq.) and para-toluenesulfonic acid (8.60 mg, 44.5 mmol, 1.5 eq.) were
refluxed in methanol (500 mL) for 72 h. The mixture was cooled to room temperature and NaHCO3 (sat., aq.,
100 mL) and water (300 mL) were added. The product was extracted with CH2Cl2 (2×400 mL). The combined
organic fractions were dried over MgSO4 and evaporated under reduced pressure. 151 was obtained as a white
amorphous solid (9.16 g, 26.5 mmol, 83%).
TLC Rf = 0.13 (5% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2948 (C-H), 2835 (C-H), 1721 (ester C=O), 1617 (quinolone C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 8.55 (s, 1 H, ortho to C(=O)OCH3), 7.71 (d, J = 13.5 Hz, 1 H, ortho
to F), 7.41 (d, J = 7.2 Hz, 1 H, meta to F), 3.83 (s, 3 H, CH3), 3.62 (tt, J = 7.4, 3.5 Hz, 1 H, NCH(CH2)2), 3.24
- 3.29 (m, 4 H, HN(CH2CH2)CH2CH2), 3.02 - 3.10 (m, 4 H, HN(CH2)CH2), 1.31 - 1.38 (m, 2 H, NCH(CHH)2),
1.12 - 1.20 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, MeOD) δ / ppm = 175.2 (C(=O)CC(=O)OCH3), 166.8 (C(=O)OCH3), 154.9 (d, J
= 248.0 Hz, ipso to F), 150.1 (C=CC(=O)OCH3), 146.6 (d, J = 10.4 Hz, ipso to piperazine), 139.9 (para to
F), 123.3 (d, J = 6.9 Hz, para to piperazine), 113.0 (d, J = 23.4 Hz, ortho to C=O and ortho to F), 110.1
(CC(=O)OCH3), 107.1 (d, J = 3.5 Hz, meta to C=O and meta to F), 52.3 (CH3), 51.7 (HN(CH2CH2)CH2CH2),
51.6 (HN(CH2CH2)CH2CH2), 46.5 (HN(CH2)CH2), 36.4 (NCH(CH2)2), 8.7 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -124.8 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 346.1569, [M+H]+ found, [C18H21FN3O3]+ requires 346.1567
The data are consistent with the literature.216
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9.35 4-Bromo-N -(2-oxotetrahydrothiophen-3-yl)butanamide 153
S
O
H
N
O
Br (±)
3-Aminodihydrothiophen-2(3H )-one hydrochloride 152 (15.0 g, 97.6 mmol, 1 eq.) and NaHCO3 (16.4 g, 195
mmol, 2 eq.) were added to CH2Cl2 (150 mL) and water (150 mL). 4-Bromobutyryl chloride 56 (11.3 mL, 107
mmol, 1.1 eq.) was added dropwise over 45 min at 0 ◦C and the mixture was stirred for a further 1 h. The
organic layer was separated and the aqueous layer was extracted with a second portion of CH2Cl2 (150 mL).
The combined organic layers were dried over MgSO4 and evaporated under reduced pressure. 153 was obtained
as a white, amorphous solid (22.7 g, 85.8 mmol, 88%).
TLC Rf = 0.19 (50% EtOAc/PE)
IR (neat) νmax / cm−1 = 3266 (amide N-H), 3063 (amide N-H), 1694 (thiolactone C=O), 1651 (amide C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.08 (d, J = 6.1 Hz, 1 H, NH), 4.54 (dt, J = 12.9, 6.5 Hz, 1 H,
CHNH), 3.49 (t, J = 6.4 Hz, 2 H, CH2Br), 3.37 (ddd, J = 12.2, 11.5, 5.3 Hz, 1 H, SCHH), 3.26 (ddd, J =
11.5, 6.9, 1.3 Hz, 1 H, SCHH), 2.91 (dddd, J = 12.5, 6.7, 5.3, 1.3 Hz, 1 H, SCH2CHH), 2.45 (t, J = 7.4 Hz, 1
H, C(=O)CHH), 2.45 (t, J = 6.8 Hz, 1 H, C(=O)CHH), 2.20 (quin, J = 6.7 Hz, 1 H, C(=O)CH2CH2), 1.96
(dddd, J = 12.7, 12.5, 12.2, 7.0 Hz, 1 H, SCH2CHH)
13C NMR (101 MHz, CDCl3) δ / ppm = 205.4 (SC(=O)), 172.1 (NHC(=O)), 59.4 (CHNH), 34.1 (C(=O)CH2),
33.1 (CH2Br), 31.8 (SCH2CH2), 28.0 (C(=O)CH2CH2), 27.5 (SCH2)
LRMS (AP+) m/z / Da = 266.1, [M+H]+ found, [C8H12BrNO2S]+ requires 266.0
The compound has been synthesised previously61,149 but characterisation was not published.
9.36 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxotetrahydrothiophen-
3-yl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 154
N
N
N
O O
OF
O
N
H
O
S
(±)
Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 151 (50 mg, 0.145
mmol, 1 eq.), 4-bromo-N -(2-oxotetrahydrothiophen-3-yl)butanamide 153 (34.5 mg, 0.145 mmol, 1 eq.) and
K2CO3 (20 mg, 0.145 mmol, 1 eq.) were stirred in acetonitrile (2 mL) at 50 ◦C under argon. After 24 h a further
portion of 153 (34.5 mg, 0.145 mmol, 1 eq.) was added. After another 24 h a further portion was added (69.0
mg, 0.290 mmol, 2 eq.). After another 24 h the temperature was raised so the mixture was at reflux. After a
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final 24 h the precipitate was filtered off and the filtrate was purified by column chromatography (SiO2, 5-10%
MeOH/CH2Cl2) followed by preparative HPLC (5-95% acetonitrile/water over 20 min). 154 was obtained as a
pale cream amorphous solid (9.4 mg, 0.018 mmol, 12%).
TLC Rf = 0.47 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2944 (C-H), 2832 (C-H), 1722 (ester C=O), 1700 (thiolactone C=O), 1670 (amide
C=O), 1617 (quinolone C=O)
1H NMR (500 MHz, MeOD) δ / ppm = 8.53 (s, 1 H, ortho to C(=O)OCH3), 7.68 (d, J = 13.4 Hz, 1 H, ortho
to F), 7.41 (d, J = 7.3 Hz, 1 H, meta to F), 4.67 (dd, J = 12.9, 6.9 Hz, 1 H, CHNH), 3.83 (s, 3 H, OCH3),
3.61 (tt, J = 6.9, 4.1 Hz, 1 H, NCH(CH2)2), 3.39 - 3.49 (m, 1 H, SCHH), 3.26 - 3.33 (m, 5 H, SCHH and
CH2CH2CH2N(CH2CH2)CH2CH2), 2.93 - 3.03 (m, 4 H, CH2CH2CH2N(CH2)CH2), 2.79 (br. t, J = 7.2, 7.2
Hz, 2 H, C(=O)CH2CH2CH2), 2.59 (dddd, J = 12.4, 6.9, 5.4, 1.4 Hz, 1 H, SCH2CHH), 2.39 (t, J = 7.20 Hz,
1 H, C(=O)CHH), 2.38 (t, J = 6.94 Hz, 1 H, C(=O)CHH), 2.18 (qd, J = 12.4, 7.0 Hz, 1 H, SCH2CHH), 1.97
(quin, J = 7.2 Hz, 2 H, C(=O)CH2CH2), 1.32 - 1.37 (m, 2 H, NCH(CHH)2), 1.13 - 1.19 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, MeOD) δ / ppm = 207.0 (SC(=O)), 175.7 (NHC(=O)), 175.1 (C(=O)CC(=O)OCH3),
166.6 (C(=O)OCH3), 154.7 (d, J = 249.0 Hz, ipso to F), 150.2 (s, CH=CC(=O)OCH3), 145.6 (d, J = 10.6
Hz, ipso to piperazine), 139.8 (para to F), 123.5 (d, J = 6.9 Hz, para to piperazine), 113.1 (d, J = 23.6 Hz,
ortho to C=O and ortho to F), 110.0 (CC(=O)OCH3), 107.4 (meta to C=O and meta to F), 60.2 (CHNH), 58.5
(C(=O)CH2CH2CH2), 53.8 (CH2CH2CH2N(CH2)CH2), 52.3 (OCH3), 50.1 (CH2CH2CH2N(CH2CH2)CH2CH2),
50.0 (CH2CH2CH2N(CH2CH2)CH2CH2), 36.5 (NCH(CH2)2), 34.5 (C(=O)CH2), 31.7 (SCH2CH2), 28.1 (SCH2),
22.9 (C(=O)CH2CH2CH2), 8.7 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -125.4 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 531.2083, [M+H]+ found, [C26H32FN4O5S]+ requires 531.2077
The compound has been synthesised previously.61,149 Only HRMS characterisation was published, and this
agrees with the result above.
9.37 4-Azido-N -(2-oxotetrahydrothiophen-3-yl)butanamide 155
S
O
H
N
O
N3
(±)
4-Bromo-N -(2-oxotetrahydrothiophen-3-yl)butanamide 153 (6.00 g, 27.0 mmol, 1 eq.) and NaN3 (3.51 g, 54.1
mmol, 2 eq.) were refluxed in acetonitrile (120 mL) for 1.5 h. The solvent was evaporated under reduced
pressure and the residue was partitioned between water (150 mL) and CH2Cl2 (150 mL). The aqueous layer
was extracted twice more with CH2Cl2 (2×150 mL) and the combined organic fractions were dried with MgSO4
and evaporated under reduced pressure. 155 was obtained as a yellow, sticky solid (4.60 g, 20.1 mmol, 89%).
TLC Rf = 0.19 (50% EtOAc/PE)
125
IR (neat) νmax / cm−1 = 3286 (N-H), 2964 (C-H), 2100 (azide), 1697 (thiolactone C=O), 1647 (amide C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.71 (d, J = 7.3 Hz, 1 H, NH), 4.54 (dt, J = 13.0, 7.0 Hz, 1 H,
CHNH), 3.30 (t, J = 6.7 Hz, 2 H, CH2N3), 3.31 (td, J = 11.7, 5.3 Hz, 1 H, SCHH), 3.19 (ddd, J = 11.3,
7.0, 1.2 Hz, 1 H, SCHH), 2.70 (dddd, J = 12.4, 6.8, 5.3, 1.2 Hz, 1 H, SCH2CHH), 2.29 (t, J = 7.5 Hz, 1 H,
C(=O)CHH), 2.28 (t, J = 7.1 Hz, 1 H, C(=O)CHH), 1.97 (qd, J = 12.4, 7.0 Hz, 1 H, SCH2CHH), 1.85 (quin,
J = 6.9 Hz, 2 H, C(=O)CH2CH2)
13C NMR (101 MHz, CDCl3) δ / ppm = 205.4 (SC(=O)), 172.3 (NHC(=O)), 59.4 (CHNH), 50.6 (CH2N3),
32.8 (C(=O)CH2), 31.8 (SCH2CH2), 27.5 (SCH2), 24.6 (C(=O)CH2CH2)
HRMS (ESI+) m/z / Da = 251.0565, [M+Na]+ found, [C8H12N4NaO2S]+ requires 251.0573
The compound has not been reported previously.
9.38 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-
3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquin
oline-3-carboxylic acid 156
N N
S
O
H
N
O
N
N
N
N
O O
OHF
(±)
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (15
mg, 36.7 µmol, 1 eq.) and 4-azido-N -(2-oxotetrahydrothiophen-3-yl)butanamide 155 (12.5 mg, 55.1 µmol, 1.5
eq.) were dissolved in 1:9:10 water/t-BuOH/DMSO (3 mL), and the mixture was degassed by bubbling N2
through it. A solution of CuSO4 and THPTA (182 µl, 18.2 µmol, 0.5 eq. 100 mM, aq.) was added, followed by
a solution of sodium ascorbate (367 µl, 36.7 µmol, 1 eq., 100 mM, aq.). The mixture was stirred at r.t. under
argon for 4 d. Water (10 mL) and 10% i-PrOH/CHCl3 (10 mL) were added, the organic layer was separated
and the aqueous layer was extracted again with 10% i-PrOH/CHCl3 (2×10 mL). The combined organic layers
were dried with MgSO4 and evaporated under reduced pressure. The residue was purified by preparative HPLC
(5-95% acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure
and then partitioned between NaHCO3 (aq., sat., 50 mL) and 10% i-PrOH/CHCl3 (50 mL). The organic layer
was dried with MgSO4 and evaporated under reduced pressure. 156 was obtained as a white amorphous solid
(16.5 mg, 25.9 µmol, 71%).
IR (neat) νmax / cm−1 = 2919 (C-H), 1713 (carboxylic acid C=O and thiolactone C=O), 1658 (amide C=O),
1627 (quinolone C=O), 1616 (triazole)
1H NMR (500 MHz, DMSO d6) δ / ppm = 15.23 (br s, 1 H, C(=O)OH), 8.66 (s, 1 H, ortho to C(=O)OH),
8.23 (d, J = 8.5 Hz, 1 H, NH), 7.90 (d, J = 13.4 Hz, 1 H, ortho to F), 7.84 (s, 1 H, CH=CCH2), 7.56 (d,
J = 7.5 Hz, 1 H, meta to F), 4.59 (ddd, J = 12.7, 8.4, 6.8 Hz, 1 H, CHNH), 4.31 (t, J = 7.0 Hz, 2 H,
CH2NCH=C), 3.80 - 3.86 (6.9, 4.0 Hz, 1 H, NCH(CH2)2), 3.34 - 3.37 (m, 1 H, SCHH), 3.32 (br t, J = 4.1 Hz,
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4 H, CH2CH2CH2N(CH2CH2)CH2CH2), 3.27 (ddd, J = 11.1, 6.9, 1.4 Hz, 1 H, SCHH), 2.64 (t, J = 7.6 Hz, 2
H, CH=CCH2), 2.57 (br t, J = 4.7 Hz, 4 H, CH2CH2CH2N(CH2)CH2), 2.34 - 2.44 (m, 3 H, SCH2CHH and
CH=CCH2CH2CH2CH2), 2.12 (t, J = 7.9 Hz, 1 H, C(=O)CHH), 2.12 (t, J = 7.0 Hz, 1 H, C(=O)CHH), 2.04
(m, 3 H, SCH2CHH and C(=O)CH2CH2), 1.64 (quin, J = 7.5 Hz, 2 H, CH=CCH2CH2), 1.51 (quin, J = 7.5
Hz, 2 H, CH=CCH2CH2CH2), 1.28 - 1.34 (m, 2 H, NCH(CHH)2), 1.15 - 1.20 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO d6) δ / ppm = 205.6 (SC(=O)), 176.4 (C(=O)CC(=O)OH), 171.4 (NHC(=O)),
166.0 (C(=O)OH), 153.1 (d, J = 249.3 Hz, ortho to F), 148.0 (CH=CC(=O)OH), 146.9 (CH=CCH2), 145.3 (d, J
= 10.1 Hz, ipso to piperazine), 139.2 (para to F), 121.8 (CH=CCH2), 118.6 (d, J = 7.7 Hz, para to piperazine),
111.0 (d, J = 23.3 Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.4 (d, J = 2.9 Hz, meta to
C=O and meta to F), 58.2 (SC(=O)CHNH), 57.4 (CH=CCH2CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2),
49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 48.6 (CH2NCH=C), 35.9
(NCH(CH2)2), 31.9 (NHC(=O)CH2), 30.1 (CH2CHNH), 26.9 (CH=CCH2CH2), 26.8 (SCH2), 25.9 (NHC(=O)
CH2CH2), 25.8 (CH=CCH2CH2CH2), 25.0 (CH=CCH2), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -124.9 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 640.2739, [M+H]+ found, [C31H39FN7O5S]+ requires 640. 2712
The compound has not been reported previously.
9.39 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-((((4-(1-(4-oxo-4-((2-oxotetrahydrothiophe
n-3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butanoyl)oxy)methoxy)carbonyl)pip
erazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 157
N N
S
O
H
N
O
N
N
NOO
N
O O
OHF
OO
(±)
1-Cyclopropyl-6-fluoro-7-(4-(((hex-5-ynoyloxy)methoxy)carbonyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid 221 (203 mg, 0.407 mmol, 1 eq.), 4-azido-N -(2-oxotetrahydrothiophen-3-yl)butanamide 155
(92.8 mg, 0.407 mmol, 1 eq.), CuI (40 mg, 0.190 mmol, 0.5 eq.) and DIPEA (0.356 mL, 0.264 mg, 2.04 mmol,
5 eq.) were stirred in CH2Cl2 (18.6 mL) at r.t. under Ar for 3 h. The mixture was fitered and the filtrate was
dry-loaded onto SiO2 and purified by column chromatography (SiO2, 5-10% MeOH/CH2Cl2). 157 was obtained
as pale brown/yellow amorphous solid (14.7 mg, 20.2 µmol, 5%).
TLC Rf = 0.40 (5% CH2Cl2/MeOH)
IR (neat) νmax / cm−1 = 3055 (C-H), 1716 (carboxylic acid C=O and ester C=O), 1696 (carbamate C=O and
thiolactone C=O), 1651 (amide C=O), 1629 (quinolone C=O)
1H NMR (400 MHz, DMSO d6) δ / ppm = 15.16 (br s, 1 H, C(=O)OH), 8.65 (s, 1 H, ortho to C(=O)OH),
8.21 (d, J = 8.5 Hz, 1 H, NH), 7.89 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, CH=CCH2), 7.57 (d, J =
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7.4 Hz, 1 H, meta to F), 5.74 (s, 1 H, OCH2O), 4.58 (ddd, J = 12.6, 8.1, 7.2 Hz, 1 H, CHNH), 4.30 (t, J =
6.9 Hz, 2 H, C(=O)CH2CH2CH2N), 3.80 (tt, J = 6.9, 3.6 Hz, 1 H, NCH(CH2)2), 3.62 (br t, J = 5.2 Hz, 4 H,
C(=O)N(CH2)CH2), 3.38 (td, J = 11.4, 5.5 Hz, 1 H, SCHH), 3.34 (br. s, 4 H, C(=O)N(CH2CH2)CH2CH2),
3.27 (ddd, J = 11.0, 6.9, 1.6 Hz, 1 H, SCHH), 2.64 (t, J = 7.6 Hz, 2 H, CH=CCH2), 2.44 (t, J = 7.5 Hz, 2 H,
CH2C(=O)O), 2.40 (dddd, J = 12.3, 6.8, 5.4, 1.4 Hz, 1 H, SCH2CHH), 2.12 (t, J = 7.8 Hz, 1 H, NHC(=O)CHH),
2.12 (t, J = 6.8 Hz, 1 H, NHC(=O)CHH), 1.98 - 2.07 (m, 3 H, SCH2CHH and NHC(=O)CH2CH2), 1.86 (quin,
J = 7.5 Hz, 2 H, CH=CCH2CH2), 1.29 - 1.36 (m, 2 H, NCH(CHH)2), 1.14 - 1.21 (m, 2 H, NCH(CHH)2)
13CNMR (101 MHz, DMSO d6) δ / ppm = 205.5 (SC(=O)), 176.4 (C(=O)CC(=O)OH), 171.8 (C(=O)OCH2O),
171.3 (NHC(=O)), 165.9 (C(=O)OH), 152.8 (d, J = 249.7 Hz, ipso to F), 152.9 (OC(=O)N), 148.1 (CH=CC(=O)
OH), 146.0 (CH=CCH2), 144.9 (d, J = 9.6 Hz, ipso to piperazine), 139.1 (para to F), 122.0 (CH=CCH2), 118.9
(d, J = 7.5 Hz, para to piperazine), 111.0 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.8 (CC(=O)OH,
and meta to C=O and meta to F), 80.3 (OCH2O), 58.2 (CHNH), 49.1 (C(=O)N(CH2CH2)CH2CH2), 49.1
(C(=O)N(CH2CH2)CH2CH2), 48.6 (C(=O)CH2CH2CH2N), 43.4 (N(CH2)CH2), 43.0 (N(CH2)CH2), 35.9 (NCH
(CH2)2), 32.7 (CH=CCH2CH2CH2C(=O)), 31.8 (NHC(=O)CH2), 30.1 (SCH2CH2), 26.8 (SCH2), 25.8 (C(=O)
CH2CH2CH2N), 24.2 (CH=CCH2CH2CH2C(=O)), 24.0 (CH=CCH2CH2CH2C(=O)), 7.6 (NCH(CH2)2)
HRMS (ESI+) m/z / Da = 728.2502, [M+H]+ found, [C33H39FN7O9S]+ requires 728.2503
The compound has not been reported previously.
9.40 4-Bromo-N -(2-methoxyphenyl)butanamide 159
2-Methoxyaniline 158 (9.12 mL, 10.0 g, 81.2 mmol, 1 eq.) and NaHCO3 (8.19 g, 97.4 mmol, 1.2 eq.) were
dissolved in water (100 mL) and CH2Cl2 (100 mL). The mixture was cooled to 0 ◦C and 4-bromobutyryl
chloride 56 (9.40 mL, 15.1 g, 81.2 mmol, 1 eq.) was added dropwise over 15 min. The mixture was stirred at
0 ◦C for 1.5 h, then the aqueous layer was removed. The organic layer was dried with MgSO4 and purified by
column chromatography (SiO2, 5-25% EtOAc/P.E.). The combined pure fractions were dried with MgSO4 and
evaporated under reduced pressure. 159 was obtained as an initially colourless liquid which slowly turned blue
then black if left out on the bench (11.0 g, 40.6 mmol, 50%).
TLC Rf = 0.16 (10% EtOAc/P.E.)
IR (neat) νmax / cm−1 = 3410 (N-H), 3313 (N-H), 2962 (C-H), 2940 (C-H), 2903 (C-H), 1676 (amide C=O)
1H NMR (400 MHz, CDCl3 d1) δ / ppm = 8.32 (dd, J = 8.0, 1.7 Hz, 1 H, ortho to NH), 7.85 (br s, 1 H, NH),
7.02 (td, J = 7.9, 1.7 Hz, 1 H, para to NH), 6.93 (td, J = 7.7, 1.4 Hz, 1 H, para to OCH3), 6.85 (dd, J = 8.1,
1.5 Hz, 1 H, ortho to OCH3), 3.85 (s, 3 H, CH3), 3.50 (t, J = 6.4 Hz, 2 H, CH2Br), 2.56 (t, J = 7.1 Hz, 2 H,
C(=O)CH2), 2.25 (quin, J = 6.7 Hz, 2 H, C(=O)CH2CH2)
13C NMR (101 MHz, CDCl3 d1) δ / ppm = 169.4 (C(=O)), 147.6 (ipso to OCH3), 127.2 (ipso to NH), 123.5
(para to NH), 120.7 (para to OCH3), 119.6 (ortho to NH and meta to OCH3), 109.8 (ortho to OCH3 and meta
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to NH), 55.5 (CH3), 35.4 (C(=O)CH2), 33.1 (CH2Br), 27.9 (C(=O)CH2CH2)
HRMS (ESI+) m/z / Da = 272.0287, [M+H]+ found, [C11H15BrNO2]+ requires 272.0286
The compound has not been reported previously.
9.41 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 160
Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 151 (500 mg, 1.45
mmol, 1 eq.), 4-bromo-N -(2-methoxyphenyl)butanamide 159 (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 mL, 950
mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 mL) were stirred in a microwave
reactor at 100 ◦C for 4 h. The mixture was dry-loaded onto SiO2 and purified by column chromatography (SiO2,
4% MeOH/CH2Cl2). The combined pure fractions were dried with MgSO4 and evaporated under reduced pres-
sure. 160 was obtained as a bright pink amorphous solid (79.7 mg, 0.149 mmol, 10%).
TLC Rf = 0.40 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2947 (C-H), 2834 (C-H), 1719 (ester C=O), 1685 (amide C=O), 1617 (quinolone
C=O)
1H NMR (400 MHz, CDCl3 d1) δ / ppm = 8.48 (s, 1 H, ortho to C(=O)OCH3), 8.36 (d, J = 7.9 Hz, 1
H, ortho to NH), 7.87 - 7.99 (m, 2 H, ortho to F and NH), 7.19 (d, J = 6.5 Hz, 1 H, meta to F), 7.01 (t, J
= 7.5 Hz, 1 H, para to NH), 6.93 (t, J = 7.7 Hz, 1 H, para to OCH3), 6.85 (d, J = 7.9 Hz, 1 H, ortho to
OCH3), 3.88 (s, 3 H, C(=O)OCH3), 3.85 (s, 3 H, aromatic OCH3), 3.41 (tt, J = 6.9, 4.0 Hz, 1 H, NCH(CH2)2),
3.25 (br t, J = 5.0, 5.0 Hz, 4 H, C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 2.67 (br t, J = 5.0 Hz, 4 H,
C(=O)CH2CH2CH2N(CH2)CH2), 2.53 (t, J = 7.0 Hz, 2 H, C(=O)CH2CH2CH2N), 2.47 (t, J = 7.1 Hz, 2 H,
C(=O)CH2CH2CH2N), 1.97 (quin, J = 6.8 Hz, 2 H, C(=O)CH2CH2CH2N), 1.25 - 1.33 (m, 2 H, NCH(CHH)2),
1.07 - 1.14 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, CDCl3 d1) δ / ppm = 172.9 (C(=O)CC(=O)OCH3), 170.8 (NHC(=O)), 166.2 (C(=O)O
CH3), 153.3 (d, J = 248.0 Hz, ipso to F), 148.2 (C=CC(=O)OCH3), 147.6 (ipso to OCH3), 144.4 (d, J =
10.4 Hz, ipso to piperazine), 137.9 (para to F), 127.6 (ipso to NH), 123.4 (para to NH), 122.7 (d, J = 7.8
Hz, para to piperazine), 121.0 (para to OCH3), 119.7 (ortho to NH and meta to OCH3), 113.0 (d, J = 22.5
Hz, ortho to C=O and ortho to F), 109.8 (ortho to OCH3 and meta to NH, and CC(=O)OCH3), 104.7 (meta
to C=O and meta to F), 57.2 (CH2CH2CH2N), 55.6 (aromatic OCH3), 52.7 (CH2CH2CH2N(CH2)CH2), 51.9
(C(=O)OCH3), 49.8 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.8 (CH2CH2CH2N(CH2CH2)CH2CH2), 35.5 (CH2
CH2CH2N), 34.5 (NCH(CH2)2), 22.3 (CH2CH2CH2N), 8.0 (NCH(CH2)2)
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HRMS (ESI+) m/z / Da = 537.2523, [M+H]+ found, [C29H34FN4O5]+ requires 537.2513
The compound has not been reported previously.
9.42 4-Azido-N -(2-methoxyphenyl)butanamide 161
4-Bromo-N -(2-methoxyphenyl)butanamide 159 (2.05 g, 7.51 mmol, 1 eq.) and NaN3 (1.17 g, 18.0 mmol, 2.4
eq.) were refluxed in acetonitrile (100 mL) for 2 h. The mixture was cooled and filtered, and the fitrate was
dry-loaded onto SiO2 and purified by column chromatography using a Combiflash (SiO2, 8-14% then held at
14% EtOAc/P.E.). 161 was obtained as an initially colourless liquid which slowly turned blue then black if left
out on the bench (0.469 g, 2.00 mmol, 27%).
TLC Rf = 0.20 (25% EtOAc/P.E.)
IR (neat) νmax / cm−1 = 3420 (N-H), 3330 (N-H), 2095 (azide), 1672 (amide C=O)
1H NMR (400 MHz, CDCl3 d1) δ / ppm = 8.32 (dd, J = 7.9, 1.0 Hz, 1 H, ortho to NH), 7.86 (br s, 1 H, NH),
7.00 (td, J = 7.5, 1.5 Hz, 1 H, para to NH), 6.90 (td, J = 7.7, 1.1 Hz, 1 H, para to OCH3), 6.83 (dd, J = 8.1,
1.4 Hz, 1 H, ortho to OCH3), 3.81 (s, 3 H, CH3), 3.33 (t, J = 6.7 Hz, 2 H, CH2Br), 2.42 (t, J = 7.2 Hz, 2 H,
C(=O)CH2), 1.94 (quin, J = 6.9 Hz, 2 H, C(=O)CH2CH2)
13C NMR (101 MHz, CDCl3 d1) δ / ppm = 169.5 (C(=O)), 147.6 (ipso to OCH3), 127.1 (ipso to NH), 123.4
(para to NH), 120.5 (para to OCH3), 119.5 (ortho to NH and meta to OCH3), 109.6 (ortho to OCH3 and meta
to NH), 55.2 (CH3), 50.3 (CH2N3), 33.9 (C(=O)CH2), 24.3 (C(=O)CH2CH2)
HRMS (ESI+) m/z / Da = 257.1010, [M+H]+ found, [C11H14N4NaO2]+ requires 257.1014
The data are consistent with the literature.240
9.43 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-
1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carb
oxylic acid 162
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1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (24.1
mg, 58.6 µmol, 1 eq.) and 4-azido-N -(2-methoxyphenyl)butanamide 161 (13.7 mg, 58.5 µmol, 1 eq.) were dis-
solved in water (3 mL), t-BuOH (9 mL) and CH2Cl2 (9 mL), and the mixture was degassed by bubbling through
N2. A solution of CuSO4 and THPTA (117 µl, 5.85 µmol, 0.1 eq., 50 mM, aq.) was added, followed by a solution
of sodium ascorbate (234 µl, 11.7 µmol, 0.2 eq., 50 mM, aq.). The mixture was stirred at room temperature
under argon for 16 h. Water (25 mL), CH2Cl2 (25 mL) and MeOH (5 mL) were added and the organic layer was
separated off, dry-loaded onto SiO2 and purified by column chromatography using a Combiflash (SiO2, 3-23%
MeOH/CH2Cl2). The combined pure fractions were dried with MgSO4 and evaporated under reduced pressure.
162 was obtained as a clear amorphous solid (14.7 mg, 22.8 µmol, 39%).
TLC Rf = 0.28 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2927 (C-H), 2847 (C-H), 1723 (carboxylic acid C=O), 1682 (amide C=O), 1626
(quinolone C=O), 1613 (triazole)
1H NMR (400 MHz, CDCl3) δ / ppm = 15.05 (br s, 1 H, C(=O)OH), 8.76 (s, 1 H, ortho to C(=O)OH), 8.31
(dd, J = 8.0, 1.7 Hz, 1 H, ortho to NH), 8.00 (d, J = 13.0 Hz, 1 H, ortho to F), 7.83 (br s, 1 H, NH), 7.37 (s,
1 H, CH=CCH2), 7.35 (d, J = 7.2 Hz, 1 H, meta to F), 7.04 (td, J = 7.7, 1.7 Hz, 1 H, para to NH), 6.95 (td,
J = 7.8, 1.5 Hz, 1 H, para to OCH3), 6.88 (dd, J = 8.1, 1.4 Hz, 1 H, ortho to OCH3), 4.47 (t, J = 6.7 Hz, 2
H, C(=O)CH2CH2CH2N), 3.88 (s, 3 H, CH3), 3.54 (tt, J = 6.9, 4.0 Hz, 1 H, NCH(CH2)2), 3.35 (br t, J = 4.7
Hz, 4 H, CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 2.76 (t, J = 7.5 Hz, 2 H, CH=CCH2), 2.66 (t, J = 4.7
Hz, 4 H, CH=CCH2CH2CH2CH2N(CH2)CH2), 2.47 (t, J = 7.3 Hz, 2 H, CH=CCH2CH2CH2CH2N), 2.44 (t,
J = 6.8 Hz, 2 H, C(=O)CH2CH2CH2N), 2.32 (quin, J = 6.7 Hz, 2 H, C(=O)CH2CH2CH2N), 1.75 (quin, J =
7.6 Hz, 2 H, CH=CCH2CH2CH2CH2N), 1.61 (quin, J = 7.5 Hz, 2 H, CH=CCH2CH2CH2CH2N), 1.35 - 1.42
(m, 2 H, NCH(CHH)2), 1.17 - 1.22 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, CDCl3) δ / ppm = 177.1 (C(=O)CC(=O)OH), 169.5 (NHC(=O)), 167.0 (C(=O)OH),
153.7 (d, J = 251.4 Hz, ipso to F), 148.1 (CH=CCH2), 147.8 (ipso to OCH3), 147.3 (C=CC(=O)OH), 145.9
(d, J = 10.4 Hz, ipso to piperazine), 139.1 (para to F), 127.3 (ipso to NH), 123.9 (para to NH), 121.0 (para to
OCH3), 120.9 (CH=CCH2), 119.7 (para to piperazine, and ortho to NH and meta to OCH3), 112.4 (d, J = 23.4
Hz, ortho to C=O and ortho to F), 109.9 (ortho to OCH3 and meta to NH), 108.1 (CC(=O)OH), 104.7 (meta to
C=O andmeta to F), 58.1 (CH=CCH2CH2CH2CH2N), 55.6 (CH3), 52.8 (CH=CCH2CH2CH2CH2N(CH2)CH2),
49.8 (CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 49.8 (CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 49.1
(C(=O)CH2CH2CH2N), 35.2 (NCH(CH2)2), 33.8 (C(=O)CH2CH2CH2N), 27.3 (CH=CCH2CH2CH2CH2N),
26.4 (CH=CCH2CH2CH2CH2N), 26.0 (C(=O)CH2CH2CH2N), 25.5 (CH=CCH2CH2CH2CH2N), 8.2 (NCH
(CH2)2)
19F NMR (376.45 MHz, CDCl3) δ / ppm = -120.7 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 646.3132, [M+H]+ found, [C34H41FN7O5]+ requires 646.3153
The compound has not been reported previously.
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9.44 4-Bromo-N -(3-methoxyphenyl)butanamide 164
3-Methoxyaniline 163 (3.04 mL, 3.33 g, 27.1 mmol, 1 eq.) and NaHCO3 (2.73 g, 32.5 mmol, 1.2 eq.) were
dissolved in water (30 mL) and CH2Cl2 (30 mL). The mixture was cooled to 0 ◦C and 4-bromobutyryl chloride
56 (3.13 mL, 5.03 g, 27.1 mmol, 1 eq.) was added dropwise over 5 min. The mixture was stirred at 0 ◦C for
1 h, then the aqueous layer was removed. The organic layer was dry-loaded onto SiO2 and purified by column
chromatography using a Combiflash (SiO2, 0-100% EtOAc/P.E.). The combined pure fractions were dried with
MgSO4 and evaporated under reduced pressure. 164 was obtained as a pale pink amorphous solid (3.66 g, 13.5
mmol, 50%).
TLC Rf = 0.18 (25% EtOAc/P.E.)
IR (neat) νmax / cm−1 = 1671 (amide C=O)
1H NMR (400 MHz, CDCl3 d1) δ / ppm = 8.45 (s, 1 H, NH), 7.27 (t, J = 2.2 Hz, 1 H, ortho to OCH3 and
ortho to NH), 7.14 (t, J = 8.1 Hz, 1 H, meta to OCH3 and meta to NH), 7.02 (d, J = 8.3 Hz, 1 H, para to
OCH3), 6.62 (dd, J = 8.2, 2.1 Hz, 1 H, para to NH), 3.71 (s, 3 H, CH3), 3.42 (t, J = 6.5 Hz, 2 H, CH2Br), 2.51
(t, J = 6.9 Hz, 2 H, C(=O)CH2), 2.19 (quin, J = 6.8 Hz, 2 H, C(=O)CH2CH2)
13C NMR (101 MHz, CDCl3 d1) δ / ppm = 170.3 (C(=O)), 159.9 (ipso to OCH3), 139.0 (ipso to NH), 129.5
(meta to OCH3 and meta to NH), 112.1 (para to OCH3), 109.9 (para to NH), 105.7 (ortho to OCH3 and ortho
to NH), 55.2 (CH3), 35.3 (C(=O)CH2), 33.2 (CH2Br), 28.0 (C(=O)CH2CH2)
HRMS (ESI+) The compound does not ionise.
The compound has not been reported previously.
9.45 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 165
Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 151 (500 mg, 1.45
mmol, 1 eq.), 4-bromo-N -(3-methoxyphenyl)butanamide 164 (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 mL, 950
mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 mL) were stirred in a microwave
reactor at 100 ◦C for 4 h. The mixture was evaporated under reduced pressure and partitioned between CH2Cl2
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(50 mL) and water (50 mL). The organic layer was separated off and the aqueous layer was extracted again with
CH2Cl2 (50 mL). The combined organic layers were dried with MgSO4 and purified by column chromatogra-
phy (SiO2, 0-4% MeOH/CH2Cl2). The combined pure fractions were dried with MgSO4 and evaporated under
reduced pressure. 165 was obtained as an off-white amorphous solid (81.7 mg, 0.152 mmol, 11%).
TLC Rf = 0.38 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3271 (amide N-H) 2944 (C-H), 2817 (C-H), 1730 (ester C=O), 1682 (amide C=O),
1614 (quinolone C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 8.56 (s, 1 H, ortho to C(=O)OCH3), 8.06 (d, J = 13.3 Hz, 1 H, ortho to
F), 8.02 (br s, 1 H, NH), 7.34 (t, J = 1.7 Hz, 1 H, ortho to OCH3 and ortho to NH), 7.25 (d, J = 7.0 Hz, 1 H,meta
to F), 7.20 (t, J = 8.2 Hz, 1 H, meta to OCH3 and meta to NH), 6.98 (dd, J = 7.8, 1.7 Hz, 1 H, para to OCH3),
6.65 (dd, J = 8.2, 2.1 Hz, 1 H, para to NH), 3.93 (s, 3 H, C(=O)OCH3), 3.80 (s, 3 H, aromatic OCH3), 3.42
(tt, J = 6.8, 3.7 Hz, 1 H, NCH(CH2)2), 3.31 (br t, J = 4.3 Hz, 4 H, C(=O)CH2CH2CH2N(CH2CH2)CH2CH2),
2.73 (br t, J = 4.5 Hz, 4 H, C(=O)CH2CH2CH2N(CH2)CH2), 2.58 (t, J = 6.5 Hz, 2 H, C(=O)CH2CH2CH2N),
2.48 (t, J = 6.8 Hz, 2 H, C(=O)CH2CH2CH2N), 2.00 (quin, J = 6.8 Hz, 2 H, C(=O)CH2CH2CH2N), 1.29 -
1.36 (m, 2 H, NCH(CHH)2), 1.11 - 1.17 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, CDCl3) δ / ppm = 173.1 (C(=O)CC(=O)OCH3), 170.9 (NHC(=O)), 166.3 (C(=O)O
CH3), 160.1 (ipso to OCH3), 153.3 (d, J = 250.1 Hz, ipso to F), 148.4 (C=CC(=O)OCH3), 144.1 (d, J = 10.1
Hz, ipso to piperazine), 139.4 (ipso to NH), 138.0 (para to F), 129.6 (meta to NH and meta to OCH3), 123.3 (d,
J = 6.4 Hz, para to piperazine), 113.4 (d, J = 23.3 Hz, ortho to C=O and ortho to F), 111.8 (para to OCH3),
110.0 (CC(=O)OCH3), 109.8 (para to NH), 105.5 (ortho to OCH3 and ortho to NH), 105.0 (meta to C=O and
meta to F), 57.0 (CH2CH2CH2N), 55.3 (aromatic OCH3), 52.6 (CH2CH2CH2N(CH2)CH2), 52.1 (C(=O)OCH3),
49.2 (CH2CH2CH2N(CH2CH2)CH2CH2), 35.2 (CH2CH2CH2N), 34.6 (NCH(CH2)2), 21.7 (CH2CH2CH2N), 8.2
(NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -123.5 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 537.2500, [M+H]+ found, [C29H34FN4O5]+ requires 537.2513
The compound has not been reported previously.
9.46 4-Azido-N -(3-methoxyphenyl)butanamide 166
4-Bromo-N -(3-methoxyphenyl)butanamide 164 (2.05 g, 7.51 mmol, 1 eq.) and NaN3 (1.17 g, 18.0 mmol, 2.4
eq.) were refluxed in acetonitrile (100 mL) for 7 h. The mixture was cooled and filtered, and the fitrate was
dry-loaded onto SiO2 and purified by column chromatography using a Combiflash (SiO2, 0-100% EtOAc/P.E.).
The combined pure fractions were dried with MgSO4 and evaporated under reduced pressure. 166 was obtained
as a straw-coloured liquid (0.294 g, 1.25 mmol, 17%).
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TLC Rf = 0.37 (50% EtOAc/P.E.)
IR (neat) νmax / cm−1 = 3298 (N-H), 2095 (azide), 1662 (amide C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 8.63 (br s, 1 H, NH), 7.26 (t, J = 2.3 Hz, 1 H, ortho to OCH3 and
ortho to NH), 7.15 (t, J = 8.1 Hz, 1 H, meta to OCH3 and meta to NH), 7.01 (dd, J = 7.8, 1.6 Hz, 1 H, para
to OCH3), 6.63 (dd, J = 8.2, 1.9 Hz, 1 H, para to NH), 3.69 (s, 3 H, CH3), 3.28 (t, J = 6.7 Hz, 2 H, CH2N3),
2.39 (t, J = 7.4 Hz, 2 H, C(=O)CH2), 1.91 (quin, J = 7.0 Hz, 2 H, C(=O)CH2CH2)
13C NMR (101 MHz, MeOD) δ / ppm = 170.8 (C(=O)), 159.6 (ipso to OCH3), 138.9 (ipso to NH), 129.2
(meta to OCH3 and meta to NH), 112.3 (para to OCH3), 109.5 (para to NH), 106.0 (ortho to OCH3 and ortho
to NH), 54.8 (CH3), 50.4 (CH2N3), 33.6 (C(=O)CH2), 24.4 (C(=O)CH2CH2)
HRMS (ESI+) The compound does not ionise.
The compound has not been reported previously.
9.47 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-
1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carb
oxylic acid 167
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (24.1
mg, 58.6 µmol, 1 eq.) and 4-azido-N -(3-methoxyphenyl)butanamide 166 (13.7 mg, 58.5 µmol, 1 eq.) were dis-
solved in water (1 mL), t-BuOH (9 mL) and CH2Cl2 (10 mL), and the mixture was degassed by bubbling
through N2. A solution of CuSO4 and THPTA (58.5 µl, 5.85 µmol, 0.1 eq. 100 mM, aq.) was added, followed by
a solution of sodium ascorbate (117 µl, 11.7 µmol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room tem-
perature under argon for 2 h, then the solvent was removed under reduced pressure. The residue was partitioned
between water (15 mL) and CH2Cl2 (15 mL), and the aqueous layer was extracted a further four times with
CH2Cl2 (4×15 mL). The combined organic layers were dried with MgSO4, dry-loaded onto SiO2 and purified by
column chromatography (SiO2, 0-10% MeOH/CH2Cl2). The combined pure fractions were dried with MgSO4
and evaporated under reduced pressure. 167 was obtained as a clear amorphous solid (1.9 mg, 2.9 µmol, 5%).
TLC Rf = 0.22 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2923 (C-H), 2850 (C-H), 1726 (carboxylic acid C=O), 1685 (amide C=O), 1625
(quinolone C=O), 1612 (triazole)
1H NMR (400 MHz, DMSO d6) δ / ppm = 15.23 (br s, 1 H, C(=O)OH), 9.89 (s, 1 H, NH), 8.66 (s, 1 H,
ortho to C(=O)OH), 7.90 (d, J = 13.4 Hz, 1 H, ortho to F), 7.88 (s, 1 H, CH=CCH2), 7.55 (d, J = 7.6 Hz,
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1 H, meta to F), 7.27 (t, J = 2.1 Hz, 1 H, ortho to C=O and ortho to F), 7.16 (t, J = 8.1 Hz, 1 H, meta
to OCH3 and meta to NH), 7.08 (d, J = 7.8 Hz, 1 H, para to OCH3), 6.59 (ddd, J = 8.1, 2.4, 0.7 Hz, 1 H,
para to NH), 4.36 (t, J = 6.9 Hz, 2 H, C(=O)CH2CH2CH2N), 3.81 (tt, J = 6.7, 4.0 Hz, 1 H, NCH(CH2)2),
3.70 (s, 3 H, CH3), 3.28 - 3.32 (m, 4 H, CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 2.64 (t, J = 7.5 Hz, 2
H, CH=CCH2), 2.56 (m, J = 4.2, 4.2 Hz, 4 H, CH=CCH2CH2CH2CH2N(CH2)CH2), 2.38 (t, J = 7.3 Hz, 2
H, CH=CCH2CH2CH2CH2N), 2.30 (t, J = 7.4 Hz, 2 H, C(=O)CH2CH2CH2N), 2.10 (quin, J = 7.1 Hz, 2 H,
C(=O)CH2CH2CH2N), 1.64 (quin, J = 7.5 Hz, 2 H, CH=CCH2CH2CH2CH2N), 1.51 (quin, J = 7.2 Hz, 2 H,
CH=CCH2CH2CH2CH2N), 1.27 - 1.33 (m, 2 H, NCH(CHH)2), 1.15 - 1.20 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 176.3 (C(=O)CC(=O)OH), 170.1 (NHC(=O)), 165.9 (C(=O)OH),
159.4 (ipso to OCH3), 153.0 (d, J = 248.6 Hz, ipso to F), 148.0 (CH=CCH2), 146.9 (C=CC(=O)OH), 145.2
(d, J = 10.7 Hz, ipso to piperazine), 140.3 (para to F), 139.2 (ipso to NH), 129.4 (meta to OCH3 and
meta to NH), 121.7 (CH=CCH2), 118.5 (d, J = 7.5 Hz, para to piperazine), 111.3 (para to OCH3), 110.9
(d, J = 22.4 Hz, ortho to C=O and ortho to F), 108.4 (para to NH), 106.7 (CC(=O)OH), 106.3 (meta
to C=O and meta to F), 104.8 (ortho to OCH3 and ortho to NH), 57.3 (CH=CCH2CH2CH2CH2N), 54.9
(CH3), 52.4 (CH=CCH2CH2CH2CH2N(CH2)CH2), 49.5 (CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 49.4
(CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 48.7 (C(=O)CH2CH2CH2N), 35.8 (NCH(CH2)2), 32.9 (C(=O)
CH2CH2CH2N), 26.8 (CH=CCH2CH2CH2CH2N), 25.7 (CH=CCH2CH2CH2CH2N), 25.5 (C(=O)CH2CH2CH2
N), 24.9 (CH=CCH2CH2CH2CH2N), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, DMSO d6) δ / ppm = -121.5 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 646.3159, [M+H]+ found, [C34H41FN7O5]+ requires 646.3153
The compound has not been reported previously.
9.48 (1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 170 and (1R,2R)-2-
(((S)-1-phenylethyl)amino)cyclopentan-1-ol 171
H
N
OH
H
N
OH
PSfrag replacements
171170
(S)-1-Phenylethan-1-amine 169 (7.85 mL, 7.38 g, 60.9 mmol, 1 eq.) was dissolved in CH2Cl2 (50 mL) and
stirred rapidly at 0 ◦C. A solution of AlMe3 (31 mL, 2.0 M in heptane, 60.9 mmol) was added dropwise and the
mixture was stirred at 0 ◦C for 1 h. A solution of cyclohexene oxide 168 (5.71 mL, 5.50 g, 65.4 mmol, 1.1 eq.)
in CH2Cl2 (50 mL) was then added dropwise, and the mixture was stirred at 0 ◦C for a further 3 h, followed
by 48 h at r.t.. The mixture was cooled to 0 ◦C and NaF (11 g, 262 mmol, 4.3 eq.) was added portionwise,
followed by water (7.00 mL, 7.00 g, 389 mmol, 6.4 eq.) and CH2Cl2 (50 mL). The suspension was allowed to
warm to r.t. and stirred for 1 h, then filtered through Celite and washed with CH2Cl2 (500 mL). The filtrate
was dried with K2CO3, concentrated under reduced pressure and purified by column chromatography (SiO2,
20:5:1 hexane:EtOAc:TEA). 171 was obtained as a pale yellow oil (4.08 g, 19.9 mmol, 33%). 170 was obtained
as pale yellow crystals (4.48 g, 21.8 mmol, 36%).
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(1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 170
TLC Rf = 0.36 (15:5:1 hexane:EtOAc:TEA)
mp T / ◦C = 66-72 (hexane, EtOAc, TEA)
IR (neat) νmax / cm−1 = 3150 (br, O-H), 2951 (C-H), 2868 (C-H)
1H NMR (400 MHz, CDCl3) δ / ppm = 7.28 - 7.34 (m, 4 H, ortho and meta to CHCH3), 7.20 - 7.26 (m, 1 H,
para to CHCH3), 3.86 (q, J = 6.6 Hz, 1 H, CHCH3), 3.85 (q, J = 6.6 Hz, 1 H, CHOH), 2.83 (td, J = 7.6, 5.7
Hz, 1 H, CHNH), 1.85 - 1.97 (m, 1 H, CHHCHOH), 1.77 (dtd, J = 12.9, 7.9, 4.9 Hz, 1 H, CHHCHNH), 1.55 -
1.68 (m, 2 H, CH2CH2CHOH), 1.47 - 1.55 (m, 1 H, CHHCHOH), 1.36 (d, J = 6.6 Hz, 3 H, CH3), 1.12 (dq, J
= 12.7, 8.1 Hz, 1 H, CHHCHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 145.61 (ipso to CHCH3), 128.08 (meta to CHCH3), 126.61 (para to
CHCH3), 126.33 (ortho to CHCH3), 77.43 (CHOH), 64.45 (CHNH), 56.62 (CHCH3), 32.01 (CH2CHOH), 30.56
(CH2CHNH), 23.30 (CH3), 20.06 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 206.1553, [M+H]+ found, [C13H20NO]+ requires 206.1545
[α]20D / ◦10−1cm2g−1 = -23.9, lit. = -22.1 (c / g(100 mL)−1 = 0.96 , MeOH)
(1R,2R)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 171
TLC Rf = 0.25 (15:5:1 hexane:EtOAc:TEA)
IR (neat) νmax / cm−1 = 3300 (br, O-H), 2960 (C-H), 2870 (C-H)
1H NMR (400 MHz, CDCl3) δ / ppm = 7.28 - 7.38 (m, 4 H, ortho and meta to CHCH3), 7.21 - 7.28 (m, 1 H,
para to CHCH3), 3.83 (q, J = 6.6 Hz, 1 H, CHCH3), 3.78 (q, J = 7.0 Hz, 1 H, CHOH), 2.62 (dt, J = 8.2, 7.2
Hz, 1 H, CHNH), 1.97 (quin, J = 6.7 Hz, 1 H, CH2CHNH), 1.90 (quin, J = 6.9 Hz, 1 H, CH2CHOH), 1.56 -
1.68 (m, CH2CH2CHOH), 1.43 (dq, J = 12.5, 8.0 Hz, 1 H, CH2CHOH), 1.37 (d, J = 6.6 Hz, 3 H, CH3), 1.25 -
1.36 (m, 1 H, CH2CHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 144.75 (ipso to CHCH3), 128.26 (meta to CHCH3), 126.72 (para to
CHCH3), 126.30 (ortho to CHCH3), 77.65 (CHOH), 63.38 (CHNH), 56.20 (CHCH3), 31.74 (CH2CHOH), 29.22
(CH2CHNH), 24.58 (CH3), 19.57 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 206.1554, [M+H]+ found, [C13H20NO]+ requires 206.1545
[α]20D / ◦10−1cm2g−1 = -92.8, lit. = -76.8 (c / g(100 mL)−1 = 1.19, MeOH)
The compounds have been synthesised previously,219,220 but NMR data were not published. The enantiomers
of both compounds have also been synthesised previously, and the 1H NMR data for these are consistent with
the the above data.221
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9.49 (1S,2S)-2-Aminocyclopentan-1-ol 172
(1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 170 (3.00 g, 14.6 mmol, 1 eq.), Pd(OH)2 (20 wt. % on
C, moistened with 50 wt. % water, 0.5 g, 0.356 mmol, 0.025 eq.) and MeOH (50 mL) were stirred in a Paar
hydrogenator at r.t. and 2.5 atm for 2 days. The mixture was then filtered through Celite and evaporated under
reduced pressure. 172 was obtained as a yellow oil (1.48 g, 14.6 mmol, >99%).
TLC Rf = 0.10 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3300 (O-H), 2969 (C-H), 2873 (C-H)
1H NMR (400 MHz, MeOD) δ / ppm = 3.77 (ddd, J = 6.6, 6.2, 5.6, 1 H, CHOH), 3.00 (td, J = 7.4, 5.6
Hz, 1 H, CHNH2), 2.00 (dtd, J = 13.0, 7.7, 5.6 Hz, 1 H, CHHCHNH2), 1.97 (ddt, J = 13.0, 8.7, 6.4 Hz, 1 H,
CHHCHOH), 1.64 - 1.77 (m, 2 H, CH2CH2CHOH), 1.53 (ddt, J = 13.0, 9.5, 6.2 Hz, 1 H, CHHCHOH), 1.37
(ddt, J = 12.8, 8.5, 7.7 Hz, 1 H, CHHCHNH2)
13C NMR (101 MHz, MeOD) δ / ppm = 80.6 (CHOH), 60.7 (CHNH2), 33.2 (CH2CHOH), 32.2 (CH2CHNH2),
21.2 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 102.0915, [M+H]+ found, [C5H12NO]+ requires 102.0913
[α]20D / ◦10−1cm2g−1 = 33.4, lit. = 29.7 (c / g(100 mL)−1 = 0.5, EtOH)
The data are consistent with the literature.220,241
9.50 (1R,2R)-2-Aminocyclopentan-1-ol 173
(1R,2R)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 171 (3.90 g, 19.0 mmol, 1 eq.), Pd(OH)2 (20 wt. % on
C, moistened with 50 wt. % water, 1 g, 0.712 mmol, 0.04 eq.) and MeOH (50 mL) were stirred in a Paar
hydrogenator at r.t. and 3 atm for 2 days. The mixture was then filtered through Celite and evaporated under
reduced pressure. 173 was obtained as a yellow oil (1.92 g, 19.0 mmol, >99%).
TLC Rf = 0.10 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3300 (br, O-H), 2958 (C-H), 2872 (C-H)
1H NMR (400 MHz, MeOD) δ / ppm = 3.77 (ddd, J = 6.6, 6.2, 5.6, 1 H, CHOH), 3.00 (td, J = 7.3, 5.6
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Hz, 1 H, CHNH2), 2.00 (dtd, J = 13.0, 7.7, 5.6 Hz, 1 H, CHHCHNH2), 1.97 (ddt, J = 13.0, 8.7, 6.6 Hz, 1 H,
CHHCHOH), 1.63 - 1.77 (m, 2 H, CH2CH2CHOH), 1.53 (ddt, J = 13.0, 9.5, 6.2 Hz, 1 H, CHHCHOH), 1.37
(ddt, J = 13.0, 8.3, 7.8 Hz, 1 H, CHHCHNH2)
13C NMR (101 MHz, MeOD) δ / ppm = 80.7 (CHOH), 60.8 (CHNH2), 33.2 (CH2CHOH), 32.1 (CH2CHNH2),
21.2 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 102.0917, [M+H]+ found, [C5H12NO]+ requires 102.0913
[α]20D / ◦10−1cm2g−1 = -30.9, lit. = -32.9 (c / g(100 mL)−1 = 1.5 , EtOH)
The data are consistent with the literature.220,241
9.51 4-Azido-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 176
4-Chloro-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 193 (35.0 mg, 0.170 mmol, 1 eq.) and NaN3 (22.1 mg,
0.340 mmol, 2 eq.) were stirred in acetonitrile (2 mL) at 50 ◦C for 24 h. The reaction mixture was then
partitioned between water (20 mL) and 10% i-PrOH/CHCl3 (5 mL). The aqueous layer was extracted again
with 10% i-PrOH/CHCl3 (2×5 mL) and the combined organic fractions were dried with MgSO4 and evaporated
under reduced pressure. 176 was obtained as white needles (16.2 mg, 0.0764 mmol, 45%).
TLC Rf = 0.35 (EtOAc)
IR (neat) νmax / cm−1 = 3287 (N-H and O-H), 2958 (C-H), 2931 (C-H), 2861 (C-H), 2095 (azide), 1642 (amide
C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 5.82 (br s, 1 H, NH), 4.45 (br. s., 1 H, OH), 3.96 (q, J = 6.6 Hz, 1
H, CHOH), 3.83 (tdd, J = 8.5, 6.0, 4.6 Hz, 1 H, CHNH), 3.37 (t, J = 6.4 Hz, 2 H, CH2N3), 2.31 (t, J = 7.2
Hz, 2 H, CH2C=O), 2.09 - 2.19 (m, 1 H, CHHCHNH), 1.99 - 2.06 (m, 1 H, CHHCHOH), 1.90 - 1.97 (m, 2 H,
CH2CH2N3), 1.60 - 1.85 (m, 3 H, CH2CHHCHOH), 1.42 (dq, J = 12.8, 8.3 Hz, 1 H, CHHCHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 173.8 (C=O), 79.7 (CHOH), 61.0 (CHNH), 50.7 (CH2N3), 32.8
(CH2C=O), 32.6 (CH2CHOH), 30.5 (CH2CHNH), 24.7 (CH2CH2N3), 21.3 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 235.1178, [M+Na]+ found, [C9H16N4NaO2]+ requires 235.1171
[α]20D / ◦10−1cm2g−1 = 10.0 (c / g(100 mL)−1 = 0.01, MeOH)
The compound has not been reported previously.
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9.52 4-Azido-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 177
4-Chloro-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 194 (200 mg, 0.972 mmol, 1 eq.) and NaN3 (126 mg,
1.94 mmol, 2 eq.) were stirred in acetonitrile (4 mL) at 50 ◦C for 16 h. The solvent was then evaporated under
reduced pressure and the residue was partitioned between water (20 mL) and 10% i-PrOH/CHCl3 (20 mL). The
aqueous layer was extracted again with 10% i-PrOH/CHCl3 (3×20 mL) and the combined organic fractions
were dried with MgSO4 and evaporated under reduced pressure. 177 was obtained as white needles (181 mg,
0.852 mmol, 88%).
TLC Rf = 0.35 (EtOAc)
mp T / ◦C = 56-60 (i-PrOH, CHCl3)
IR (neat) νmax / cm−1 = 3280 (N-H and O-H), 2966 (C-H), 2875 (C-H), 2095 (azide), 1637 (amide C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.72 (d, J = 4.4 Hz, 1 H, NH), 4.82 (br. s., 1 H, OH), 3.88 (q, J =
6.6 Hz, 1 H, CHOH), 3.75 (tdd, J = 8.4, 6.6, 4.4 Hz, 1 H, CHNH), 3.28 (t, J = 6.6 Hz, 2 H, CH2N3), 2.23 (t, J
= 7.3 Hz, 2 H, CH2C=O), 2.04 (dtd, J = 13.0, 8.0, 4.9 Hz, 1 H, CHHCHNH), 1.92 (dtd, J = 13.0, 7.6, 5.8 Hz,
1 H, CHHCHOH), 1.84 (quin, J = 7.0 Hz, 2 H, CH2CH2N3), 1.59 - 1.77 (m, 2 H, CH2CH2CHOH), 1.54 (ddt,
J = 12.7, 9.0, 6.7 Hz, 1 H, CHHCHOH), 1.39 (dq, J = 12.9, 8.4 Hz, 1 H, CHHCHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 173.8 (C=O), 78.8 (CHOH), 59.9 (CHNH), 50.5 (CH2N3), 32.5
(CH2C=O), 32.0 (CH2CHOH), 29.5 (CH2CHNH), 24.6 (CH2CH2N3), 20.7 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 235.1174, [M+Na]+ found, [C9H16N4NaO2]+ requires 235.1171
[α]20D / ◦10−1cm2g−1 = -10.2 (c / g(100 mL)−1 = 0.5, MeOH)
The compound has not been reported previously.
9.53 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-
4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 178
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4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid
trifluoroacetate 198 (52.1 mg, 95.5 µmol, 1 eq.), (1S,2S)-2-aminocyclopentan-1-ol 172 (19.5 mg, 193 µmol, 2
eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (29.7 mg, 155 µmol, 1.6 eq.), 1-hydroxyben
zotriazole (25.8 mg, 191 µmol, 2 eq.) and DIPEA (33.3 µl, 24.7 mg, 191 µmol, 2 eq.) were dissolved in DMF (2
mL) and stirred at r.t. for 16 h. The solvent was removed using a stream of N2 and the residue was purified by
preparative HPLC (5-50% acetonitrile/water over 15 min). The combined pure fractions were evaporated under
reduced pressure and then partitioned between NaHCO3 (aq., sat., 5 mL) and CH2Cl2 (5 mL). The organic
layer was removed and the aqueous layer was extracted twice more with CH2Cl2 (2×5 mL). The combined
organic fractions were dried with MgSO4 and evaporated under reduced pressure. 178 was obtained as a white
amorphous solid (26.9 mg, 52.3 µmol, 55%).
TLC Rf = 0.38 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2938 (C-H), 1721 (ester C=O), 1621 (amide C=O and quinolone C=O)
1H NMR (500 MHz, DMSO d6) δ / ppm = 8.44 (s, 1 H, ortho to C(=O)OCH3), 7.75 (d, J = 13.5 Hz, 1 H, ortho
to F), 7.69 (d, J = 6.9 Hz, 1 H, CHNH), 7.43 (d, J = 7.6 Hz, 1 H, meta to F), 4.73 (br s, 1 H, CHOH), 3.77 - 3.81
(m, 1 H, CHOH), 3.74 - 3.77 (m, 1 H, CHNH), 3.73 (s, 3 H, CH3), 3.65 (tt, J = 6.9, 4.0 Hz, 1 H, NCH(CH2)2),
3.24 (br. t, J = 4.2 Hz, 4 H, CH2N(CH2CH2)CH2CH2), 2.55 (br t, J = 5.0 Hz, 4 H, CH2N(CH2)CH2), 2.32
(t, J = 7.2 Hz, 2 H, CH2N(CH2)CH2), 2.10 (t, J = 7.4 Hz, 2 H, CH2CH2CH2N(CH2)CH2), 1.92 (dddd, J =
13.0, 8.7, 7.3, 6.0 Hz, 1 H, CHHCHNH), 1.77 (ddt, J = 12.6, 8.9, 6.3 Hz, 1 H, CHHCHOH), 1.68 (quin, J =
7.4 Hz, 2 H, CH2CH2N(CH2)CH2), 1.53 - 1.64 (m, 2 H, CH2CH2CHOH), 1.42 (ddt, J = 12.9, 8.4, 5.2 Hz, 1
H, CHHCHOH), 1.31 (ddt, J = 13.0, 8.6, 6.4 Hz, 1 H, CHHCHNH), 1.22 - 1.28 (m, 2 H, NCH(CHH)2), 1.06 -
1.12 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO d6) δ / ppm = 171.9 (NHC(=O)CH2), 171.5 (C(=O)CC(=O)OCH3), 165.0
(C(=O)OCH3), 152.6 (d, J = 247.4 Hz, ipso to F), 148.2 (C=CC(=O)OCH3), 143.9 (d, J = 10.3 Hz, ipso to
piperazine), 138.1 (para to F), 121.7 (d, J = 6.4 Hz, para to piperazine), 111.5 (d, J = 23.0 Hz, ortho to C=O
and ortho to F), 109.0 (CC(=O)OCH3), 106.2 (meta to C=O and meta to F), 76.2 (CHOH), 57.6 (CHNH), 57.2
(CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2), 51.3 (CH3), 49.6 (CH2CH2CH2N(CH2CH2)CH2CH2), 49.6
(CH2CH2CH2N(CH2CH2)CH2CH2), 34.7 (NCH(CH2)2), 33.2 (C(=O)CH2), 32.2 (CH2CHOH), 29.5 (CH2CH
NH), 22.5 (C(=O)CH2CH2), 20.6 (CH2CH2CHOH), 7.5 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -125.5
HRMS (ESI+) m/z / Da = 515.2667, [M+H]+ found, [C27H36FN4O5]+ requires 515.2670
[α]20D / ◦10−1cm2g−1 = 8.0 (c / g(100 mL)−1 = 0.05, MeOH)
The compound has not been reported previously.
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9.54 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1R,2R)-2-hydroxycyclopentyl)amin
o)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 179
4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid
trifluoroacetate 198 (200 mg, 0.367 mmol, 1 eq.), (1R,2R)-2-aminocyclopentan-1-ol 173 (80 mg, 0.791 mmol, 2.1
eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxyben
zotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 µl, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5
mL) and stirred at r.t. for 16 h. The solvent was removed using a stream of N2 and the residue was purified by
preparative HPLC (5-60% acetonitrile/water over 12 min). The combined pure fractions were evaporated under
reduced pressure and then partitioned between NaHCO3 (aq., sat., 10 mL) and CH2Cl2 (10 mL). The organic
layer was removed and the aqueous layer was extracted twice more with CH2Cl2 (2×10 mL). The combined
organic fractions were dried with MgSO4 and evaporated under reduced pressure. 179 was obtained as a white
amorphous solid (73.0 mg, 0.142 mmol, 39%).
TLC Rf = 0.43 (30% MeOH/EtOAc)
IR (neat) νmax / cm−1 = 2973 (C-H), 2902 (C-H), 1728 (ester C=O), 1656 (amide C=O), 1613 (quinolone
C=O)
1H NMR (400 MHz, DMSO d6) δ / ppm = 8.44 (s, 1 H, ortho to C(=O)OCH3), 7.75 (d, J = 13.5 Hz, 1 H,
ortho to F), 7.70 (d, J = 7.2 Hz, 1 H, CHNH), 7.43 (d, J = 7.5 Hz, 1 H, meta to F), 4.74 (d, J = 4.0 Hz, 1 H,
CHOH), 3.78 - 3.82 (m, 1 H, CHOH), 3.74 - 3.78 (m, 1 H, CHNH), 3.74 (s, 3 H, CH3), 3.65 (tt, J = 7.2, 3.9 Hz,
1 H, NCH(CH2)2), 3.25 (t, J = 4.8 Hz, 4 H, CH2N(CH2CH2)CH2CH2), 2.57 (br s, 4 H, CH2N(CH2)CH2), 2.34
(t, J = 7.4 Hz, 2 H, CH2N(CH2)CH2), 2.11 (t, J = 7.4 Hz, 2 H, CH2CH2CH2N(CH2)CH2), 1.92 (dddd, J =
13.0, 8.7, 7.3, 6.0 Hz, 1 H, CHHCHNH), 1.78 (dddd, J = 12.6, 8.9, 6.3, 6.3 Hz, 1 H, CHHCHOH), 1.69 (quin, J
= 7.3 Hz, 2 H, CH2CH2N(CH2)CH2), 1.54 - 1.65 (m, 2 H, CH2CH2CHOH), 1.42 (ddt, J = 13.1, 8.2, 5.3 Hz, 1
H, CHHCHOH), 1.32 (dddd, J = 13.4, 8.5, 6.8, 5.8 Hz, 1 H, CHHCHNH), 1.21 - 1.29 (m, 2 H, NCH(CHH)2),
1.07 - 1.13 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 171.9 (CH2C(=O)NH), 171.6 (C(=O)CC(=O)OCH3), 165.0
(C(=O)OCH3), 152.6 (d, J = 246.5 Hz, ipso to F), 148.3 (C=CC(=O)OCH3), 143.9 (d, J = 10.7 Hz, ipso to
piperazine), 138.1 (para to F), 121.8 (d, J = 6.4 Hz, para to piperazine), 111.5 (d, J = 22.4 Hz, ortho to C=O
and ortho to F), 109.0 (CC(=O)OCH3), 106.2 (meta to C=O and meta to F), 76.3 (CHOH), 57.6 (CHNH),
57.2 (CH2CH2CH2N), 52.4 (CH2CH2CH2N(CH2)CH2), 51.3 (CH3), 49.6 (CH2CH2CH2N(CH2CH2)CH2CH2),
34.8 (NCH(CH2)2), 33.3 (C(=O)CH2), 32.2 (CH2CHOH), 29.5 (CH2CHNH), 22.5 (C(=O)CH2CH2), 20.6
(CH2CH2CHOH), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, DMSO d6) δ / ppm = -124.3 (ciprofloxacin F)
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HRMS (ESI+) m/z / Da = 515.2661, [M+H]+ found, [C27H36FN4O5]+ requires 515.2670
[α]20D / ◦10−1cm2g−1 = -6.0 (c / g(100 mL)−1 = 0.05, MeOH)
The compound has not been reported previously.
9.55 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquin
oline-3-carboxylic acid 180
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (82.0
mg, 199 µmol, 4 eq.) and 4-azido-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 176 (11.0 mg, 51.8 µmol, 1 eq.)
were dissolved in 10% water/t-BuOH (3 mL), and the mixture was degassed by bubbling N2 through it. A
solution of CuSO4 and THPTA (156 µl, 15.6 µmol, 0.3 eq. 100 mM, aq.) was added, followed by a solution of
sodium ascorbate (312 µl, 31.2 µmol, 0.6 eq., 100 mM, aq.). The mixture was stirred at room temperature under
argon for 3 d. Water (10 mL) and 10% i-PrOH/CHCl3 (10 mL) were added, then the organic layer was separated
and dried with MgSO4 and evaporated under reduced pressure. The residue was purified by preparative HPLC
(5-95% acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure
and then partitioned between NaHCO3 (aq., sat., 10 mL) and 10% i-PrOH/CHCl3 (10 mL). The organic layer
was dried with MgSO4 and evaporated under reduced pressure. 180 was obtained as a white amorphous solid
(7.2 mg, 11.5 µmol, 22%).
IR (neat) νmax / cm−1 = 2955 (C-H), 2918 (C-H), 2850 (C-H), 1722 (carboxylic acid C=O), 1647 (amide
C=O), 1627 (quinolone C=O) 1612 (triazole)
1H NMR (400 MHz, DMSO d6) δ / ppm = 15.22 (br s, 1 H, C(=O)OH), 8.67 (s, 1 H, ortho to C(=O)OH),
7.91 (d, J = 13.3 Hz, 1 H, ortho to F), 7.84 (s, 1 H, CH=CCH2), 7.74 (d, J = 6.7 Hz, 1 H, CHNH), 7.56
(d, J = 7.4 Hz, 1 H, meta to F), 4.71 (d, J = 3.7 Hz, 1 H, CHOH), 4.29 (t, J = 6.6 Hz, 2 H, CH2NCH=C),
3.82 (tt, J = 6.5, 4.3 Hz, 1 H, NCH(CH2)2), 3.69 - 3.79 (m, 2 H, CHOH and CHNH), 3.30 - 3.34 (m, 6 H,
CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 2.64 (t, J = 7.4 Hz, 2 H, CH=CCH2), 1.95 - 2.08 (m, 4 H,
C(=O)CH2CH2), 1.89 (dddd, J = 12.8, 8.9, 7.4, 5.8 Hz, 1 H, CHHCHNH), 1.75 (ddt, J = 12.7, 9.0, 6.2 Hz, 1
H, CHHCHOH), 1.48 - 1.68 (m, 6 H, CH=CCH2CH2CH2 and CH2CH2CHOH), 1.40 (ddt, J = 13.0, 8.3, 5.3
Hz, 1 H, CHHCHOH), 1.28 - 1.35 (m, 2 H, NCH(CHH)2), 1.24 - 1.31 (m, 1 H, CHHCHNH), 1.15 - 1.21 (m, 2
H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 170.9 (NHC(=O)CH2), 166.0
(C(=O)OH), 153.0 (d, J = 249.6 Hz, ipso to F), 148.1 (C=CC(=O)OH), 146.7 (CH=CCH2), 145.2 (d, J = 8.3
Hz, ipso to piperazine), 139.2 (para to F), 121.8 (NCH=CCH2), 118.7 (para to piperazine), 111.0 (d, J = 23.2
Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.5 (meta to C=O and meta to F), 76.2 (CHOH), 57.5
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(CHNH), 57.4 (br s, CH=CCH2CH2CH2CH2N), 52.3 (br s, CH=CCH2CH2CH2CH2N(CH2)CH2), 49.3 (br s,
CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 48.8 (CH2NCH=CCH2), 35.9 (NCH(CH2)2), 32.2 (CH2CHOH),
32.0 (C(=O)CH2), 29.4 (CH2CHNH), 26.7 (CH=CCH2CH2), 26.0 (C(=O)CH2CH2), 25.5 (CH=CCH2CH2CH2),
24.9 (CH=CCH2), 20.5 (CH2CH2CHOH), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -121.5
HRMS (ESI+) m/z / Da = 624.3298, [M+H]+ found, [C32H43FN7O5]+ requires 624.3310
[α]20D / ◦10−1cm2g−1 = -25.0 (c / g(100 mL)−1 = 0.08, MeOH)
The compound has not been reported previously.
9.56 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquin
oline-3-carboxylic acid 181
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (42.9
mg, 104 µmol, 1 eq.) and 4-azido-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 177 (22.0 mg, 104 µmol, 1 eq.)
were dissolved in 10% water/t-BuOH (3 mL), and the mixture was degassed by bubbling N2 through it. A
solution of CuSO4 and THPTA (104 µl, 10.4 µmol, 0.1 eq. 100 mM, aq.) was added, followed by a solution
of sodium ascorbate (208 µl, 20.8 µmol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature
under argon for 16 h. Water (30 mL) and CH2Cl2 (30 mL) were added, the organic layer was separated and
the aqueous layer was extracted again with CH2Cl2 (4×30 mL). The combined organic layers were dried with
MgSO4 and evaporated under reduced pressure. The residue was purified by preparative HPLC (5-95% ace-
tonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure and then
partitioned between NaHCO3 (aq., sat., 10 mL) and 10% i-PrOH/CHCl3 (10 mL). The organic layer was dried
with MgSO4 and evaporated under reduced pressure. 181 was obtained as a white amorphous solid (17.6 mg,
28.2 µmol, 27%).
IR (neat) νmax / cm−1 = 2967 (C-H), 2902 (C-H), 1721 (carboxylic acid C=O), 1647 (amide C=O), 1627
(quinolone C=O), 1613 (triazole)
1H NMR (700 MHz, DMSO d6) δ / ppm = 8.64 (s, 1 H, ortho to C(=O)OH), 7.87 (d, J = 13.3 Hz, 1 H, ortho
to F), 7.84 (s, 1 H, CH=CCH2), 7.75 (d, J = 7.1 Hz, 1 H, CHNH), 7.54 (d, J = 7.5 Hz, 1 H, meta to F), 4.73
(d, J = 3.8 Hz, 1 H, CHOH), 4.29 (t, J = 6.9 Hz, 2 H, CH2NCH=C), 3.78 - 3.83 (m, 1 H, NCH(CH2)2), 3.75
- 3.78 (m, 1 H, CHOH), 3.71 - 3.75 (m, 1 H, CHNH), 3.31 (br t, J = 4.3 Hz, 4 H, CH2N(CH2CH2)CH2CH2),
2.63 (t, J = 7.5 Hz, 2 H, CH=CCH2), 2.56 (br t, J = 4.2 Hz, 4 H, CH2N(CH2)CH2), 2.37 (t, J = 7.3 Hz, 2
H, CH2N(CH2)CH2), 2.03 - 2.06 (m, 2 H, C(=O)CH2), 1.97 - 2.02 (m, 2 H, C(=O)CH2CH2), 1.89 (dddd, J =
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13.1, 8.9, 7.4, 5.7 Hz, 1 H, CHHCHNH), 1.75 (ddt, J = 13.0, 8.9, 6.4, 6.4 Hz, 1 H, CHHCHOH), 1.61 - 1.66
(m, 2 H, CH=CCH2CH2), 1.57 - 1.61 (m, 1 H, CHHCH2CHOH), 1.54 - 1.57 (m, 1 H, CHHCH2CHOH), 1.49 -
1.53 (m, 2 H, CH=CCH2CH2CH2), 1.40 (ddt, J = 13.0, 8.4, 5.3, 5.3 Hz, 1 H, CHHCHOH), 1.29 - 1.32 (m, 2
H, NCH(CHH)2), 1.25 - 1.29 (m, 1 H, CHHCHNH), 1.13 - 1.20 (m, 2 H, NCH(CHH)2)
13C NMR (175 MHz, DMSO d6) δ / ppm = 176.3 (C(=O)CC(=O)OH), 170.9 (NHC(=O)CH2), 166.1
(C(=O)OH), 153.0 (d, J = 251.4 Hz, ipso to F), 147.9 (C=CC(=O)OH), 146.9 (CH=CCH2), 145.2 (d, J
= 8.7 Hz, ipso to piperazine), 139.2 (para to F), 121.7 (NCH=CCH2), 118.7 (d, J = 5.8 Hz, para to piperazine),
111.0 (d, J = 23.3 Hz, ortho to C=O and ortho to F), 106.3 (meta to C=O and meta to F and CC(=O)OH),
76.2 (CHOH), 57.6 (CHNH), 57.4 (CH=CCH2CH2CH2CH2N), 52.5 (CH=CCH2CH2CH2CH2N(CH2)CH2), 49.5
(d, J = 4.4 Hz, CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 48.8 (CH2NCH=CCH2), 35.8 (NCH(CH2)2),
32.2 (CH2CHOH), 32.0 (C(=O)CH2), 29.5 (CH2CHNH), 26.9 (CH=CCH2CH2), 26.0 (C(=O)CH2CH2), 25.8
(CH=CCH2CH2CH2), 25.0 (CH=CCH2), 20.5 (CH2CH2CHOH), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -122.1 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 624.3314, [M+H]+ found, [C32H43FN7O5]+ requires 624.3310
[α]20D / ◦10−1cm2g−1 = -3.6 (c / g(100 mL)−1 = 0.0833, MeOH)
The compound has not been reported previously.
9.57 (1S,2S)-2-((tert-Butyldimethylsilyl)oxy)cyclopentan-1-amine 182
(1S,2S)-2-Aminocyclopentan-1-ol 172 (0.480 g, 4.75 mmol) was stirred in dry CH2Cl2 (20 mL) under N2 at 0
◦C. TEA (3.14 mL, 2.28 g, 22.5 mmol, 5 eq.) was added dropwise, followed by TBDMSOTf (3 mL, 3.45 g, 13.1
mmol, 3 eq.) dropwise. The reaction was allowed to reach r.t. and stirred for 1 h. The reaction was washed with
water (20 mL) and the organic phase dried with Na2SO4, concentrated under reduced pressure and purified by
column chromatography (SiO2, 4% MeOH/CH2Cl2). 182 was obtained as a yellow oil (1.00 g, 4.64 mmol, 98%).
TLC Rf = 0.23 (10% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2954 (C-H), 2931 (C-H), 2888 (C-H), 2859 (C-H), 1625 (N-H bend)
1H NMR (400 MHz, CDCl3) δ / ppm = 4.13 (q, J = 5.8 Hz, 1 H, CHOSi), 3.31 (td, J = 7.1, 5.2 Hz, 1 H,
CHNH2), 2.09 - 2.19 (m, 1 H, CHHCHNH2), 1.97 (ddq, J = 8.8, 7.0, 6.0 Hz, 1 H, CHHCHOSi), 1.74 - 1.86 (m,
2 H, CH2CH2CHOSi), 1.64 - 1.74 (m, 1 H, CHHCHOSi), 1.58 (ddt, J = 13.2, 9.1, 6.0 Hz, 1 H, CHHCHNH2),
0.88 (s, 9 H, C(CH3)3), 0.09 (s, 3 H, SiCH3), 0.07 (s, 3 H, SiCH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 76.3 (CHOSi), 59.7 (CHNH), 32.2 (CH2CHOSi), 26.8 (CH2CHNH2),
25.6 (C(CH3)3), 19.7 (CH2CH2CHOSi), 17.7 (C(CH3)3), -4.8 (SiCH3), -5.2 (SiCH3)
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HRMS (ESI+) m/z / Da = 216.1785, [M+H]+ found, [C11H26NOSi]+ requires 216.1784
[α]20D / ◦10−1cm2g−1 = 40.0 (c / g(100 mL)−1 = 0.05 , MeOH) The compound has not been reported previously.
9.58 4-Azido-N -((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)butanamide
186
(1S,2S)-2-((tert-Butyldimethylsilyl)oxy)cyclopentan-1-amine 182 (50 mg, 0.232 mmol, 1 eq.) and NaHCO3 (22.0
mg, 0.262 mmol, 1.1 eq.) were added to CH2Cl2 (3 mL) and water (3 mL) at 0 ◦C, and 4-bromobutyryl chloride
(25.3 mL, 40.5 mg, 0.219 mmol, 0.95 eq.) was added dropwise. The mixture was stirred for 3 h at 0 ◦C. The
aqueous layer was removed and NaN3 (100 mg, 1.54 mmol, 6.6 eq.) and DMF (3 mL) were added. The mixture
was then stirred at 40 ◦C for 6 h. The solvents were then evaporated using a N2 stream and the residue was
purified by column chromatography (SiO2, 1% MeOH/CH2Cl2). The combined pure fractions were dried with
MgSO4 and evaporated under reduced pressure. 186 was obtained as a clear liquid (71 mg, 0.217 mmol, 99%).
TLC Rf = 0.84 (1% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3288 (N-H), 2953 (C-H), 2933 (C-H), 2883 (C-H), 2857 (C-H), 2095 (azide), 1639
(amide C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 5.35 (d, J = 5.1 Hz, 1 H, NH), 3.97 - 4.01 (m, 1 H, CHOSi), 3.93
- 3.98 (m, 1 H, CHNH), 3.35 (t, J = 6.6 Hz, 2 H, CH2N3), 2.24 (t, J = 7.0 Hz, 2 H, CH2C=O), 2.09 - 2.19
(m, 1 H, CHHCHNH), 1.89 - 1.97 (quin, J = 6.8 Hz, 2 H, CH2CH2N3), 1.74 - 1.84 (m, 2 H, CHHCHOSi and
CHHCH2CHOSi), 1.60 - 1.70 (m, 1 H, CHHCH2CHOSi), 1.51 - 1.61 (m, 1 H, CHHCHOSi), 1.31 - 1.39 (m, 1
H, CHHCHNH), 0.87 (s, 9 H, C(CH3)3), 0.08 (s, 3 H, SiCH3), 0.06 (s, 3 H, SiCH3)
13C NMR (101 MHz, CDCl3) δ / ppm = 171.17 (C=O), 77.80 (CHOSi), 58.36 (CHNH), 50.77 (CH2N3), 33.29
(CH2C=O), 32.57 (CH2CHOSi), 29.36 (CH2CHNH), 25.72 (C(CH3)3), 24.77 (CH2CH2N3), 20.40 (CH2CH2CHO
Si), 17.95 (C(CH3)3), -4.75 (SiCH3)
HRMS (ESI+) m/z / Da = 327.2221, [M+H]+ found, [C15H31N4O2Si]+ requires 327.2216
[α]20D / ◦10−1cm2g−1 = 12.4 (c / g(100 mL)−1 = 0.5, MeOH)
The compound has not been reported previously.
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9.59 7-(4-(4-(1-(4-(((1S,2S)-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)amino)-4-
oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylic acid 190
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (42.9
mg, 104 µmol, 1 eq.) and 4-azido-N -((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)butanamide 186 (33.9
mg, 104 µmol, 1 eq.) were dissolved in 10% water/t-BuOH (3 mL), and the mixture was degassed by bubbling
N2 through it. A solution of CuSO4 and THPTA (104 µl, 10.4 µmol, 0.1 eq. 100 mM, aq.) was added, followed
by a solution of sodium ascorbate (208 µl, 20.8 µmol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room
temperature under argon for 16 h, then solvent was removed under reduced pressure. The residue was parti-
tioned between water (10 mL) and CH2Cl2 (10 mL), the organic layer was separated and the aqueous layer was
extracted again with CH2Cl2 (10 mL). The combined organic layers were dried with MgSO4 and evaporated
under reduced pressure. 190 was obtained as a clear amorphous solid (67.1 mg, 90.9 µmol, 87%).
IR (neat) νmax / cm−1 = 2951 (C-H), 2929 (C-H), 2856 (C-H), 1741 (carboxylic acid C=O), 1640 (amide
C=O), 1627 (quinolone C=O), 1612 (triazole)
1H NMR (400 MHz, CDCl3) δ / ppm = 8.67 (s, 1 H, ortho to C(=O)OH), 7.87 (d, J = 13.1 Hz, 1 H, ortho
to F), 7.34 (s, 1 H, CH=CCH2), 7.33 (d, J = 8.2 Hz, 1 H, meta to F), 5.92 (t, J = 6.6 Hz, 1 H, CHNH), 4.35
(t, J = 6.7 Hz, 2 H, CH2NCH=C), 3.96 - 4.02 (m, 1 H, CHOSi), 3.90 - 3.96 (m, 1 H, CHNH), 3.55 (tt, J =
6.7, 4.0 Hz, 1 H, NCH(CH2)2), 3.34 (br t, J = 5.0 Hz, 4 H, CH2N(CH2CH2)CH2CH2), 2.71 (t, J = 7.5 Hz,
2 H, CH=CCH2), 2.66 (br s, 4 H, CH2N(CH2)CH2), 2.46 (t, J = 7.3 Hz, 2 H, CH2N(CH2)CH2), 2.03 - 2.22
(m, 5 H, CHHCHNH, C(=O)CH2 and C(=O)CH2CH2), 1.65 - 1.83 (m, 4 H, CHHCHOSi, CHHCH2CHOSi and
NCH=CCH2CH2), 1.47 - 1.65 (m, 4 H, CHHCHOSi, CHHCH2CHOSi and NCH=CCH2CH2CH2), 1.33 - 1.41
(m, 3 H, CHHCHNH and NCH(CHH)2), 1.14 - 1.20 (m, 2 H, NCH(CHH)2), 0.82 (s, 9 H, C(CH3)3), 0.03 (s, 3
H, SiCH3), 0.01 (s, 3 H, SiCH3)
13CNMR (101 MHz, CDCl3) δ / ppm = 176.9 (C(=O)CC(=O)OH), 170.9 (CH2C(=O)NH), 166.9 (C(=O)OH),
153.5 (d, J = 251.4 Hz, ipso to F), 147.9 (CH=CCH2), 147.2 (C=CC(=O)OH), 145.8 (d, J = 10.4 Hz, ipso to
piperazine), 139.0 (para to F), 120.9 (NCH=CCH2), 119.4 (d, J = 7.8 Hz, para to piperazine), 112.0 (d, J =
23.4 Hz, ortho to C=O and ortho to F), 107.7 (CC(=O)OH), 104.7 (d, J = 3.5 Hz, meta to C=O and meta to
F), 77.7 (CHOSi), 58.2 (CHNH), 57.9 (CH=CCH2CH2CH2CH2N), 52.6 (CH=CCH2CH2CH2CH2N(CH2)CH2),
49.5 (d, J = 6.1 Hz, CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 48.9 (d, J = 3.5 Hz, CH2NCH=CCH2),
35.3 (NCH(CH2)2), 32.6 (C(=O)CH2), 32.6 (CH2CHOSi), 29.3 (CH2CHNH), 27.2 (CH=CCH2CH2), 26.0 -
26.3 (C(=O)CH2CH2 and CH=CCH2CH2CH2), 25.6 (C(CH3)3), 25.4 (CH=CCH2), 20.4 (CH2CH2CHOSi),
17.8 (C(CH3)3), 8.1 (NCH(CH2)2), -4.8 (SiCH3)
HRMS (ESI+) m/z / Da = 738.4164, [M+H]+ found, [C38H57FN7O5Si]+ requires 738.4169
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[α]20D / ◦10−1cm2g−1 = 4.5 (c / g(100 mL)−1 = 0.2, MeOH)
The compound has not been reported previously.
9.60 4-Chloro-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 193
(1S,2S)-2-Aminocyclopentan-1-ol 172 (72.3 mg, 716 µmol, 1 eq.), TEA (500 µl, 363 mg, 3.58 mmol, 5 eq.) and
CH2Cl2 (5 mL) were stirred at 0 ◦C, and 4-chlorobutyryl chloride 192 (179 µl, 226 mg, 1.60 mmol, 1.1 eq.)
was added dropwise over 5 min. The mixture was stirred at 0 ◦C for 30 min, then water (10 mL) was added.
The organic layer was separated off, and the aqueous layer was extracted with 10% i-PrOH/CHCl3 (2×10 mL).
The combined organic layers were dried with MgSO4, concentrated under reduced pressure and purified by
column chromatography (SiO2, Et2O). The combined pure fractions were dried with MgSO4 and evaporated
under reduced pressure. 193 was obtained as a white amorphous solid (35.6 mg, 173 µmol, 24%).
TLC Rf = 0.35 (EtOAc)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.05 (br s, 1 H, NH), 4.55 (br s, 1 H, OH), 3.95 (q, J = 6.6 Hz, 1
H, CHOH), 3.82 (tt, J = 8.4, 5.3 Hz, 1 H, CHNH), 3.60 (t, J = 6.2 Hz, 2 H, CH2Cl), 2.38 (t, J = 7.0 Hz, 2
H, CH2C=O), 2.05 - 2.17 (m, 3 H, CHHCHNH and CH2CH2Cl), 1.94 - 2.05 (m, 1 H, CHHCHOH), 1.74 - 1.86
(m, 1 H, CHHCH2CHOH), 1.58 - 1.74 (m, 2 H, CHHCH2CHOH and CHHCHOH), 1.42 (dq, J = 12.5, 8.4 Hz,
1 H, CHHCHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 173.8 (C=O), 79.4 (CHOH), 60.6 (CHNH), 44.4 (CH2Cl), 32.8
(CH2C=O), 32.4 (CH2CHOH), 30.2 (CH2CHNH), 28.0 (CH2CH2Cl), 21.2 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 206.0939, [M+H]+ found, [C9H17ClNO2]+ requires 206.0948
[α]20D / ◦10−1cm2g−1 = 10.0 (c / g(100 mL)−1 = 0.05, MeOH)
The compound has not been reported previously.
9.61 4-Chloro-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 194
(1R,2R)-2-Aminocyclopentan-1-ol 173 (500 mg, 4.94 mmol, 1 eq.), TEA (827 µl, 600 mg, 5.93 mmol, 1.2 eq.)
and CH2Cl2 (20 mL) were stirred at 0 ◦C and 4-chlorobutyryl chloride 192 (608 µl, 766 mg, 5.43 mmol, 1.1
eq.) was added dropwise over 5 min. The mixture was stirred at 0 ◦C for 30 min, then water (50 mL) was
added. The organic layer was separated off, and the aqueous layer was extracted with CH2Cl2 (7×50 mL). The
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combined organic layers were dried with MgSO4, concentrated under reduced pressure and purified by column
chromatography (SiO2, Et2O). The combined pure fractions were dried with MgSO4 and evaporated under
reduced pressure. 194 was obtained as a white amorphous solid (651 mg, 3.16 mmol, 64%).
TLC Rf = 0.35 (EtOAc)
IR (neat) νmax / cm−1 = 3278 (N-H and O-H), 2962 (C-H), 2876 (C-H), 1636 (amide C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 6.12 (br s, 1 H, NH), 4.42 (br s, 1 H, OH), 3.94 (q, J = 6.6 Hz, 1
H, CHOH), 3.82 (tt, J = 8.4, 5.3 Hz, 1 H, CHNH), 3.60 (t, J = 6.2 Hz, 2 H, CH2Cl), 2.38 (t, J = 7.2 Hz, 2
H, CH2C=O), 2.05 - 2.16 (m, 3 H, CHHCHNH and CH2CH2Cl), 1.96 - 2.04 (m, 1 H, CHHCHOH), 1.74 - 1.85
(m, 1 H, CHHCH2CHOH), 1.58 - 1.73 (m, 2 H, CHHCH2CHOH and CHHCHOH), 1.43 (dq, J = 12.7, 8.3 Hz,
1 H, CHHCHNH)
13C NMR (101 MHz, CDCl3) δ / ppm = 173.8 (C=O), 79.4 (CHOH), 60.6 (CHNH), 44.4 (CH2Cl), 32.8
(CH2C=O), 32.4 (CH2CHOH), 30.1 (CH2CHNH), 28.0 (CH2CH2Cl), 21.1 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 228.0787, [M+Na]+ found, [C9H16ClNNaO2]+ requires 228.0762
[α]20D / ◦10−1cm2g−1 = -13.0 (c / g(100 mL)−1 = 0.5, MeOH)
The compound has not been reported previously.
9.62 Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-flu-
oro-4-oxo-1,4-dihydroquinoline-3-carboxylate 197
Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 151 (200 mg, 0.579
mmol, 1 eq.), tert-butyl 4-bromobutanoate 196 (103 µl, 130 mg, 0.581 mmol, 1 eq.), NaI (86.9 mg, 0.580 mmol,
1 eq.), TEA (316 µl, 229 mg, 2.27 mmol, 4 eq.) and acetonitrile (10 mL) were stirred in a microwave reactor at
100 ◦C for 8 h. A second portion of tert-butyl 4-bromobutanoate 222 (103 µl, 130 mg, 0.581 mmol, 1 eq.) was
added, and the mixture was stirred in the microwave reactor at 100 ◦C for a further 8 h. The mixture was then
dry-loaded onto SiO2 and purified by column chromatography (SiO2, 0-4% MeOH/CH2Cl2). 197 was obtained
as a white amorphous solid (141 mg, 0.289 mmol, 50%).
TLC Rf = 0.12 (4% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2962 (C-H), 2831 (C-H), 1732 (t-Bu ester C=O) 1717 (ciprofloxacin ester C=O),
1621 (quinolone C=O)
1H NMR (400 MHz, CDCl3) δ / ppm = 8.39 (s, 1 H, ortho to C(=O)OCH3), 7.82 (d, J = 13.3 Hz, 1 H, ortho
148
to F), 7.17 (d, J = 7.2 Hz, 1 H, meta to F), 3.83 (s, 3 H, CH3), 3.40 (tt, J = 7.2, 3.6 Hz, 1 H, NCH(CH2)2),
3.22 (t, J = 4.3 Hz, 4 H, CH2N(CH2CH2)CH2CH2), 2.63 (t, J = 4.4 Hz, 4 H, CH2N(CH2)CH2), 2.41 (t, J=7.3
Hz, 2 H, CH2N(CH2)CH2), 2.25 (t, J=7.4 Hz, 2 H, CH2CH2CH2N(CH2)CH2), 1.78 (quin, J=7.3 Hz, 2 H,
CH2CH2N(CH2)CH2), 1.41 (s, 9 H, C((CH)3)3), 1.24 (m, 2 H, NCH(CHH)2), 1.09 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, CDCl3) δ / ppm = 172.7 (C(=O)CC(=O)OCH3), 172.6 (C(=O)OC(CH3)3), 165.9
(C(=O)OCH3), 153.1 (d, J = 249.7 Hz, ipso to F), 148.1 (C=CC(=O)OCH3), 144.3 (d, J = 10.4 Hz, ipso
to piperazine), 137.7 (para to F), 122.5 (d, J = 6.9 Hz, para to piperazine) 112.6 (d, J = 22.5 Hz, ortho
to C=O and ortho to F), 109.5 (CC(=O)OCH3) 104.7 (meta to C=O and meta to F), 80.0 (C(CH3)3), 57.4
(C(=O)CH2CH2CH2N), 52.7 (C(=O)CH2CH2CH2N(CH2)CH2), 51.7 (CH3), 49.7 (C(=O)CH2CH2CH2N(CH2
CH2)CH2CH2), 49.7 (C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 34.4 (NCH(CH2)2), 33.2 (C(=O)CH2), 28.0
(C(CH3)3), 22.0 (C(=O)CH2CH2), 7.9 (NCH(CH2)2)
19F NMR (376.45 MHz, CDCl3) δ / ppm = -123.5 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 488.2562, [M+H]+ found, [C26H35FN3O5]+ requires 488.2561
The compound has not been reported previously.
9.63 4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-
7-yl)piperazin-1-yl)butanoic acid trifluoroacetate 198
N
N
N
O O
OF
HO
O
O
O F
F
F
H
Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-car-
boxylate 197 (20 mg, 41.0 µmol) and TFA (0.2 mL) were stirred in CH2Cl2 (1.8 mL) at r.t. for 16 h then
evaporated under reduced pressure. 198 was obtained as a white solid (21.4 mg, 39.2 µmol, 96%).
mp T / ◦C = 225-231 (CH2Cl2, decomposes)
IR (neat) νmax / cm−1 = 1723 (ciprofloxacin ester C=O), 1699 (alkyl carboxylic acid C=O), 1673 (TFA C=O),
1615 (quinolone C=O)
1H NMR (400 MHz, DMSO d6) δ / ppm = 8.47 (s, 1 H, ortho to C(=O)OH), 7.80 (d, J = 13.2 Hz, 1 H, ortho
to F), 7.47 (d, J = 7.4 Hz, 1 H, meta to F), 3.73 (s, 3 H, CH3), 3.66 (tt, J = 7.2, 3.7 Hz, 1 H, NCH(CH2)2),
3.30 - 3.54 (br s, 8 H, CH2N(CH2)CH2 and CH2N(CH2CH2)CH2CH2) 3.13 - 3.22 (m, 2 H, CH2N(CH2)CH2),
2.36 (t, J = 7.1 Hz, 2 H, CH2CH2CH2N(CH2)CH2), 1.87 - 1.98 (m, 2 H, CH2CH2N(CH2)CH2), 1.22 - 1.30 (m,
2 H, NCH(CHH)2), 1.06 - 1.15 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 173.5 (CH2C(=O)OH), 171.6 (C(=O)CC(=O)OCH3), 164.9
(C(=O)OCH3), 158.2 (q, J = 31.5 Hz, CF3C(=O)OH), 152.5 (d, J = 247.6 Hz, ipso to F), 148.5 (C=CC(=O)OH),
142.3 (d, J = 10.7 Hz, ipso to piperazine), 138.0 (para to F), 122.6 (d, J = 6.4 Hz, para to piperazine), 117.2 (q,
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J = 299.8 Hz, CF3), 111.9 (d, J = 22.4 Hz, ortho to C=O and ortho to F), 109.1 (CC(=O)OCH3), 106.9 (meta
to C=O and meta to F), 55.1 (C(=O)CH2CH2CH2N), 51.4 (CH3), 50.8 (C(=O)CH2CH2CH2N(CH2)CH2),
46.7 (C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 46.7 (C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 34.9 (NCH
(CH2)2), 30.6 (C(=O)CH2), 19.1 (C(=O)CH2CH2), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, DMSO d6) δ / ppm = -73.6 (s, CF3), -124.6 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 432.1921, [M+H]+ found, [C22H27FN3O5]+ requires 432.1935
The compound has not been reported previously.
9.64 (trans)-2-Aminocyclohexan-1-ol 200
NH2
OH
(±)
Cyclohexene oxide 199 (10 mL, 9.70 g, 98.8 mmol, 1 eq.), NH3 (90 mL, 35% w/w aq., 27.7 g, 791 mmol, 8 eq.)
and MeOH (100 mL) were stirred at r.t. for 72 h. The solvent was removed by blowing a stream of N2 over it,
followed by evaporation under high vacuum. 200 was obtained as a white amorphous solid (9.90 g, 85.2 mmol,
86%)
TLC Rf = 0.04 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 3350 (N-H), 3306 (br, O-H), 2927 (C-H), 2853 (C-H)
1H NMR (400 MHz, CDCl3) δ / ppm = 3.01 (td, J = 9.4, 4.8 Hz, 1 H, CHOH), 2.80 - 2.92 (m, 2 H, OH and
NH2), 2.35 (ddd, J = 11.1, 9.1, 4.1 Hz, 1 H, CHNH2), 1.77 - 1.84 (m, 1 H, CHHCHOH), 1.69 - 1.76 (m, 1 H,
CHHCHNH2), 1.56 - 1.66 (m, 1 H, CHHCH2CHOH), 1.45 - 1.56 (m, 1 H, CHHCH2CHNH2), 1.07 - 1.19 (m, 3
H, CHHCH2CHOH, CHHCH2CHNH2 and CHHCHOH), 0.94 - 1.05 (m, 1 H, CHHCHNH2)
13C NMR (101 MHz, CDCl3) δ / ppm = 75.4 (CHOH), 56.6 (CHN2), 33.8 (CH2CHOH and CH2CHN2), 24.7
(CH2CH2CHNH2), 24.6 (CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 116.1070, [M+H]+ found, [C6H14NO]+ requires 116.1070
The data are consistent with the literature.228
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9.65 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-
4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 201
N
N
N
O O
OF
O
N
HOH
(±)
4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid
trifluoroacetate 198 (200 mg, 0.367 mmol, 1 eq.), (trans)-2-aminocyclohexan-1-ol 200 (91.1 mg, 0.791 mmol, 2.1
eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxyben
zotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 µl, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5
mL) and stirred at r.t. for 16 h. The solvent was removed using a stream of N2 and the residue was purified by
preparative HPLC (5-50% acetonitrile/water over 10 min). The combined pure fractions were evaporated under
reduced pressure and then partitioned between NaHCO3 (aq., sat., 10 mL) and CH2Cl2 (10 mL). The organic
layer was dried with MgSO4 and evaporated under reduced pressure. 201 was obtained as a white amorphous
solid (61.2 mg, 0.116 mmol, 32%).
IR (neat) νmax / cm−1 = 3303 (N-H), 2930 (C-H), 2851 (C-H), 2833 (C-H), 1698 (ester C=O), 1646 (amide
C=O), 1614 (quinolone C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 8.60 (s, 1 H, ortho to C(=O)OCH3), 7.79 (d, J = 13.5 Hz, 1 H,
ortho to F), 7.46 (d, J = 7.2 Hz, 1 H, meta to F), 3.84 (s, 3 H, CH3), 3.62 - 3.68 (m, 1 H, NCH(CH2)2), 3.58
(td, J = 10.3, 4.2 Hz, 1 H, CHNH), 3.38 (br s, 4 H, CH2N(CH2CH2)CH2CH2), 3.32 - 3.36 (m, 1 H, CHOH),
2.83 (br s, 4 H, CH2N(CH2)CH2), 2.60 (t, J = 7.3 Hz, 2 H, C(=O)CH2CH2CH2N), 2.32 (td, J = 7.1, 3.1 Hz,
2 H, C(=O)CH2), 1.96 - 2.04 (m, 1 H, CHHCHOH), 1.87 - 1.96 (m, 3 H, CHHCHNH and C(=O)CH2CH2),
1.72 - 1.77 (m, 1 H, CHHCH2CHOH), 1.66 - 1.72 (m, 1 H, CHHCH2CHNH), 1.25 - 1.39 (m, 5 H, CHHCHOH,
CHHCH2CHOH, CHHCH2CHNH and NCH(CHH)2), 1.15 - 1.25 (m, 3 H, CHHCHOH and NCH(CHH)2)
13C NMR (101 MHz, MeOD) δ / ppm = 175.8 (CH2C(=O)NH), 175.3 (C(=O)CC(=O)OCH3), 166.8 (C(=O)
OCH3), 154.9 (d, J = 248.8 Hz, ipso to F), 150.2 (C=CC(=O)OCH3), 146.1 (d, J = 10.8 Hz, ipso to
piperazine), 139.9 (para to F), 123.5 (d, J = 7.5 Hz, para to piperazine), 113.2 (d, J = 23.2 Hz, ortho
to C=O and ortho to F), 110.2 (CC(=O)OCH3), 107.2 (meta to C=O and meta to F), 74.1 (CHOH), 58.9
(C(=O)CH2CH2CH2N), 56.4 (CHNH), 54.0 (C(=O)CH2CH2CH2N(CH2)CH2), 52.3 (CH3), 50.5 (d, J = 5.0
Hz, C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 36.4 (NCH(CH2)2), 35.7 (CH2CHOH), 35.1 (C(=O)CH2), 32.8
(CH2CHNH), 25.9 (CH2CH2CHNH), 25.5 (CH2CH2CHOH), 23.5 (C(=O)CH2CH2), 8.7 (NCH(CH2)2)
19F NMR (376.45 MHz, MeOD) δ / ppm = -124.7 (ciprofloxacin F)
HRMS (ESI+) m/z / Da = 529.2827, [M+H]+ found, [C28H38FN4O5]+ requires 529.2826
The compound has not been reported previously.
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9.66 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-
butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 202
N
N
N
O O
OF
O
N
HO
(±)
Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,
4-dihydroquinoline-3-carboxylate 201 (5.2 mg, 9.84 µmol, 1 eq.) and Dess-Martin periodinane (16.4 mg, 38.7
µmol, 4 eq.) were stirred in CH2Cl2 (3 mL) at r.t. for 6 h. The solvent was removed under reduced pressure
and the residue was purified by preparative HPLC (5-95% acetonitrile/water over 20 min). The combined pure
fractions were evaporated under reduced pressure to a volume of 20 mL, then NaHCO3 (aq., sat., 30 mL) and
10% i-PrOH/CHCl3 (30 mL) were added. The organic layer was dried with MgSO4 and evaporated under re-
duced pressure. 202 was obtained as a white amorphous solid (3.6 mg, 6.8 µmol, 69%).
TLC Rf = 0.74 (30% MeOH/CH2Cl2)
IR (neat) νmax / cm−1 = 2921 (C-H), 2852 (C-H), 1721 (ketone C=O), 1698 (ester C=O), 1639 (amide C=O),
1620 (quinolone C=O)
1H NMR (400 MHz, DMSO d6) δ / ppm = 8.45 (s, 1 H, ortho to C(=O)OCH3), 7.87 (d, J = 6.2 Hz, 1 H,
NH), 7.76 (d, J = 13.4 Hz, 1 H, ortho to F), 7.44 (d, J = 7.5 Hz, 1 H, meta to F), 4.42 (dddd, J = 13.0,
7.6, 6.0, 1.0 Hz, 1 H, CHNH), 3.73 (s, 3 H, CH3), 3.65 (tt, J = 7.1, 3.9 Hz, 1 H, NCH(CH2)2), 3.25 (br s,
4 H, CH2N(CH2CH2)CH2CH2), 2.58 (br s, 4 H, CH2N(CH2)CH2), 2.45 - 2.53 (m, 1 H, CHHC(=O)CHNH),
2.36 (br s, 2 H, C(=O)CH2CH2CH2N), 2.26 (dtt, J = 13.4, 2.6, 1.6 Hz, 1 H, CHHC(=O)CHNH), 2.16 - 2.22
(m, 2 H, C(=O)CH2CH2CH2N), 2.12 (ddq, J = 12.7, 6.0, 2.8 Hz, 1 H, CHHCHNH), 2.00 (ddquin, J = 13.2,
6.0, 2.9 Hz, 1 H, CHHCH2C(=O)), 1.65 - 1.83 (m, 4 H, CH2CH2CHNH), 1.41 - 1.56 (m, 2 H, CHHCHNH and
CHHCH2C(=O)), 1.20 - 1.30 (m, 2 H, NCH(CHH)2), 1.05 - 1.13 (m, 2 H, NCH(CHH)2)
13C NMR (101 MHz, DMSO d6) δ / ppm = 207.5 (C(=O)CHNH), 171.7 (C(=O)CC(=O)OCH3), 171.6
(CH2C(=O)NH), 165.0 (C(=O)OCH3), 152.6 (d, J = 247.6 Hz, ipso to F), 148.3 (C=CC(=O)OCH3), 143.9
(br s, ipso to piperazine), 138.1 (para to F), 121.8 (d, J = 6.4 Hz, para to piperazine), 111.5 (d, J =
22.4 Hz, ortho to C=O and ortho to F), 109.0 (CC(=O)OCH3), 106.3 (meta to C=O and meta to F),
57.0 (CHNH and C(=O)CH2CH2CH2N), 52.3 (br s, C(=O)CH2CH2CH2N(CH2)CH2), 51.3 (CH3), 49.5 (br
s, C(=O)CH2CH2CH2N(CH2CH2)CH2CH2), 40.6 (CH2C(=O)CHNH), 34.8 (NCH(CH2)2), 33.9 (CH2CHNH),
32.9 (C(=O)CH2CH2CH2N), 27.2 (CH2CH2C(=O)CHNH), 23.8 (CH2CH2CHNH), 22.4 (br s, C(=O)CH2CH2
CH2N), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, DMSO d6) δ / ppm = -124.3 (ciprofloxacin F)
HRMS (ESI+) m/z / Da = 527.2654, [M+H]+ found, [C28H36FN4O5]+ requires 527.2670
The compound has not been reported previously.
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9.67 4-Chloro-N -((trans)-2-hydroxycyclohexyl)butanamide 203
O
N
HOH
Cl (±)
(trans)-2-Aminocyclohexan-1-ol 200 (1.04 g, 9.03 mmol, 1 eq.), TEA (1.65 mL, 1.20 g, 11.8 mmol, 1.3 eq.) and
CH2Cl2 (50 mL) were stirred at 0 ◦C. 4-Chlorobutyryl chloride 192 (1.22 mL, 1.54 g, 10.9 mmol, 1.2 eq.) was
added dropwise over 5 min. The mixture was stirred at 0 ◦C for 30 min, then water (50 mL) was added. The
organic layer was separated off, and the aqueous layer was extracted with 10% i-PrOH/CHCl3 (2×50 mL). The
combined organic layers were dried with MgSO4, concentrated under reduced pressure and purified by column
chromatography (SiO2, 0-100% EtOAc/Et2O). The combined organic fractions were dried with MgSO4 and
evaporated under reduced pressure. 203 was obtained as white needles (1.51 g, 6.87 mmol, 76%).
TLC Rf = 0.19 (Et2O)
mp T / ◦C = 73-76 (i-PrOH, CHCl3)
IR (neat) νmax / cm−1 = 3290 (N-H), 3250 (O-H), 2928 (C-H), 2857 (C-H), 1629 (amide C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 3.60 (t, J = 6.6 Hz, 2 H, CH2Cl), 3.51 - 3.60 (m, 1 H, CHNH), 3.28 -
3.39 (m, 1 H, CHOH), 2.37 (td, J = 7.4, 2.3 Hz, 2 H, C(=O)CH2), 2.06 (quin, J = 7.0 Hz, 2 H, C(=O)CH2CH2),
1.97 - 2.01 (m, 1 H, CHHCHOH), 1.85 - 1.93 (m, 1 H, CHHCHNH), 1.70 - 1.77 (m, 1 H, CHHCH2CHOH), 1.64
- 1.70 (m, 1 H, CHHCH2CHNH), 1.24 - 1.35 (m, 3 H, CHHCH2CHOH, CHHCH2CHNH and CHHCHOH), 1.13
- 1.25 (m, 1 H, CHHCHNH2)
13C NMR (101 MHz, MeOD) δ / ppm = 175.0 (C(=O)), 74.1 (CHOH), 56.3 (CHNH), 45.3 (CH2Cl),
35.6 (CH2CHOH), 34.5 (C(=O)CH2), 32.7 (CH2CHNH), 30.1 (C(=O)CH2CH2), 25.8 (CH2CH2CHNH), 25.5
(CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 242.0925, [M+Na]+ found, [C10H18ClNNaO2]+ requires 242.0924
The compound has not been reported previously.
9.68 4-Azido-N -((trans)-2-hydroxycyclohexyl)butanamide 204
O
N
HOH
N3 (±)
4-Chloro-N -((trans)-2-hydroxycyclohexyl)butanamide 203 (345 mg, 1.57 mmol, 1 eq.) and NaN3 (180 mg, 2.77
mmol, 1.75 eq.) were stirred in DMF (12 mL) at 50 ◦C for 16 h. Water (50 mL) and 10% i-PrOH/CHCl3
(50 mL) were added, and the organic layer was removed. The aqueous layer was extracted again with 10% i-
PrOH/CHCl3 (50 mL) and the combined organic fractions were dried with MgSO4. The solvent was evaporated
under reduced pressure, and then by using a N2 stream. 204 was obtained as large white prisms (347 mg, 1.53
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mmol, 98%).
TLC Rf = 0.23 (EtOAc)
mp T / ◦C = 75-76 (i-PrOH, CHCl3)
IR (neat) νmax / cm−1 = 3299 (N-H), 3208 (O-H), 2944 (C-H), 2928 (C-H), 2859 (C-H), 2089 (azide), 1624
(amide C=O)
1H NMR (400 MHz, MeOD) δ / ppm = 7.87 (d, J = 7.9 Hz, 1 H, NH), 5.27 (d, J = 4.3 Hz, 1 H, OH),
3.56 (td, J = 10.5, 4.4 Hz, 1 H, CHNH), 3.28 - 3.41 (m, 3 H, CHOH and CH2N3), 2.30 (td, J = 7.4, 2.7 Hz,
2 H, C(=O)CH2), 1.95 - 2.03 (m, 1 H, CHHCHOH), 1.87 (m, 3 H, C(=O)CH2CH2 and CHHCHNH), 1.70 -
1.76 (m, 1 H, CHHCH2CHOH), 1.63 - 1.70 (m, 1 H, CHHCH2CHNH), 1.25 - 1.38 (m, 3 H, CHHCH2CHOH,
CHHCH2CHNH and CHHCHOH), 1.14 - 1.24 (m, 1 H, CHHCHNH2)
13C NMR (101 MHz, MeOD) δ / ppm = 175.1 (C(=O)), 74.0 (CHOH), 56.3 (CHNH), 52.0 (CH2N3),
35.5 (CH2CHOH), 34.3 (C(=O)CH2), 32.7 (CH2CHNH), 26.3 (C(=O)CH2CH2), 25.8 (CH2CH2CHNH), 25.5
(CH2CH2CHOH)
HRMS (ESI+) m/z / Da = 249.1331, [M+Na]+ found, [C10H18N4NaO2]+ requires 249.1327
The compound has not been reported previously.
9.69 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-
oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquino-
line-3-carboxylic acid 205
N
N
N
O O
OHF
N N
N
O
H
N
OH (±)
1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 68 (40
mg, 97.2 µmol, 1 eq.) and 4-azido-N -((trans)-2-hydroxycyclohexyl)butanamide 204 (22.0 mg, 97.2 µmol, 1 eq.)
were dissolved in 10% water/t-BuOH (3 mL), and the mixture was degassed by bubbling N2 through it. A
solution of CuSO4 and THPTA (97.2 µl, 9.72 µmol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of
sodium ascorbate (194 µl, 19.4 µmol, 0.2 eq., 100 mM, aq.). The mixture was stirred at r.t. under argon for 16
h. Water (50 mL) and 10% i-PrOH/CHCl3 (50 mL) were added, then the organic layer was separated, dried
with MgSO4 and evaporated under reduced pressure. The residue was purified by preparative HPLC (5-70%
acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then
partitioned between NaHCO3 (aq., sat., 50 mL) and 10% i-PrOH/CHCl3 (50 mL). The organic layer was dried
with MgSO4 and evaporated under reduced pressure. 205 was obtained as a white amorphous solid (30.3 mg,
47.5 µmol, 49%).
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IR (neat) νmax / cm−1 = 3345 (N-H), 2928 (C-H), 2860 (C-H), 2815 (C-H), 1727 (carboxylic acid C=O), 1642
(amide C=O), 1626 (quinolone C=O), 1619 (triazole)
1H NMR (400 MHz, DMSO d6) δ / ppm = 8.64 (s, 1 H, ortho to C(=O)OH), 7.86 (d, J = 13.9 Hz, 1 H, ortho
to F), 7.84 (s, 1 H, CH=CCH2), 7.64 (d, J = 8.1 Hz, 1 H, NH), 7.54 (d, J = 7.5 Hz, 1 H, meta to F), 4.54 (d, J
= 4.7 Hz, 1 H, OH), 4.30 (t, J = 6.8 Hz, 2 H, C(=O)CH2CH2CH2N), 3.77 - 3.86 (m, 1 H, NCH(CH2)2), 3.33 -
3.40 (m, 1 H, CHNH), 3.31 (br t, J = 4.8 Hz, 4 H, CH=CCH2CH2CH2N(CH2CH2)CH2CH2), 3.14 - 3.24 (m, 1
H, CHOH), 2.63 (t, J = 7.4 Hz, 2 H, CH=CCH2), 2.56 (br t, J = 4.6 Hz, 4 H, CH=CCH2CH2CH2N(CH2)CH2),
2.38 (t, J = 6.9 Hz, 2 H, CH=CCH2CH2CH2CH2N), 2.04 - 2.08 (m, 2 H, C(=O)CH2CH2CH2N), 1.96 - 2.04 (m,
2 H, C(=O)CH2CH2CH2N), 1.78 - 1.87 (m, 1 H, CHHCHOH), 1.69 - 1.78 (m, 1 H, CHHCHNH), 1.63 (quin,
J = 7.5 Hz, 2 H, CH=CCH2CH2CH2CH2N), 1.54 - 1.60 (m, 2 H, CHHCH2OH), 1.51 (quin, J = 7.4 Hz, 2 H,
CH=CCH2CH2CH2CH2N), 1.28 - 1.35 (m, 2 H, NCH(CHH)2), 1.11 - 1.22 (m, 5 H, NCH(CHH)2, CHHCHOH,
CHHCH2CHOH and CH2CH2CHNH), 1.04 - 1.13 (m, 1 H, CHHCHNH)
13C NMR (101 MHz, DMSO d6) δ / ppm = 176.4 (C(=O)CC(=O)OH), 170.9 (CH2C(=O)NH), 166.0
(C(=O)OH), 153.1 (d, J = 252.1 Hz, ipso to F), 148.0 (C=CC(=O)OH), 146.9 (CH=CCH2), 145.3 (d, J = 10.0
Hz, ipso to piperazine), 139.2 (para to F), 121.8 (NCH=CCH2), 118.5 (d, J = 8.3 Hz, para to piperazine), 110.9
(d, J = 23.2 Hz, ortho to C=O and ortho to F), 106.7 (CC(=O)OH), 106.3 (d, J = 3.3 Hz,meta to C=O andmeta
to F), 71.4 (CHOH), 57.4 (CH=CCH2CH2CH2CH2N), 54.2 (CHNH), 52.4 (CH=CCH2CH2CH2CH2N(CH2)CH2),
49.5 (CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 49.5 (CH=CCH2CH2CH2CH2N(CH2CH2)CH2CH2), 48.8
(C(=O)CH2CH2CH2NCH=C), 35.9 (NCH(CH2)2), 34.1 (CH2CHOH), 32.3 (C(=O)CH2CH2CH2NCH=C), 31.1
(CH2CHNH), 26.9 (CH=CCH2CH2CH2CH2N), 26.1 (C(=O)CH2CH2CH2NCH=C), 25.8 (CH=CCH2CH2CH2
CH2N), 25.0 (CH=CCH2CH2CH2CH2N), 24.2 (CH2CH2CHNH), 23.8 (CH2CH2CHOH), 7.6 (NCH(CH2)2)
19F NMR (376.45 MHz, DMSO d6) δ / ppm = -121.4 (ciprofloxacin F)
HRMS (ESI+) m/z / Da = 638.3480, [M+H]+ found, [C33H45FN7O5]+ requires 638.3466
The compound has not been reported previously.
9.70 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxocyclohexyl)amino)bu
tyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carbo
xylic acid 206
N
N
N
O O
OHF
N N
N
O
H
N
O (±)
1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)but
yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 205 (15.0 mg, 23.6 mmol, 1 eq.) and Dess-Martin
periodinane (35.0 mg, 82.5 mmol, 3.5 eq.) were stirred in CH2Cl2 (3 mL) at r.t. for 4 h. The solvent was removed
under reduced pressure and the residue was purified by preparative HPLC (5-70% acetonitrile/water over 15
min). The combined pure fractions were evaporated under reduced pressure, then NaHCO3 (aq., sat., 30 mL)
155
and 10% i-PrOH/CHCl3 (30 mL) were added. The organic layer was dried with MgSO4 and evaporated under
reduced pressure. 206 was obtained as a clear gum (11.7 mg, 18.4 µmol, 78%).
IR (neat) νmax / cm−1 = 2941 (C-H), 2860 (C-H), 1720 (carboxylic acid C=O and ketone C=O), 1657 (amide
C=O), 1626 (quinolone C=O), 1614 (triazole)
1H NMR (500 MHz, DMSO d6) δ / ppm = 8.65 (s, 1 H, ortho to C(=O)OH), 7.94 (d, J = 7.7 Hz, 1 H, NH),
7.88 (d, J = 13.4 Hz, 1 H, ortho to F), 7.85 (s, 1 H, CH=CCH2), 7.55 (d, J = 7.3 Hz, 1 H, meta to F), 4.40
(dddd, J = 12.8, 7.6, 6.1, 1.1 Hz, 1 H), 4.31 (t, J = 7.0 Hz, 1 H, C(=O)CH2CH2CHHN), 4.31 (t, J = 6.9 Hz, 1 H,
C(=O)CH2CH2CHH2N), 3.74 - 3.84 (m, 1 H, NCH(CH2)2), 3.31 (br. s, 4 H, CH2CH2CH2N(CH2CH2)CH2CH2),
2.64 (t, J = 7.5 Hz, 2 H, CH=CCH2), 2.56 (br t, J = 5.0, 5.0 Hz, 4 H, CH2CH2CH2N(CH2)CH2), 2.45 -
2.52 (m, 1 H, CHHC(=O)), 2.38 (t, J = 7.1 Hz, 2 H, CH=CCH2CH2CH2CH2N), 2.25 (dtt, J = 13.4, 2.6,
1.6 Hz, 1 H, CHHC(=O)), 2.07 - 2.17 (m, 3 H, C(=O)CH2CH2CH2N and CHHCHNH), 1.96 - 2.05 (m, 3 H,
C(=O)CH2CH2CH2N and CHHCH2C(=O)), 1.68 - 1.81 (m, 2 H, CHHCH2CHNH), 1.64 (quin, J = 7.5 Hz, 2 H,
CH=CCH2CH2CH2CH2N), 1.40 - 1.56 (m, 5 H, CHHCH2C(=O), CHHCHNH and CH=CCH2CH2CH2CH2N),
1.27 - 1.34 (m, 2 H, NCH(CHH)2), 1.13 - 1.20 (m, 2 H, NCH(CHH)2)
13C NMR (126 MHz, DMSO d6) δ / ppm = 207.4 (C(=O)CHNH), 176.3 (C(=O)CC(=O)OH), 170.8 (CH2C
(=O)NH), 166.0 (C(=O)OH), 153.0 (d, J = 246.4 Hz, ipso to F), 147.9 (C=CC(=O)OH), 146.8 (CH=CCH2),
145.1 (d, J = 10.1 Hz, ipso to piperazine), 139.1 (para to F), 121.7 (NCH=CCH2), 118.7 (d, J = 6.9 Hz,
para to piperazine), 110.9 (d, J = 23.0 Hz, ortho to C=O and ortho to F), 106.3 (CC(=O)OH, and meta to
C=O and meta to F), 57.3 (CH=CCH2CH2CH2CH2N), 57.0 (CHNH), 52.4 (CH2CH2CH2N(CH2)CH2), 49.5
(CH2CH2CH2N(CH2CH2)CH2CH2), 49.5 (CH2CH2CH2N(CH2CH2)CH2CH2), 48.7 (C(=O)CH2CH2CH2NCH=C),
40.5 (CH2C(=O)), 35.8 (NCH(CH2)2), 33.7 (CH2CHNH), 31.8 (C(=O)CH2CH2CH2NCH=C), 27.1 (CH2CH2C(=O)),
26.9 (CH=CCH2CH2CH2CH2N), 26.0 (C(=O)CH2CH2CH2NCH=C), 25.7 (CH=CCH2CH2CH2CH2N), 24.9
(CH=CCH2CH2CH2CH2N), 23.8 (CH2CH2CHNH), 7.6 (NCH(CH2)2)
19F NMR (376 MHz, DMSO d6) δ / ppm = -121.7 (s, ciprofloxacin F)
HRMS (ESI+) m/z / Da = 636.3303, [M+H]+ found, [C33H43FN7O5]+ requires 636.3310
The compound has not been reported previously.
9.71 Biological testing
Compounds were tested against P. aeruginosa PAO1180 and YM64.181 C4-HSL 19, HHQ 21, PQS 22, ciprofloxacin
24, trimethoprim 25 and DMSO were included as controls, along with LB to check for contamination of the
plates.
The first set of autoinducer-antibiotic conjugates (see 7.5) were tested at 2, 1, 0.5, 0.25, 0.125 and 0.0625 µM.
Breathe-EasyR© sealing membranes from Diversified Biotech were used and the plates were placed without lids
in a open box containing tissue paper wetted with distilled water in order to control evaporation. OD readings
at 595 nm were taken at 5 and 24 h, and biofilm quantification was carried out soon after the 24 h OD reading.
Crystal violet-stained plates were also read at 595 nm. Only a 5 h OD reading in YM64 was obtained for the
cleavable HSL-Cip conjugates.
The HSL analogue-Cip(Me) conjugates (see 8.7) were tested at 25, 2, 1, 0.5, 0.25 and 0.125 µM in triplicate.
AeraSealTM films from Excel Scientific were used. A plate lid was used, but the humidified box was not. OD
readings at 600 nm were taken at 0, 1, 2, 3, 4, 5, 6, 7, 8, 24 and 48 h. Biofilm inhibition testing was carried
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out on plates grown for 24 and 48 h. Biofilm dispersal testing was carried out by growing plates for 24 h,
followed by addition of the compounds, incubation for a further 24 h and quantification of the biofilms. Crystal
violet-stained plates were read at 550 nm.
9.71.1 Antibiotic susceptibility
Antibiotic susceptibility was determined using spectrophotometry measurements. Colonies of the desired strains
were grown at 37 ◦C overnight on LB agar. The colonies were used to inoculate LB (10 mL) and these cultures
were grown at 37 ◦C overnight. The cultures were diluted 1/100 with LB, and 99 µl diluted culture per well
was added to NunclonR© flat-bottomed clear 96-well plates. 1 µl of compound solution in DMSO was then added
from master plates and the plates were covered with adhesive aeration filters. The plates were shaken at 37 ◦C
and 100 rpm and OD was recorded periodically using a Biochrom EZ Read 400 microplate reader.
9.71.2 Quantification of biofilms
Biofilms were quantified using a method described previously.126,242 After the bacteria had grown for the desired
amount of time, the culture was aspirated out of the wells using a pipette tip attached to a vacuum pump,
making sure not to touch the sides of the wells. Water (120 µl) was then added and aspirated out again. This
process was repeated twice more to thoroughly wash out planktonic cells. Crystal violet (120 µl, 0.1% m/v) was
added and left for 15 min, then aspirated out. The wells were washed again with water (3 × 120 µl). Acetic acid
(120 µl, 30% v/v aq.) was added and left for 15 min then the plate was vortexed and read using a Biochrom
EZ Read 400 microplate reader at 595 nm.
9.71.3 Biofilm inhibition
The plates were prepared as in 9.71.1. The plates were shaken at 37 ◦C and 100 rpm for 24 h followed by
quantification of biofilm growth as shown in 9.71.2.
9.71.4 Biofilm dispersal
The plates were prepared as in 9.71.1, initially without the addition of compound solutions. The box of plates
was shaken at 37 ◦C and 100 rpm for 24. 1 µl of compound solution in DMSO was then added to each well
from master plates and the plates were shaken as above for a further 24 h followed by measurement of OD and
quantification of biofilm growth as shown in 9.71.2.
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10 NMR spectra
10.1 (S)-4-Bromo-N -(2-oxotetrahydrofuran-3-yl)butanamide 57
158
10.2 (S)-6-Bromo-N -(2-oxotetrahydrofuran-3-yl)hexanamide 60
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10.3 (S)-6-Azido-N -(2-oxotetrahydrofuran-3-yl)hexanamide 61
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10.4 tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 65
161
10.5 1-(Hex-5-yn-1-yl)piperazine 66
162
10.6 1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroqu
inoline-3-carboxylic acid 68
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10.7 5-(4-(Hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 71
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10.8 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(2-oxo-2-((2-oxotetrahydrofuran-
3-yl)amino)ethyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinol
ine-3-carboxylic acid 72
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10.9 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrofuran-
3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinol
ine-3-carboxylic acid 77
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10.10 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(6-oxo-6-((2-oxotetrahydrofuran
-3-yl)amino)hexyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroqui
noline-3-carboxylic acid 78
N
27
26
25
N
24 29
28
23
22
21
20
30
39
38
33
32
31
N
37
36
35
34
O
41
44
45 46
42
O
47
OH
43
F
40
14
N
16
N
17
18
19
N
15
2 3
4
5
O
1
O
9
NH
6 7
O
8
10
13
12
11
HL6T4CIP_H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
4.122.054.152.062.034.062.993.872.164.021.041.022.001.081.020.990.991.000.941.02
19
DMSO-d6
46<’’>,45<’’>
36
28,26
39
14
32
20
46<’>,45<’>
6
2<’>
25,29
2<’’>
12
44
23,3<’>
4 2113
10,3<’’>
11,22
1.
18
1.
23
1.
311.
32
1.
33
1.
49
1.
511
.5
2
1.
54
1.
63
1.
64
1.
66
1.
79
1.
80
1.
822.
06
2.
09
2.
11
2.
362.
36
2.
37
2.
37
2.
38
2.
39
2.
57
2.
63
2.
64
3.
32
3.
33
3.
803.
813.
82
3.
82
3.
84
4.
184.
18
4.
20
4.
20
4.
26
4.
28
4.
29
4.
33
4.
50
4.
50
4.
514.
52
4.
52
4.
53
7.
55
7.
56
7.
84
7.
87
7.
90
8.
31
8.
33
8.
65
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/
N
27
26
25
N
24 29
28
23
22
21
20
30
39
38
33
32
31
N
37
36
35
34
O
41
44
45 46
42
O
47
OH
43
F
40
14
N
16
N
17
18
19
N
15
2 3
4
5
O
1
O
9
NH
6 7
O
8
10
13
12
11
HL6T4CIP_C.ESP
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
5
42
36
14
3
19
35
2
23
29,25
4
44
10 13
22
12
20
11
46,45
7 18
38
34
3930
28,26
33 32
DMSO-d6
31
7.
59
24
.4
5
25
.3
9
26
.8
9
28
.2
6
29
.4
9
34
.8
1
35
.8
8
47
.8
4
49
.0
2
49
.4
7
52
.4
1
57
.3
5
65
.2
5
10
6.
3410
6.
72
11
0.
83
11
1.
02
11
8.
50
11
8.
57
12
1.
63
13
9.
21
14
5.
21
14
5.
28
14
6.
77
14
7.
99
15
2.
05
15
4.
03
16
5.
99
17
2.
10
17
5.
39
17
6.
36
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/
167
10.11 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-
1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carbo
xylic acid 80
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10.12 (S)-4-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)
butyl)-1H -1,2,3-triazol-1-yl)-N -(2-oxotetrahydrofuran-3-yl)butanamide 84
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10.13 (S)-6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)bu
tyl)-1H -1,2,3-triazol-1-yl)-N -(2-oxotetrahydrofuran-3-yl)hexanamide 85
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10.14 6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)butyl)
-1H -1,2,3-triazol-1-yl)-2-heptylquinolin-4(1H )-one 87
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10.15 2-(6-(4-(4-(4-((2,4-Diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)bu
tyl)-1H -1,2,3-triazol-1-yl)hexyl)-3-hydroxyquinolin-4(1H )-one 89
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10.16 4-Bromo-N -(2-oxotetrahydrothiophen-3-yl)butanamide 153
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10.17 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxotetrahydrothiophen-
3-yl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 154
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10.18 4-Azido-N -(2-oxotetrahydrothiophen-3-yl)butanamide 155
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10.19 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-
3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquin
ol-ine-3-carboxylic acid 156
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10.20 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-((((4-(1-(4-oxo-4-((2-oxotetrahydrothiophen
-3-yl)amino)butyl)-1H -1,2,3-triazol-4-yl)butanoyl)oxy)methoxy)carbonyl)pip
er-azin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 157
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10.21 4-Bromo-N -(2-methoxyphenyl)butanamide 159
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10.22 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 160
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10.23 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-
1H -1,2,3-triazol-4-yl)butyl) piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-car-
boxylic acid 162
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10.24 4-Bromo-N -(3-methoxyphenyl)butanamide 164
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10.25 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 165
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10.26 4-Azido-N -(3-methoxyphenyl)butanamide 166
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10.27 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-
1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-car-
boxylic acid 167
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10.28 4-Azido-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 176
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10.29 4-Azido-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 177
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10.30 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)
-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 178
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10.31 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)
-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 179
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10.32 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquin
oline-3-carboxylic acid 180
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10.33 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquin
oline-3-carboxylic acid 181
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10.34 4-Azido-N -((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)butanamide
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10.35 7-(4-(4-(1-(4-(((1S,2S)-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid 190
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10.36 4-Chloro-N -((1S,2S)-2-hydroxycyclopentyl)butanamide 193
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10.37 4-Chloro-N -((1R,2R)-2-hydroxycyclopentyl)butanamide 194
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10.38 Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-flu-
oro-4-oxo-1,4-dihydroquinoline-3-carboxylate 197
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10.39 4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-
7-yl)piperazin-1-yl)butanoic acid, trifluoroacetic acid salt 198
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10.40 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-
4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 201
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10.41 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-
butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 202
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10.42 4-Chloro-N -((trans)-2-hydroxycyclohexyl)butanamide 203
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10.43 4-Azido-N -((trans)-2-hydroxycyclohexyl)butanamide 204
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10.44 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-
4-oxobutyl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquino-
line-3-carboxylic acid 205
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10.45 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxocyclohexyl)amino)but
yl)-1H -1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxy
lic acid 206
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